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Immunity and metabolism have been viewed as separate fields, however recent 
evidence show that these two systems are intimately integrated, share resources and 
cross-regulate each other. Activated immune cells have to alter their metabolism in 
order to support effector functions. On the other hand, viruses are obligatory parasites 
that counter and exploit host pathways, including metabolism, to effectively propagate. 
Like immune cells, viruses have to alter the metabolic profile of infected cells in order 
to propagate. 
The regulation of metabolism in immune cells or virally infected cells has been well 
studied. However, the precise metabolic regulation that ensues when both immune 
system and viral infection in immune cells interact and compete for the limited 
resources and metabolic pathways available is not clear. In this thesis, I have sought 
to investigate the integrative process by studying the metabolic programming of 
macrophages infected with murine cytomegalovirus (MCMV)  
The central hypothesis of this thesis is that productive infection of macrophages by 
MCMV takes advantage of the early inflammatory metabolomic reprogramming of 
activated macrophages to establish infection, and modulates metabolism at late stages 
of infection towards fatty acid (FA) production to promote viral progeny. 
To study this interaction, I have analysed the temporal profile of the transcriptome and 
metabolome of bone marrow derived macrophages (BMDM) infected with productive 
(WT) and non-productive (attenuated) (MCMV) strains. This aimed to unravel the 
host-directed versus virus-driven metabolic alterations.  
I show evidence indicating that during early times of productive and non-productive 
MCMV infection glycolysis is, in infected BMDM, markedly increased. Furthermore, 
pharmacological and siRNA mediated inhibition of glycolysis resulted in attenuation 
of viral growth demonstrating the dependency of MCMV on this pathway. 
Additionally, using interferon receptor A (IFNAR) and interferon receptor A (IFNB) 
deficient BMDM showed that type-I interferon (IFN) signalling is essential for the 
early upregulation of glycolysis that was observed. In addition to the changes in 
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glycolysis, MCMV infection alters the tricarboxylic acid (TCA) cycle in infected 
BMDM. Metabolomic and transcriptomic data revealed a shift from catabolic to 
anabolic function for the TCA to promote production of TCA intermediates. Finally, 
the urea cycle is also altered both on transcriptional and metabolomic level, consistent 
with the support of Nitric oxide (NO) production which is a hallmark metabolite in 
classically activated macrophages. 
These changes observed in the TCA cycle and glycolysis are consistent with 
supporting the FA elongation pathway during late time points of productive infection. 
Only productive MCMV infection upregulates this pathway. Αt the same time, 
pharmacological and siRNA mediated inhibition of FA elongation pathway greatly 
attenuates viral growth. This indicates that MCMV growth is dependenton FA 
elongation. The effect was very specific for the elongation and not the de novo 
synthesis pathway indicating that MCMV remodels FA that already in the cells. It is 
argued, that in agreement to known literature, MCMV uses these FA for the formation 
of its lipid membrane. 
To further investigate the dependency of MCMV on FA elongation pathways I studied 
additional lipids pathway associated with the former. I found that MCMV infection 
also upregulates the triacylglycerol formation and membrane remodelling pathways, 
which are dependent on FA biosynthesis and elongation. The inhibition of 
triacylglycerol formation and membrane remodelling pathway also attenuated MCMV 
growth. This indicates that apart from the formation of its lipid membrane MCMV 
requires FA to remodel the cellular environment. 
I have also explored the effects of infection on regulating lipid mediators, in particular 
eicosanoids. Eicosanoids are lipid signalling molecules that can act as potent 
inflammation modulators. Here I demonstrated that productive MCMV infection 
specifically increases PGE2 production in infected BMDM. Moreover, addition of 
PGE2 increased viral replication in infected fibroblasts in comparison to non-treated 
cells, while pharmacological blocking of EP4 (PGE2 receptor) rescued the phenotype. 




In conclusion, the data presented in this thesis support my hypothesis and provide an 
insight in the role of metabolism during viral infection. Evidence is provided to show 
that MCMV co-ops the early alterations that metabolic pathways undergo in activated 
macrophage, including but not limited to glycolysis, TCA cycle and urea cycle. These 
early changes in metabolism appear to be coupled with upregulation of FA elongation 
pathways and remodeling of lipids in infected cells. Finally, MCMV co-ops the 
function of regulatory lipids, in particular PGE2, to promote viral growth. It is further 
argued that MCMV productive infection dictates these fatty acid metabolism 
alterations in order to remodel the host cell’s environment, regulate the immune system 




The immune system protects the host from infections. Recent advances in the field of 
immunology have shown that when immune cells are activated they alter their 
metabolomic profile/metabolic state. This has been shown to be crucial to support their 
immune effector functions. The alterations of metabolism allow immune cells to 
accumulate more energy and nutrients that allow them, among others, to replicate and 
generate cytokines, a class of proteins necessary for immune cells to communicate 
with each other. On the other hand, viruses are obligate parasites that need to use the 
host’s cellular machinery to replicate. They have evolved multiple ways to co-op, 
supress and evade the immune response of the host. Multiple studies have shown that 
for various viruses alter the metabolism of infected cells to support their own growth. 
In this thesis, I attempt to study the interaction between host immune system-viral 
infection-and metabolism. By infecting immune cells with virus, I uncovered a link 
between the metabolism of immune cells and the metabolism of virally infected cells 
immune cells metabolism and viral infected cells metabolism. Murine 
cytomegalovirus, the virus that I use as a model throughout my thesis, was shown to 
co-opt the metabolism of activated macrophages to establish infection in the cells. 
Moreover, it is revealed that fatty acid (FA) biosynthesis is crucial for generation of 
viral progeny. Inhibition of FA biosynthesis and/or other enzymes that are involved in 
lipid remodelling in cells, block viral growth. Although it is not clear, there are some 
indications of how FA biosynthesis facilitates viral growth. It is hypothesised that 
alterations of lipid membrane content might support the assembly of virions in cells. 
Additionally, some of the FA synthesised might be crucial components of viral lipid 
membranes. 
The results presented in this thesis provide insight into how metabolism is crucial in 
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1 Chapter 1 Introduction 
1.1 Characteristics of Cytomegalovirus 
Cytomegalovirus (CMV) is a double-stranded enveloped DNA virus, which belongs 
to the Herpesviridae family. Its name is derived from two Greek words; cyto which 
means cell and megalo which means big. The name is a reference to the characteristic 
morphology that CMV infected cells exhibit, which become enlarged and rounded. 
Human CMV (HCMV) is the human adapted strain and it is ubiquitous in human 
population with infection rates ranging from 40-100% depending on socio-economic 
background, race/ethnicity, geographic location, age (Cannon, Schmid, and Hyde 
2010). 
Infection with HCMV usually goes unnoticed in healthy individuals, but it has been 
related to long term health risks (Reinhardt et al. 2006). After infection, HCMV 
establishes a lifelong infection that is not life-threatening to immunocompetent 
individuals. However, the virus can cause life threatening infections in 
immunocompromised individuals, such as HIV infected patients and transplant 
recipients (Crough and Khanna 2009; Griffiths and Grundy 1987). HCMV also poses 
a serious threat to neonates and foetuses. Congenital infection with HCMV can result 
in death, or serious defects, including hearing loss and microcephaly (Gerna, Baldanti, 
and Revello 2004; Burny et al. 2004).  
1.2 Murine cytomegalovirus as a model for HCMV 
One of the characteristics of HCMV is its high species specificity, which prevents in 
vivo studies of HCMV using animal models. For this reason, several other CMV strains 
have been used in animal models, with murine cytomegalovirus (MCMV) being the 
most established model. Despite their genetic differences, HCMV and MCMV share 
a lot of biological and pathological similarities (Schleiss 2013; M. J. Reddehase et al. 
2008). The two viruses have about 70% genomic sequence homology, they have 
similar virion structure, viral life cycle, cell tropism and interact with the host in a 
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similar way (Krmpotic et al. 2003; Matthias J Reddehase, Podlech, and Grzimek 
2002). 
As stated above HCMV is a clinically important pathogen from immunocompromised 
individuals, to neonates and foetuses. Recipients of organs and HIV infected people 
are also in danger because the latent virus can opportunistically reactivate under 
unspecified conditions. Additionally, it has been observed that secondary reactivation 
of the virus during pregnancy leads to less severe effects to the foetus than congenital 
infection does (Arvin et al. 2004; Stratton et al. 1999). Finally, there are a lot 
indications linking HCMV infection to heart disease (Nieto et al. 1999; Lenzo et al. 
2002). For these reasons, a great deal of research is dedicated to studying the 
mechanisms through which the immune system pushes the virus into latency and how 
it reactivates, as well as for the development of a vaccine in an attempt to curb HCMV. 
One of the characteristics of HCMV, and other cytomegalovirus species, is the high 
host species specificity. This readily reduces our ability to perform in vivo studies with 
HCMV and thus some of the most important aspects of the viral life cycle cannot be 
studied extensively. Studying HCMV can only be done using human immortalised cell 
lines that are permissive to the virus or recruiting human volunteers that donate 
primary cells. This latter procedure is very time consuming due to the ethical issues 
that arise and the difficulty in finding suitable donors. Moreover, host genetics that are 
important to viral infections and cannot be standardised as easily when human donors 
are recruited(Nolan, Gaudieri, and Mallal 2006). To circumvent the difficulties in 
studying HCMV infection, the murine model system and MCMV infection has been 
extensively used. In its favour, an extensive number of knockdown mice models exists, 
allowing studies to better understand the role of different host factors in MCMV 
infection. Finally, the development of human vaccines is to date practically impossible 
and any effects of CMV immunisations should ideally, be studied in animal models 
first (Schleiss 2006). 
For these reasons, several other CMV strains have been used in animal models, with 
murine cytomegalovirus (MCMV) being the most established model to study HCMV 
infection. Despite their genetic differences, HCMV and MCMV share a lot of 
biological and pathological similarities (Schleiss 2013; M. J. Reddehase et al. 2008). 
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The two viruses have about 70% genomic sequence homology, a similar virion 
structure, viral life cycle, cell tropism and they interact with the host in a similar way 
(Krmpotic et al. 2003; Matthias J Reddehase, Podlech, and Grzimek 2002). Moreover, 
the immune system of the mouse is one of the most well-defined, making the murine 
model of the infection very attractive for host-virus studies. For these reasons, the use 
of an animal model in the study of HCMV infection is not just useful, but necessary. 
MCMV is the most extensively studied cytomegalovirus and the mouse is the most 
extensively studied animal models making the use of this system to study HCMV 
infection one of the most suitable.  
1.3 MCMV and HCMV infection cycle 
1.3.1 Viral entry 
MCMV and HCMV share similar host cell entry mechanisms. The entry of HCMV is 
facilitated through the interaction of the viral glycoprotein complexes gB, gM, gL, gO 
and gN, on the surface of the virion with cellular receptors (Compton, Nepomuceno, 
and Nowlin 1992; Xin Wang et al. 2005; Marisa K Isaacson and Compton 2009). 
HCMV entry in fibroblasts occurs through direct fusion, or endocytosis into epithelial 
and endothelial cells (Ryckman et al. 2008; Compton, Nepomuceno, and Nowlin 
1992). MCMV infects fibroblasts in a similar manner as HCMV, by using the m74 
encoded protein, which is homologous to the gO of HCMV (Scrivano et al. 2010). 
After the virus enters the cell, the capsid is internalized and migrates to the nucleus 
with the help of tegument proteins associated with microtubules (Kalejta 2008; Li, 
Chen, and Cristea 2013; Cristea et al. 2010; Bresnahan and Shenk 2000). 
1.3.2 Viral gene expression 
In the nucleus, the viral gene transcription begins. Viral transcription is a tightly 
regulated process and the genes involved can be organised into 3 categories based on 
the time of their transcription; immediate early, early and late genes (Keil, Ebeling-
Keil, and Koszinowski 1987). Genes that do not require de novo viral protein synthesis 
are defined as immediate early genes. Genes that require de novo viral protein 
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synthesis, but not viral genome replication are categorised as early genes, and finally 
genes that require both de novo protein synthesis and viral gene replication are late 
genes. 
The immediate early genes IE1 and IE2 do not require de novo protein synthesis and 
begin transcription immediately (Greaves and Mocarski 1998; Iskenderian et al. 1996; 
Meier and Pruessner 2000).  Their functions include acting as master transcriptional 
regulators of viral gene expression, promoting viral DNA replication, while also 
altering the host intercellular environment making it suitable for viral replication by 
arresting cell cycle, inhibiting apoptosis and the host immune response (Bresnahan et 
al. 1996; Castillo, Yurochko, and Kowalik 2000) 
Following the replication of viral DNA and the transcription of late viral proteins, the 
DNA is packed in capsids. The capsids get an initial envelopment as they pass through 
the nuclear envelope to the cytoplasm. In the cytoplasm mature virions with the 
addition of tegument proteins are formed followed by secondary envelopment (Das, 
Vasanji, and Pellett 2007; AuCoin et al. 2006; Sanchez et al. 1998, 2000).Finally, the 
infectious virions are released from the cell. 
1.3.3 Latency 
Herpesviruses establish latency in their host, during which, viral DNA exist in the host 
cells, but it does not produce infectious virions (M. J. Reddehase et al. 2008; Redpath 
et al. 2001). MCMV and HCMV can establish latency in multiple sites. Latent MCMV 
infections have been shown to occur in lungs, heart, kidneys salivary glands and other 
body organs (Kurz et al. 1997; Matsuzawa et al. 1995; Koffron et al. 1998; M J 
Reddehase et al. 1994), but for both pathogens the myeloid cells are considered an 
important site of latency and reactivation in these tissues (Pollock et al. 1997; Sinclair 
2008; Mendelson et al. 1996). Reactivation of CMV can occur after latency and 
represents a serious threat in immune compromised patients.  
The precise reactivation mechanisms for MCMV and HCMV are not yet known, but 
is generally believed to involve the host immune system and multiple signalling 
pathways (Sinclair and Sissons 2006; Poole, Wills, and Sinclair 2014). Interestingly, 
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there appears to be a requirement for latently myeloid cell to reach terminal 
differentiation to support productive replication(Lucin et al. 1992; Sinclair and Sissons 
2006).  
1.4 Immune response to cytomegalovirus infection 
1.4.1 Pattern recognition receptors and CMV detection by the immune system  
The innate immune system is the non-specific defence system of the host that provides 
broad non-specific protection against pathogens. Evolutionarily, it is the first form of 
immunity that appeared and it can be found in plants, fungi, and insects. Until recently 
it was considered that unlike the adaptive immunity, which is pathogen specific with 
immunological memory, the innate immunity does not confer long lasting host 
protection against the same pathogens. This dogma has started sifting with the 
discovery of trained innate immunity (Saeed et al. 2014). 
In mammals, the innate immune system includes, chemicals barriers, physical barriers 
(such as skin), innate immune cells (e.g. macrophages) and components of humoral 
immunity, such as the complement system. After the innate immune system is 
activated it drives the adaptive system response to clear an infection. 
Cells of the innate immune system can recognise pathogens through pattern 
recognition receptors (PRRs). These are receptors, which have evolved to specifically 
bind to pathogen-derived molecules that are not found in the host. The existence of 
PRRs was proposed by Charles Janeway in 1989, in the Infectious non-self-model 
(Janeway 1989). Today numerous PRRs that recognise different pathogen-associated 
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) 
have been discovered (Thompson et al. 2011). 
Lipopolysaccharide (LPS) is a lipoglycan produced specifically by gram-negative 
bacteria, and it is detected by Toll-Like receptor-4 (TLR4) (Akira and Takeda 2004; 
Poltorak et al. 1998). As LPS is only found on the membranes of gram-negative 
bacteria and not eukaryotic cells, the detection of LPS by TLR4 indicates the presence 
of bacteria, and subsequently the immune is activated to mount a response. 
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1.4.2 Toll-like receptors (TLR) 
Toll-like receptors (TLRs) are the most well studied and evolutionarily conserved PRR 
protein family and were first discovered in Drosophila melanogaster (Kluding et al. 
1985). TLRs are named after the Toll receptor that confer similar function in 
Drosophila (Hansson and Edfeldt 2005). In mice, there are 13 TLRs, with TLR 10 
having lost its function due to a retrovirus insertion (Kawai and Akira 2010). In 
humans, only 10 TLRs exist, with TLRs 1-9 being conserved in both mouse and 
humans (Kawai and Akira 2010). All TLRs are transmembrane proteins with leucine 
rich motifs that act as binding sites for PAMPs and an intracellular Toll–interleukin 1 
(IL-1) receptor (TIR) that transduces the signal (Kawai and Akira 2010; L. A. J. 
O’Neill, Golenbock, and Bowie 2013). 
After the engagement of TLRs by PAMPs the signal is transduced using two main 
pathways; the Myeloid differentiation primary response gene 88 (MyD-88) pathway 
and the TIR-domain-containing adapter-inducing interferon-β (TRIF) pathway. The 
MyD-88 dependent pathway is used by all TLRs, except TLR3, and the TRIF pathway 
is used by TLR3 and TLR4. The MyD-88 pathway results in the activation of nuclear 
factor kappa-light-chain-enhancer of activated B (NF-κB) pathways, which induces 
the production of proinflammatory cytokines and eventually type-I IFN. The TRIF 
pathway activates IRF3 and/or IRF7 depending on the signalling TLR and leads to the 
production of type-I Interferon (IFN), which then activate the transcription of 
numerous inflammatory genes (L. A. J. O’Neill, Golenbock, and Bowie 2013; Akinori 
Takaoka and Yanai 2006; Akira and Takeda 2004; Kawai and Akira 2010).  
HCMV can be detected at the surface of the cell by TLR2 (Boehme, Guerrero, and 
Compton 2006; Compton et al. 2003). TLR2 detects hydrophobic PAMPs such as 
lipoteichoic acid, but it is not clear which component of the virus it detects (Botos, 
Segal, and Davies 2011). Antibodies specific for gB and gH can block this interaction. 
Thus, it is assumed that TLR2 detects hydrophobic peptides in these proteins (Boehme, 
Guerrero, and Compton 2006). TLR2 has been shown to be important in MCMV 
immunity too, with mice lacking TLR2 showing elevated levels of the virus 
(Szomolanyi-Tsuda et al. 2006). 
7 
 
After entry of CMV in the cell, the virus can be detected by TLR9, which is located in 
endosomes. TLR9 detects DNA containing unmethylated deoxycytidylate-phosphate-
deoxyguanylate (CpG) motifs, which are abundant in viral and bacterial DNA, but not 
vertebrate (Hemmi et al. 2000). TLR9 activates IRF7, which leads to rapid induction 
of type-I IFN expression, both in humans and mice. Studies have provided evidence 
that both human and mouse CMV are detected by TLR9 (Varani et al. 2007; Tabeta et 
al. 2004). Unlike mice though, TLR9 expression in humans is restricted to B cells and 
plasmacytoid DCs (pDCs) (Takeuchi and Akira 2010). The latter are renowned for 
their ability to produce huge amounts of type-I and contribute significantly to the 
antiviral response during CMV infection (Zucchini, Bessou, Robbins, et al. 2008). 
TLR9 deficient mice infected with MCMV exhibited reduced production of IFN-γ, 
type-I IFN, higher viral loads and  were more susceptible to MCMV infection than 
what WT mice were (Delale et al. 2005). 
CMV is also detected by TLR3 and TLR7. TLR3 is located in endosomes and can 
detect dsRNA, as challenge with poly(I:C) has demonstrated (Alexopoulou et al. 
2001). Nahum et al. has demonstrated that TLR3 plays an important role in HCMV 
immunity by studying a the TLR3 receptor variant, L412F (Nahum et al. 2012). At the 
same time MCMV infected TLR3 deficient mice have been shown to  have greatly 
augmented viral load in their spleen (Tabeta et al. 2004). TLR7 can detect ssRNA and 
it is, like TLR3, located in endosomes (Nahum et al. 2012). Zucchini et al. 
demonstrated that TLR7 and TLR9 have many overlapping functions during MCMV 
infection (Zucchini, Bessou, Traub, et al. 2008). In this study it was demonstrated that 
when TLR7 or TLR9 deficient mice were challenged with MCMV the level of multiple 
cytokines in serum were similar for both mice strains(Zucchini, Bessou, Traub, et al. 
2008). 
In summary the human and mouse CMV have been shown to be detected by TLR2,3,7, 
and 9. Despite the fact that the signalling patterns in these molecules might appear 
overlapping and redundant, the differences in cell localisation and pathways through 
which they signal might contribute to slight adaptations of immune signalling allowing 
the immune system to respond to the plethora of microbes (Takeuchi and Akira 2010). 
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1.4.3 RIG-I-like receptors 
After the discovery of TLRs it became clear that they are not the only PPRs in cells.  
TLR3 deficient cells for example are capable of detecting dsRNA, indicating the 
existence of more PRRs (Yamamoto 2003; Hoebe et al. 2003). In addition to TLRs 
there are other PPRs in cells, such as NOD-like receptors (NLR), C-type lectin 
receptors (CLR), and RIG-I-Like receptors (RLR). RLR are a family of receptors 
which consist of three members; retinoic acid-inducible gene I (RIG-I), melanoma 
differentiation associated gene 5 (MDA5) and laboratory of genetics and physiology 
2 (LGP2) (Wilkins and Gale 2010) . 
The members of this family have a DExD/H- box RNA helicase domain, which is used 
to bind to the RNA. Additionally, RIG-I and MDA-5 have a Caspase activation and 
recruitment domain (CARD) that is involved in the downstream signalling after the 
activation (Yoneyama et al. 2005; Takahasi et al. 2008). RLRs reside in the cytoplasm  
and their activations results in the activation of the Interferon regulatory factor-3 
(IRF3), NF-B and the downstream activation of type-I IFN (Wilkins and Gale 2010; 
Yoneyama et al. 2004). Further studies have demonstrated that MDA-5 preferentially 
detects dsRNA while RIG-I recognizes 5-triphosphorylated, uncapped ssRNA (Kato 
et al. 2008; Sachidanandam 2011). It is not clear if MCMV or HCMV are recognised 
by RLRs, but Scott et al. has demonstrated that RIG-I is targeted for proteosomal 
degradation by HCMV(Scott 2009). 
1.4.4 Absent in melanoma 2 receptor 
Given that cytomegaloviruses are DNA viruses it is expected that they would mainly 
be detected by DNA sensors. Absent in melanoma 2 (AIM-2) is a dsDNA cytosolic 
PRR that can recognise host and pathogen DNA in the cytosol through an interaction 
with its HIN domain. Its activation stimulates the formation of caspase-1 
inflammasome in an apoptosis-associated speck-like protein (ASC) depend 
manner(Hornung et al. 2009).  
The formation of the inflammasome is critical for the maturation or pro-IL-1β and pro-
18 during MCMV infection in vitro. The expression of both cytokines is induced by 
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TLR activation, but caspase-1 inflammasome activation is critical for their maturation 
(Rathinam et al. 2010). It is tempting to infer that in vivo AIM-2 activation is also 
required for inflammasome activation and maturation of IL-1β because of the findings 
in vitro. However, the mechanism through which viral DNA reaches AIM-2 and 
activates it not yet defined(Marc; Dalod 2013). Critically, absence of AIM-2 in 
MCMV infected mice reduces the number of IFN-γ producing NK cells which is 
critical for driving the virus in latency and controlling the infection(Rathinam et al. 
2010). 
1.4.5  Dependent activator of interferon regulatory factor 
DNA Dependent activator of interferon regulatory factor (DAI) is a cytosolic DNA 
sensor that upon activation interacts with TANK-binding kinase 1 (TBK1) which leads 
to type-I IFN activation in cells (Takaoka et al. 2007). Defillips et al. reported that 
HCMV is detected by cytoplasmatic dsDNA sensors, and more specifically the ZBP1 
(also known as DAI, DNA-Dependent activator of interferon regulatory factor) 
(DeFilippis, Sali, et al. 2010; DeFilippis, Alvarado, et al. 2010). 
1.4.6 Type I, II & III IFN antiviral response 
1.4.6.1 Type-I interferons 
Interferons (IFN) are secreted cytokines that can function in a paracrine and autocrine 
manner, inducing the transcription of numerous genes as part of the immune system 
response. There are three interferon families. The family of type-I interferon family in 
humans consists of 13 homologous IFN-α proteins, one IFN-β protein and IFN-δ, IFN-
ζ, IFN-ε, IFN-κ, IFN-τ and IFN-ω, which are poorly characterised and understood. Type-
II interferon has only one member which is IFN-γ and finally the type-III IFN family 
comprises IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4 (Pestka, Krause, and Walter 2004; 
Platanias 2005). 
Upon detection of a pathogen by various PRRs, type-I IFNs are produced in vivo and in 
vitro, resulting in the induction of the transcription of multiple genes termed interferon 
stimulated genes (ISGs) that have potent antiviral, immunomodulatory and anti-
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proliferative properties (Platanias 2005). Type-I interferons are produced and recognised 
by almost all cell types (Piehler et al. 2012). 
Secreted type-I IFNs are detected by a common cell surface receptor cell surface 
receptor called IFN-α receptor (IFNAR), which consists of two subunits, IFNAR1 and 
IFNAR2. Engagement of the IFNAR leads to the activation of the receptor associated 
tyrosine kinases, Janus kinase 1 (JAK1) and TYK2. These kinases phosphorylate the 
signal transducer and activator of transcription (STAT) proteins, STAT1 and STAT2. 
Phosphorylated STAT1 and STAT2 dimerise and associate with IRF9 to form a 
complex called the ISG factor 3 (ISGF3) (Stark and Darnell 2012).  The ISGF3 
complex binds to the IFN-stimulated response elements (ISREs) on the promoter 
regions and promotes the transcription of interferon-stimulated genes (ISGs). ISGs 
have a plethora of antiviral, immunomodulation and anti-proliferative properties that 
shape the immune response to various pathogens (Stark and Darnell 2012). This order 
of events is known as the canonical type -I IFN signalling pathway. More recently, 
however, it was found that type-I interferons can signal through different pathways, 
which could explain the broad effects of IFN-I (McNab et al. 2015). For example, 
type-I interferon detection by cells can also lead to the formation of STAT1 
homodimers, which are usually associated with IFN-γ signalling. 
The regulation of this type of immune response is governed by multiple feedback loops 
and it has been observed that infection by different viruses activates different gene sets 
(M. S. Diamond and Schoggins 2013). Additionally, the ability of type-I IFNs to 
activate immune cells and to induce different ISGs depends on the type of IFN, their 
binding affinity and concentration, adding to the complexity of the system (Levin et 
al. 2014; Lavoie et al. 2011; Levin, Harari, and Schreiber 2011). 
After the MCMV has been detected, type-I interferons are secreted, which activates 
ISGs leading to the expression of more inflammatory cytokines. The lymphotoxin β 
receptor (LTβR) has been shown to contribute to this initial burst of IFNα/β production 
(Schneider et al. 2008). The first wave of the bi-phasal type-I IFN expression peaks at 
8 hours and then declines, but it is crucial for restricting viral replication through 
various mechanisms including the enhancement of NK cells cytotoxicity (Loewendorf 
and Benedict 2010; Orr, Murphy, and Lanier 2010; Schneider et al. 2008). The 
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accumulation of type-I IFN increases again at 36 hours post infection and plasmacytoid 
dendritic cells (pDCs) appear to be its main source, as stated above(Marc Dalod et al. 
2003; Zucchini, Bessou, Robbins, et al. 2008). Interestingly unlike other conventional 
DC (cDC) types (CD8+ cDCs and CD11b+ cDCs and ΜΦ), pDCs are not permissive 
to viral infection (Marc Dalod et al. 2003; Andrews et al. 2010; Marc; Dalod 2013). 
The importance of type-I interferon in the control of CMV infection has been 
demonstrated by Strobl et al. In their study they show that defects in the JAK-STAT 
signalling pathway renders cells more susceptible to infection by MCMV (Strobl et al. 
2005). Furthermore blocking IFN-/, or IFN-γ during MCMV infection in vivo 
increases viral titres  
(Heise and Virgin 1995). 
1.4.6.2 Type-II interferon 
The only member of this protein family is IFN-γ, and it is structurally distinct from 
type-I IFNs. It binds to the interferon gamma receptor (INFGR), which is a 
transmembrane dimer of IFNGR1 and IFNGR2 (Pestka, Krause, and Walter 2004). 
IFNGR binds JAK1 and JAK2 at its intracellular domain, which upon ligation to 
IFNGR phosphorylate STAT1. STAT1 forms homodimers that translocate to the 
nucleus, where they bind at the Gamma interferon activation site (GAS) promoting the 
transcription of genes. There is some overlap between the genes induced by IFN-γ and 
IFN-I, but this is not always the case(Der et al. 1998).  
IFN-γ can act on a wide range of cells that have the IFNGR. Two of the most important 
cell types affected by IFN-γ are T cells and macrophage (MΦ) (Schroder et al. 2004). 
In the case of macrophages, IFN-γ is critical for their activation due to its ability o 
induce transcription of microbicide encoding genes (J. D. MacMicking 2012). This 
has been illustrated in the case of Listeria infection, where IFN-γ is essential for the 
clearance of the parasite once it has been phagocytosed by ΜΦ (Soudja et al. 2014; S. 
H. Lee et al. 2013). 
During CMV infection, IFN-γ appears to be one of the most important cytokines to 
control the infection. IFN-γ deficient mice are unable to control the infection and drive 
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the virus into latency (Presti et al. 1998). Despite its crucial role, IFN-γ on its own is 
not sufficient to control MCMV infection (Lucin et al. 1992). Studies in MCMV 
infected ΜΦ have demonstrated that IFN-γ induces a primed state on the type-I IFΝ 
network of the cells, which enables the establishment of an antiviral state capable of 
suppressing  major immediate early promoter (MIEP) activity (K. a Kropp et al. 2011).   
1.4.6.3 Type III Interferon 
In mice, there are two type interferons IFNλ2/IL-28A and IFNλ3/IL-28B. In humans 
there are four members IFNλ1/IL-29, IFNλ2/IL-28A, IFNλ3/IL-28B, IFNλ4 (Kotenko 
et al. 2003). This last variant of IFNλ in humans, INFλ4 is frameshift variant of IL28B 
and it is associated with impaired HCV clearance (Prokunina-Olsson et al. 2013).  
Type-I INFs and type-III IFN share a lot of common characteristics. Like type-I INFs 
type-IFN is induced by a number of pathogens including RNA and DNA viruses (Ank 
et al. 2006; Sheppard et al. 2003). Type-III Interferons signal through a unique receptor 
INFλR which is compromised or two chains IL10Rβ and IL28Rα (Sheppard et al. 
2003). Finally, like the other IFN types type-III IFN are able to activate a large number 
of ISG which have a lot of potent anti-microbial properties. 
The first main difference observed between type-I and type-III interferons is their 
expression pattern. While virtually all cell types produce type-I interferons and 
respond to them only a small subset of cells express and respond to type-III IFN. There 
is a compartmentalisation to type-III IFN response and it is increasingly believed that 
this interferon regulates immune responces specifically at mucosal areas (Kotenko and 
Durbin 2017; Odendall and Kagan 2015) . 
1.5 Metabolism in infection and Immunity 
1.5.1 Introduction 
Immunity and metabolism have been viewed as separate fields for a long period of 
time. The association between the two fields was studied in the past, but only by a 
small number of groups, which showed metabolic adaptations in immune cells during 
activation (Newsholme et al. 1986). However, research in the field of 
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immunometabolism has over the last 15 years research exploded with studies clearly 
demonstrating a tight integration, sharing of resources and cross-regulation between 
the two systems (Pearce et al. 2013). In particular macrophages, among other immune 
cells, reprogram and tightly regulate their metabolism upon activation from IFN and/or 
TLRs (Van den Bossche, O’Neill, and Menon 2017). It has also become obvious that 
these changes are essential to support their effector functions. 
On the other hand, viruses are obligate parasites that both exploit and counter selective 
host pathways, including metabolism, to effectively propagate. Numerous studies have 
demonstrated that viruses depend on alterations of metabolism in infected cells to 
propagate (Munger et al. 2006; Koyuncu et al. 2013; J.-Y. Seo, Yaneva, and Cresswell 
2011; Munger et al. 2008; Vastag et al. 2011; D. L. Diamond et al. 2010). Moreover, 
recent publications from our group and others have revealed a central connection 
between infection and metabolism in regulating the host response (Blanc et al. 2013, 
2011; Kotzamanis, Angulo, and Ghazal 2015). 
Under the light of the accumulating evidence in immunometabolism and virology it is 
becoming apparent that metabolism, as a source of energy and metabolic products, is 
critical for the outcome of infection and/or other diseases. Here, I provide a summary 
of how HCMV infection modifies metabolism of the host cell; how specific immune 
cells, like ΜΦ, regulate their metabolism during activation; and how metabolic 
intermediates can regulate all three processes: infection, metabolism and the immune 
response. Throughout my thesis I attempt to place metabolism at the centre of an 
infection, metabolic and immune axis, which can determine the outcome of infection 
by intergrading signals both from host and pathogen. 
A crucial and novel aspect of my work is employing an infectious agent in its natural 
host to study metabolism in immunity. Most of the studies presented below study 
immunometabolism in innate immune cells, usually, Dendritic cells (DCs), or 
Macrophages (ΜΦ), in the content of TLR and/or other cytokine activation. While this 
might be a sufficient model to describe the state of metabolism in immune cells during, 
perhaps some autoimmune diseases, it is not sufficient to describe it during viral 
infections. During viral infection innate immune cells have to intergrade signals that 
stem from multiple PRRs and cytokines at the site of inflammation. It has already been 
14 
 
stated that different viruses activate different set of immune response genes (M. S. 
Diamond and Schoggins 2013). It is, thus, not far-fetched to assume that based on that 
different immune cells, apart from their phenotype, might also alter their metabolism 
in subtle ways.  
At the same time, most of these studies employ the use of LPS in combination with 
other cytokines to study immunometabolism. LPS is detected on the surface of gram-
negative bacteria and engages TLR4. This TLR ligand is not a suitable for the 
emulation of viral infections, but rather only specific bacterial ones. Furthermore, even 
if another TLR ligand were employed to emulate viral infection it would not be 
sufficient. Some viruses can infect immune cells and affect their m tabolism directly. 
Even if the viral infection of the cell does not result in productive infection the initial 
transcription of any genes and/or tegument proteins could affect the 
phenotype/metabolism of the cells. 
 In similar fashion, the studies of alterations in the metabolism of virally infected cells 
takes place usually outside of the context of an immune response. For this reason, these 
studies are not sufficient for describing the full range of events during infection. 
Viruses normally grow in the niche/environment/context of an immune response from 
the host. Thus, they have evolved mechanisms to counteract and subvert pathways 
including metabolic and immune signalling pathways. They have even evolved 
methods to counteract and exploit immune signalling (Bowie and Unterholzner 2008; 
Netterwald et al. 2005). Thus, studying the metabolism of infected cells outside of the 
context of an immune response might produce artefacts not encountered in a real 
infection.  
1.5.2 Central carbon metabolism in cells 
1.5.2.1 Glycolysis (glycolytic pathways) 
Cellular metabolism is the set of sustaining biochemical reactions that take place 
within a cell. Through them a cell takes up and exports the metabolites that it uses to 
generate energy and to produce the chemicals that are essential for its survival. Central 
carbon metabolism is an integral part of metabolism and it is responsible for processing 
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carbon atoms derived from sugars (Noor et al. 2010). Figure 1.1 shows an overview 
of the Central carbon metabolism in a quiescent cell. 
Although there are other pathways for the metabolism of sugars, the glycolytic 
pathway, which is responsible for the metabolism of glucose, is traditionally 
considered the most important and most common pathway that the description of most 
metabolic networks start with. The glycolytic pathway in cells starts with the import 
of glucose from the extracellular environment and its processing in the cytosol of the 
cell. 
In a quiescent cell, glycolysis catabolises glucose to pyruvate through 10 metabolic 
steps. The generated pyruvate can then enter the Tricarboxylic acid (TCA) cycle, 
where it is further oxidised and used to produce energy through oxidative 
phosphorylation. For each glucose molecule that runs through the glycolytic pathway, 
two ATP molecules are “invested” by the cell to process glucose and four ATP 
molecules are generated as end product. This provides a net generation of two new 
ATP molecules, plus the regeneration of NADH from NAD+. NADH is an important 
coenzyme in many biochemical pathways in cell, it is predominately used as a 
reductive agent and as a provider of protons for the electron transport chain (ETC) in 
the mitochondria. 
Under normoxic conditions most of the glucose is turned into pyruvate. However, 
when cells are deprived of oxygen they cannot generate enough NAD+.  The inability 
to generate NAD+ is detrimental to the cell as NAD+ is an essential cofactor for 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), the enzyme that catalyses the 
sixth reaction in the glycolytic pathway. Thus, the lack of NAD+ can inhibit glycolysis 
and deprive cells of essential molecules. To overcome this, cells reduce pyruvate to 
lactate in a reaction that oxidises NADH to NAD+, which can then be used to keep 




Figure 1.1 Overview of Cell Central Carbon metabolism. Glucose is imported into the cell and is oxidised via glycolysis or 
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the PPP. Glucose molecules oxidised via the PPP can either re-enter the glycolytic 
pathway or feed into other pathways to produce nucleotides. Glucose molecules 
oxidised via glycolysis are converted to pyruvate, which can either be reduced to 
lactate and generate NAD+ or get transported into the mitochondria and be oxidised 
via the TCA cycle. Pyruvate enters the TCA cycle to either be catabolised to produce 
energy via OXPHOS or can be utilised by other pathways anabolically. The TCA cycle 
can be replenished by glutamate if needed or via FA that can be oxidised in the 
mitochondrion to produce acetyl-CoA. Carbon atoms from pyruvate can be shuttled 
outside the mitochondrion via citrate to synthesise lipids like FA and cholesterol. 
Enzymes are indicated with blue colour. F2,6Bis-P: Fructose-2,6-Bisphosphatase; 
HK: Hexokinase; PFKFB3: 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 
3; ATPS: ATP synthase; ACL:  ATP citrate lyase; HMGCR: 3-Hydroxy-3-
Methylglutaryl-CoA Reductase; FASN: Fatty acid synthase; FA: Fatty Acid. Adopted 
and Modified from (Finley et al. 2013). 
1.5.2.2 The Pentose Phosphate Pathway  
The pentose phosphate pathway (PPP) (Fig.1.2) connects to the glucose pathway in 
two steps. Connection with the glucose pathway occurs at the first step, where D-
glucose is converted to D-glucose-6P, and at the fifth step, where D-glyceraldehyde is 
produced. The pathway acts as an alternative pathway for glucose oxidation without 
generating ATP. Instead, the PPP accomplishes two other equally important functions: 
1. It generates NADPH, which is crucial for the generation of fatty acids and the 
maintenance of the redox balance in the cytosol of cells through reduction of 
glutathione. 
2. It generates D-ribose-5P, an important precursor for nucleotides synthesis. 
The PPP pathway is composed of two branches. The first branch is the oxidative 
branch, which leads to the generation of NADPH and D-ribulose-5P from D-glucose-
6P through three irreversible reactions. The second branch is the non-oxidative branch, 
which leads to the generation of D-ribose-5P. Because of the branching of the pathway 
and the fact that the reactions in the non-oxidative branch are reversible, the flux in 
the PPP can be modulated to better suit the needs of the cells (Fig. 1.2). 
Depending on the needs of the cells, the PPP can support the generation of NADPH 
and ATP, by allowing carbon atoms to re-enter glycolysis through its non-oxidative 
branch. Alternatively, it can support the generation of nucleotides without producing 
extra NADPH by operating only its non-oxidative branch. This flexibility is important 




Figure 1.2 The Pentose Phosphate Pathway. The Pentose Phosphate pathway with 
both its branches and its interaction with the glycolytic pathway. G-6-PD: Glucose 6-
P dehydrogenase; PGLS: 6-phosphogluconolactonase: 6PGD: 6-Phosphogluconate 
dehydrogenase; RPI: Ribulose 5-Phosphate Isomerase; RPE: Ribulose 5-Phosphate 
3-Epimerase; TKT: Transketolase; TALDO: Transaldolase; SHPK: Sedoheptulose: 
GA-3P: glyceraldehyde 3-phosphate 
1.5.2.3 The tricarboxylic acid cycle or Krebs cycle 
The tricarboxylic acid cycle (TCA), or the Krebs cycle, is a series of metabolic 
reactions that takes place in the mitochondria of eukaryotic cells. It oxidises Acetyl-
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CoA coming from carbohydrates, amino acids and fatty acids. The pathway acts as a 
hub where multiple pathways converge and through which carbon atoms can flow. 
In most quiescent cells this pathway is the major generator of ATP. The oxidation of 
Acetyl-CoA does not generate large amounts of energy itself, but it is important for 
the generation of NADH and FADH2, which can be utilised for the generation of ATP 
through oxidative phosphorylation (OXPHOS). Electrons from NADH and FADH2 
can enter the electron transport chain and generate ATP through chemiosmosis created 
in the inner membrane of mitochondria. 
The TCA cycle and OXPHOS coupling is the most efficient way of producing energy, 
but it is not the only function of the TCA cycle. Due to its integral part in the heart of 
carbon metabolism it can be utilised to generate precursors for other pathways when it 
is required. Two notable examples of this are 1) citric acid that can be used for the 
generation of fatty acids through conversion into Malonyl-CoA, while 2) α-
ketoglutarate (α-KG), which can be reversibly converted to glutamate for the 
generation of glutamine, proline and arginine. 
1.5.2.4 Glutaminolysis  
Glutamine is the most abundant circulating amino acid in blood and it is critical in a 
number of cell function including, generation of antioxidants, synthesis of other amino 
acids, purine and pyrimidine synthesis and mitochondrial metabolism. Interestingly 
glutamine metabolism is a hallmark of cancer metabolism (DeBerardinis et al. 2007). 
The process by which glutamine is converted to a number of different TCA cycle 
metabolites is called glutaminolysis. Glutamine is taken up by cells and then converted 
to glutamate via glutaminase. Subsequently it can be converted to α-KG via two 
distinct pathways. The first one is transamination from glutamate–oxaloacetate 
transaminase (GOT), or glutamate–pyruvate transaminase (GPT), and the second is 
via glutamate dehydrogenase (GLUD) (L. Yang, Venneti, and Nagrath 2017). 
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1.5.2.5 Fatty acids biosynthesis and elongation  
Fatty acids (FA) are carboxylic acids with aliphatic tails. Based on the length of the 
aliphatic tail the solubility of FA in water changes and as a result only some short chain 
FA are slightly soluble in water due to the polar carboxylic moiety. The acyl- group of 
the FA can be 4-36 carbon atoms long, and is usually an even number due to the way 
that FA are synthesized by cells. 
FAs have three primary functions, 1) They are used to store energy. For this purpose, 
FAs are stored in cells, in the form of triglycerides, in lipid droplets. Triglycerides are 
formed when three FAs are attached to a glycerol molecule through the formation of 
ester bond between the carboxylic group of the FA and the alcohol moiety of the 
glycerol. 2) FAs are essential components of cellular membranes where they form an 
amphipathic lipid bilayer. 3) As signalling molecules (Iwasaki et al. 2015; Furuhashi 
and Hotamisligil 2008; Nakamura, Yudell, and Loor 2013). In general, two lipid 
classes form membranes in mammalian cells:  
1) Glycerophospholipids: consist of a glycerol molecule that has a hydrophilic 
polar group at the sn3 position and two FA attached at the other two positions. 
The hydrophilic group is a phosphoric acid that has another polar moiety 
attached to its phosphate group.  
2) Sphingolipids: which are composed of a sphingosine, a FA attached to it, 
serving as hydrophobic group, and a polar group joined by a glycosidic or a 
phosphodiester bond. 
The nature of the FAs attached to the lipids (length of tails, saturation degree etc.) 
defines the physiochemical properties of the lipids. This allows for different cells and 
cellular compartments to have membranes with properties tuned to their needs. 
Most FA can be obtained from diet or synthesized d  novo. Some specific species of 
FA though cannot be synthesized by humans and other animals and, thus, must be 
obtained by diet. The de novo synthesis of straight-chain FA requires citrate from the 
TCA cycle. Citrate is exported to the cytosol where it is converted to Acetyl-CoA, 
which acetyl-CoA carboxylase (ACC) converts to malonyl-CoA, the building block 
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for FA. The conversion of acetyl-CoA to malonyl-CoA is a commitment step for the 
formation of FA.  
The generation of Malonyl-CoA is followed by the synthesis of FA by Fatty acid 
synthase (FASN). The mammalian FASN is a huge polymer protein comprising 7 
different proteins that synthesize and elongate FA up to 16 carbon atoms long (Wakil 
1989). Fatty acids can by further elongated by the elongation system in the 
Endoplasmic reticulum (ER). Elongase Of Very Long chain fatty acid (ELOVL), in 
combination with other enzymes, are used in the ER to further elongate FA (Cinti et 
al. 1992). The FA can also be further processed by desaturases, which results in 
unsaturated FA. Because of its importance, the FA biosynthesis pathway is tightly 
regulated by mTOR and sterol regulatory element-binding proteins (SREBP) amongst 
others (Peterson et al. 2011; Porstmann et al. 2008). 
More recently, a novel function for FA in immunity has been described. It has been 
shown that FA can act as signalling molecules, exhibit anti-inflammatory properties 
and contribute to the regulation of metabolism (Nakamura, Yudell, and Loor 2013; 
Oishi et al. 2016). 
1.5.3 Central carbon metabolism in HCMV infected cell 
Viruses are obligate parasites that are dependent on the host cells biological machinery 
and biosynthetic pathways to replicate. Homeostatic regulation of these pathways and 
the limited resources associated with them enables the cell to maintain a dynamic 
equilibrium and respond to wide range of external stimuli, which is crucial for survival 
in an ever-changing environment. Given the interplay of pathways, the extreme 
coordination and integration that cells have to use to control them, in addition to the 
cost associated, both in resources and energy, with proliferation it is not a surprise that 
both viruses and the immune system have developed ways to tightly regulate them. A 
large number of viruses, including, but not limited to, HSV-1, Dengue Virus and 
HCMV have been shown to exploit host metabolic pathways to proliferate (Koyuncu 
et al. 2013; Moser, Schieffer, and Cherry 2012; Zheng et al. 2003; Vastag et al. 2011).  
Fibroblasts infected with HCMV have been shown to dramatically increased 
glycolysis and produce lactate in the presence of O2. This can be perceived as 
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unexpected given the fact that the glycolytic pathway is not very efficient in producing 
ATP in comparison to the TCA cycle (Munger et al. 2006, 2008; Vastag et al. 2011), 
however, 13C labelling experiments in HCMV infected cell have demonstrated that 
glycolysis transfers an increased number of carbon atoms to the TCA cycle.  
Pyruvate generated from glycolysis is converted through decarboxylation to Acetyl-
CoA by pyruvate dehydrogenase (PDH), which is followed by citrate synthase (CS) 
incorporating Acetyl-CoA to oxaloacetate and generating citrate. Citrate molecules are 
shuttled outside the cell at an increased rate to synthesise FA and are also used to run 
through the TCA (Fig. 1.3). At the same time uptake of glutamine is hugely increased 
to support anapleroticly (replenishment) the TCA cycle, to compensate for the 
increased efflux of citrate atoms to the cytosol. This is more evident due to the fact 
that while glutamine is not required for fibroblasts, it is for HCMV infected fibroblast 





Figure 1.3 Overview of Cell Central Carbon metabolism in HCMV infected fibroblasts.  HCMV greatly increases import of
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glucose into the infected cell. At the same time lactate and pyruvate production is 
increased. The TCA cycle shunt is greatly enchanced and carbon atoms are both 
utilised for energy production via OXHPOS and shuttled via citrate from the 
mitochondrion to the cytosol where they are utilised to synthesise FA. Glutaminolysis 
is also greatly increased to replenish the TCA cycle despite the fact that it is not 
required in uninfected fibroblasts. The main pathways upregulated by HCMV are 
indicated by orange arrows. The question mark near some pathways indicated lack 
of information regarding its contribution to the metabolism of the infected 
cell.Abreviations same as Fig.1.1 
Due to its central position in cell metabolism, the TCA cycle is, in an HCMV infected 
cell, turned into a major biosynthetic hub that synthesise precursor molecules for 
multiple pathways. HCMV manages this by increasing almost globally the metabolic 
fluxes. Given this, it should not come as a surprise that HCMV infected cells utilize 
glycolysis for ATP generation since the TCA cycle’s main function is shifted. 
To support the energy demands of viral replication, the virus employs multiple 
methods to subvert and co-op metabolic pathways within the cell. By increasing the 
expression of glucose transporter 4 (Glut4), HCMV can increase glucose uptake 
greatly in infected fibroblasts (Yu, Maguire, and Alwine 2011). However, increased 
glucose import alone is not enough, the glucose needs to be oxidised and shuttled to 
other pathways where it contributes to viral progeny. To manage this, HCMV increases 
the expression of multiple transcriptional factors while also actively interfering with 
growth, nutrient and energy sensors within the cell. The expression of carbohydrate 
response element-binding protein (ChREBP) is greatly induced and its inhibition can 
attenuate HCMV growth in infected fibroblasts (Yu, Maguire, and Alwine 2014). 
ChREBP can translocate to the nucleus and induce genes related to glycolysis, protein 
synthesis and FA synthesis (Postic et al. 2007; Denechaud et al. 2013). The ability of 
ChREBP to induce, along with glycolysis, protein and FA synthesis makes it is critical 
for HCMV metabolomic reprogramming of cells. 
Interestingly, HCMV appears to also induce sterol regulatory binding element protein 
(SREBP), another transcription factor associated with FA biosynthesis. There are two 
SREBP genes that express SREBP1 and SREBP2, respectively. Moreover, the 
SREBP1 protein exist as two isoforms SREBP1a and SREBP1c (Jeon and Osborne 
2012). Published data indicate that the two SREBP1 variants are associated with 
regulating FA metabolism and that all the SREBPs are associated with sterol 
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metabolism(Sato 2010). The studies reviewed here focus on the SREBP1 variants, as 
they are associated with FA synthesis (Yu, Maguire, and Alwine 2012). In the context 
of HCMV infection, it has been shown HCMV induces SREBP1 translocation from 
the ER, where it is bound and inactive, to the nucleus where it promotes the expression 
of FA synthesis genes (Yu, Maguire, and Alwine 2012; Spencer et al. 2011). 
Moreover, while high sterol levels normally inhibit cleavage of SREBP1, HCMV can 
still induce cleavage of SREBP1 despite of high sterol levels (Yu, Maguire, and 
Alwine 2012). HCMV has been shown to induce the translocation of inactive ER-
bound SREBP1, to the nucleus where it induces the expression of FA biosynthesis 
genes (Yu, Maguire, and Alwine 2012; Spencer et al. 2011). Moreover, while high 
sterol levels normally inhibit cleavage of SREBP1 the virus can still induce it (Yu, 
Maguire, and Alwine 2012). Yu et al. suggest that one of the mechanism, through 
which the virus induces SREBP1 activation, is the induction of PKR-like endoplasmic 
reticulum kinase (PERK) (Yu et al. 2013). 
HCMV, is furthermore, known to interfere with multiple cellular sensors, such AMP-
activated protein kinase (AMPK), which it activates. AMPK is an energy level sensor 
that is activated by high levels of AMP, an indicator that ATP reserves are low in the 
cells. Upon activation, AMPK induces pathways associated with energy production, 
such as glycolysis and FA oxidation, while it inhibits energy consuming pathways, e.g. 
FA synthesis, and stops cell growth (Hardie and Sakamoto 2006; H. M. O’Neill, 
Holloway, and Steinberg 2013). Interestingly, HCMV counteracts some of the adverse 
effects that AMPK would have for its replication by regulating AMPK signalling. For 
example, while, protein synthesis is inhibited by AMPK, the HCMV protein UL38 
supresses that AMPK function, resulting in continued protein synthesis. AMPK 
prevents inhibition of mTOR. When mTOR is deactivated, protein synthesis is 
restricted (McArdle, Moorman, and Munger 2012; Moorman et al. 2008; Mattijssen 
and Pruijn 2012), thus, by inhibiting the inhibition of mTOR, HCMV ensures 
continued protein synthesis for its own benefit. 
Seo and Creswell suggested that this cascade of events might also be regulated by 
HCMV’s interference with Viperin (J.-Y. Seo and Cresswell 2013). Viperin is an type-
I IFN, and to a lesser extent type-II IFN, induced antiviral protein (Mattijssen and 
26 
 
Pruijn 2012). Upon expression, Viperin localises to the ER and lipid droplets, where 
it has divergent antiviral roles (Hinson and Cresswell 2009b, 2009a). These include 
induction of IFN-I production in plasmacytoid DCs (pDCs), inhibition of influenza A 
virion release and inhibiting HCV replication, most likely by inhibiting HCV’s 
interaction with lipid droplets (Saitoh et al. 2011; Xiuyan Wang, Hinson, and 
Cresswell 2007; Mattijssen and Pruijn 2012). 
HCMV induces Viperin independently of IFN, which then associates with a viral 
protein called mitochondrial inhibitor of apoptosis (vMIA). Upon interaction with 
vMIA, Viperin translocate to the mitochondria where it disrupts ATP production from 
β-oxidation of FA (J.-Y. Seo et al. 2011; J.-Y. Seo, Yaneva, and Cresswell 2011; 
Mattijssen and Pruijn 2012). The decreased ATP levels disrupt cytoskeletons 
formation, which has been shown to enhance HCMV replication (Poncet et al. 2006; 
Xin Wang et al. 2005). Additionally, it is proposed that this interaction results in the 
activation of AMPK, which results in increased glucose levels in infected cell that 
activates ChREBP (J.-Y. Seo and Cresswell 2013). Taken together, these indicate that 
HCMV is a master manipulator of cellular metabolism. 
These alterations appear to converge to one metabolic pathway, FA synthesis. 13C 
labelling studies have shown that carbon atoms are shuttled from glucose to citrate and 
then to FA synthesis (Munger et al. 2008). Liu et al. showed that inhibition of HCMV 
alters the lipidome of infected cells so much that fibroblasts produce vesicles that have 
lipid patterns similar to synaptic vesicles (Liu et al. 2011). Inhibition of FA synthesis 
enzymes, ACC and FASN, or FA elongation enzymes results in the inhibition of viral 
replication (Koyuncu et al. 2013). Further examination of the data indicated that the 
virus does not engage de novo synthesis of FA, but preferentially induces FA 
elongation and remodelling of existing FA (Koyuncu et al. 2013). Additionally, 
HCMV pushes FA elongation towards the production of very long saturated FAs 
(VLSFAs). HCMV manages this by upregulating specific elongases, particularly 
Elovl7, which has been shown, albeit in vitro, to facilitate the elongation of saturated 
FA (Purdy, Shenk, and Rabinowitz 2015; Naganuma et al. 2011; Ohno et al. 2010; 
Ofman et al. 2010; Leonard et al. 2002; Tamura et al. 2009; Harkewicz et al. 2012). 
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The advantages of these complicated manipulations of cellular metabolic process by 
HCMV are not clearly understood. However, examination of viral membranes 
indicated that they are enriched with saturated FA and it is known that saturated FA 
are favourable for the curvature of membranes (Munger et al. 2008; Koyuncu et al. 
2013). It is, thus, assumed that HCMV utilises the VLSFAs synthesised in the cells to 
form its viral membrane with the physiochemical properties required for successful 
infection. This hypothesis is in agreement with data that have shown that inhibition of 
FA does not reduce greatly the number of virions, but that it greatly impairs their 
infectivity, indicating that they are not able to properly form and engage with cells to 
infect them(Yu, Maguire, and Alwine 2014). Additionally, Influenza A replication is 
also inhibited by restricting FA synthesis. Treatment of Influenza A infected cells with 
TOFA, a FA synthesis inhibitor, resulted in a reduced number of virions (Munger et 
al. 2008). Since Influenza A has almost no common elements with HCMV apart from 
the fact that it also has a lipid envelope, these results further support the notion that 
FA synthesis is critical for enveloped viruses’ life cycle (Munger et al. 2008). 
On the other hand, HSV-1, another herpes virus, does not induce the same metabolic 
programming. Studies have shown that the metabolic programming of cells infected 
with HSV-1 appears to be the opposite of that in cells infected with HCMV, indicating 
a clear divergence in replication strategies of the two viruses (Vastag et al. 2011). 
HSV-1 still uses FA from host cells to form its membrane, it just does not focus on FA 
synthesis as much as HCMV. It is difficult to understand what lead HCMV to choose 
to adopt such a complicated metabolomic program. Nevertheless, FA synthesis for 
incorporation of FA in its membrane appears to be one reason behind it. 
1.5.4 Metabolism during immunity 
Historically, immunity and metabolism have been viewed as separate fields, however 
recent evidence indicate that these two systems are intimately integrated, share 
resources and cross-regulate each other. Immune cells pre-programme and tightly 
regulate their metabolism upon activation by IFN and/or TLRs. These changes are 
essential to support their effector functions (L. A. J. O’Neill, Kishton, and Rathmell 
2016). During inflammation, different immune cell types adopt different phenotypes 
depending on the inflammatory stimulus. New studies reveal that each phenotype also 
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adopts and depends on a unique metabolomic profile (O’Sullivan and Pearce 2015; 
Cham et al. 2008; Cao, Rathmell, and Macintyre 2014; C.-H. Chang et al. 2013; Chiba 
et al. 2017; Rafael Montenegro-Burke et al. 2016; El Kasmi et al. 2008; Biswas and 
Mantovani 2012; Mills et al. 2016; EL Kasmi and Stenmark 2015; Jha et al. 2015). 
The integration of the two systems appears to be tight and important that even slight 
changes to the metabolism of certain immune cells, e.g. macrophages, can induce a 
change in the phenotype. For example, induction of GLUT1 expression in 
macrophages drive the cells to adopt an M1 (or classically activated) like phenotype 
(Freemerman et al. 2014). Alterations in the metabolism of an immune cell can affect 
the phenotype for the cell. This opens new possibilities for drug intervention on 
immune cell level, as potentially, the immune system could be regulated by inhibiting 
specific metabolic pathways without affecting cell viability (L. A. J. O’Neill, Kishton, 
and Rathmell 2016; Kotzamanis, Angulo, and Ghazal 2015). 
1.5.5 Metabolism in macrophage and dendritic cells 
While macrophages (MΦ) and dendritic cells (DCs) exhibit differences regarding 
phenotype and function in disease, the two cell types share quite a few similarities. 
Some similarities appear to be in the metabolomic profile that both cell types adopt 
when they are activated by TLR receptors in classical manner. This similarity might 
be explained by the fact that these cells types during infection have similar energy and 
metabolites requirements during infection and may explain similar metabolic profiles. 
Both MΦ and DC needs to phagocyte and process antigens. Τhe process and functional 
outcome behind phagocytosis might be different in each cell type, but the function is 
similar and should have similar metabolic requirements. Moreover, both cell types 
need to produce huge amounts of cytokines to coordinate the immune response, to 
external stimuli both by the host and the pathogens and finally resolve inflammation. 
It has recently become obvious that for all these processes, even resolution of 
inflammation, metabolism plays a pivotal role. 
Differences between the two cell types are expected to exist but it is not clear yet if, 
and which, subtle differences should be attributed to differences between the cell types 
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and/or differences in treatment. Macrophages and DCs are extremely plastic cells and 
slight differences in treatments might produce different results. Macrophages for 
example have been distinguished into distinct phenotypes for a long time. M1 
macrophages are macrophages treated with LPS or LPS+IFN-γ. These macrophages 
are associated with inflammation and are mobilised during viral, bacteria and/or fungal 
infections. M2 macrophages are macrophages treated with IL-4 and they have anti-
inflammatory properties and promote wound healing. They are associated with Th2 
immune response to helminths and other parasites. Macrophages though are highly 
plastic cells that respond to a plethora of stimuli and recent studies though have 
indicated that there is a big spectrum of activated macrophages rather than just these 
two extreme examples(Mosser and Edwards 2008). 
Conventional dendritic cells (cDCs) and Macrophages (ΜΦ) engage aerobic 
glycolysis when they are activated under certain conditions. cDCs dramatically 
increase their glucose uptake and lactate production upon TLR stimulation (Everts et 
al. 2014) and ΜΦ adopt, in a similar manner, a highly glycolytic metabolism in the 
presence of oxygen (Jha et al. 2015). This adaptation might appear unexpected because 
of the inefficiency glycolysis has in generating energy, but it has been shown to be 
important for these cell types. Both macrophages and dendritic cells have been shown 
to produce nitric oxide (NO) during inflammation by inducing expression of inducible 
Nitric oxide synthase (iNOS). NO has bacteriostatic effect, but also inhibits OXPHOS 
by inhibiting complexes I, II and IV of the electron transport chain (Beltrán et al. 2000; 
Everts et al. 2012). Thus, the switch to glycolysis is necessary for the cells to survive 
as it has been shown for DCs, that inhibition of glycolysis by 2 Deoxyglucose (2-DG) 
prevented the cells from becoming activated (Everts et al. 2012). 
The mechanisms that drive these changes appear to be complex and work on the 
transcriptional and post transcriptional level. TLR stimulation greatly induces 
expression of several genes encoding enzymes associated with glycolysis in 
macrophages, such as pyruvate kinase isoenzyme M2 (PKM2), GLUT1 and 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3). PKM2 catalyses the 
last step in glycolysis, GLUT1 facilitates import of glucose in the cells and finally 
PFKFB3 produces fructose-2,6-biphosphatase. PFKFB3 is an allosteric activator of 
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phosphofructokinase (PFK) that catalyses one of the rate limiting step of glycolysis(De 
Bock et al. 2013). In DCs it has been shown that TBK1-IKKε, through Protein kinase 
B (PKB or AKT), promotes glycolysis by translocating hexokinase 2 (HK2) to the 
mitochondrion where it presumably has access to increased levels of ATP which 
increases turnover time(Everts et al. 2014). 
In addition of the glycolytic pathway, the glucose shunt through the Pentose Phosphate 
Pathway (PPP), is also greatly increased in proinflammatory macrophages and DCs. 
Shunting glucose through PPP offers an alternative way of oxidising glucose, which 
re-enters the glycolytic pathway at a later stage, while at the same time allow for the 
generation of NADPH (Wamelink, Struys, and Jakobs 2008). NADPH is vital for M1 
macrophages and DCs as it is used for the generation of reactive oxygen species (ROS) 
(Singh et al. 2017). It is also used to reduce glutathione and prevent damage caused by 
oxidative stress and generated ROS.  
Sedoheptulose kinase (SDK or CARKL) has been demonstrated to play a critical role 
in regulation of PPP and glucose by providing Sedoheptulose-7P (S7P) independently 
of glucose (Nagy and Haschemi 2013). High S7P levels negatively regulate hexose 
phosphate isomerase and block fructose phosphorylation by phosphoglucose 
isomerase (Nagy and Haschemi 2013). LPS signalling supress SDK, which in turn has 
a positive effect on the PPP and glycolytic pathways. Contrary to M1 macrophages, 
M2 macrophages upregulate CARLK and, thus, limit the shunt in both pathways 
(Haschemi et al. 2012). 
Inflammation and metabolism are tightly interlinked. Pro-inflammatory cytokines and 
signals promote glycolysis while anti-inflammatory cytokines, such as IL-10, limit 
glycolysis in DCs. IL-4 activated macrophages (alternatively activated ΜΦ or M2 
ΜΦ) exhibit intact OXPHOS and limited glycolysis (Jha et al. 2015; Ganeshan and 
Chawla 2014). Additionally, not only proinflammatory signals and cytokines drive a 
specific type of metabolism, but metabolism can also dictate the phenotype of the cell. 
For example, macrophages overexpressing GLUT1 adopt a phenotype that is pushed 
towards the M1 spectrum(Freemerman et al. 2014). Arguably, the study was 
performed in RAW264.7 cells, which would have their own metabolic adaptations 
since they are a stable cell line and not primary cells.  
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There are on the other hand other metabolites, prostaglandins, that are known to act as 
inflammatory signals and that have been studied more extensively. Prostaglandins are 
the most well studied metabolites that, amongst others, during inflammation function 
as paracrine and endocrine signalling lipid molecules. Prostaglandins are a subset of 
prostanoids, a class of molecules that are derived from arachidonic acid (AA). All 
prostaglandins are oxygenated 20 carbon atoms long fatty acids that contain a 
cyclopentane ring(Bos et al. 2004). 
When it is required, AA is released from phospholipids by lipases. The released AA is 
converted to prostaglandin G2 (PGG2), the precursor molecule of all prostaglandins. 
This conversion is catalysed by cyclooxygenase (COX), which exists in two forms. 
COX-1 is constitutively expressed and COX-2, is not, but is greatly induced by stimuli 
such as LPS(Funk et al. 1991; Herschman 1996; Aderem et al. 1986). There are 4 
different prostaglandins, prostaglandin E2 (PGE2), PGD2, PGF2and PGI2. The 
produced prostaglandin profile differs depending on cell type. Macrophages produce 
mainly prostaglandin E2 (PGE2), while mast cells mainly produce PGD2 (Tilley, 
Coffman, and Koller 2001). After their production, prostaglandins act as signals that 
can regulate the function of immune cells, including DCs and macrophages. 
Prostaglandins can both promote or attenuate inflammation depending on the setting 
and cell type making (Ricciotti and FitzGerald 2011). 
Succinate has also been shown to act as a proinflammatory signal through different 
mechanisms in MΦ and DC. In ΜΦ, succinate accumulation inhibits propyl 
hydroxylases (PHD) from hydroxylating their target proteins, including hypoxia-
inducible factor 1 (HIF-1α) (EL Kasmi and Stenmark 2015) . This results in HIF-1α 
stabilisation and increasing expression of IL-1β and glycolytic enzymes, among others 
(EL Kasmi and Stenmark 2015; Tannahill et al. 2013). Accumulated succinate also 
increases production of reactive oxygen species (ROS), by the mitochondria, which 
also can inhibit PHDs and further stabilise HIF-1α (Brunelle et al. 2005; Dröse 2013; 
Infantino et al. 2011).  TLR signalling greatly induces ROS, enhancing the bactericidal 




These described changes might be useful as ΜΦ need to mount a robust immune 
response in open wounds and other environments where oxygen is low (Palazon et al. 
2014; Nizet and Johnson 2009). More recently, studies have found that high succinate 
levels on their own are not sufficient to act as proinflammatory signal, but that 
succinate dehydrogenase (SDH) function and high mitochondria membrane potential 
is also required (Mills et al. 2016). Under these conditions it has been shown that SDH 
contributes to the generation of ROS through reverse electron transport (RET) 
although whether this is the mechanism that contributes to the effects of succinate 
remains unresolved (Mills et al. 2016; Votyakova and Reynolds 2001; Lambert and 
Brand 2004). 
These metabolic alterations have profound effects on the TCA cycle of ΜΦ and DCs. 
M2 macrophages have an intact and functioning TCA along with OXPHOS. It is 
believed that one of the functions that this serves in M2 macrophage, is the 
glycosylation of receptors associated with M2 function (Jha et al. 2015; Palsson-
McDermott et al. 2015). On the other hand, in M1 MΦ, the TCA cycle breaks down at 
the succinate, as described above, and at citrate (Andreyev et al. 2010). Citrate is one 
of the major carbon sources for FA synthesis (Hatzivassiliou et al. 2005). Numerous 
studies have demonstrated that both macrophage and DC shuttle carbon atoms from 
glucose to FAS through citrate (Feingold et al. 2012; Jha et al. 2015; Andreyev et al. 
2010; Everts et al. 2014). In activated DCs, the newly produced FAs have been shown 
to be utilised to expand the ER and Golgi to support the increased requirement for 
protein synthesis and secretion (Everts et al. 2014). Similarly, fatty acids were found 
to be important for supporting the phagocytic function in macrophages (Ecker et al. 
2010).Thus, these changes are essential for DCs and macrophages to transform 
themselves from small quiescent cells into potent phagocytes that secrete a vast 
number of cytokines and present antigens. 
A recent study has indicated that FA synthesis might play a crucial role in regulating 
inflammation. It was demonstrated that SREBP1 contributes to resolution of 
inflammation by altering FA metabolism (Oishi et al. 2016). In the resolution phase of 
inflammation, SREBP1 is activated and promotes the transcription of FAS enzymes 
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that generate FA with anti-inflammatory properties such as Docosahexaenoic acid 
(DHA) and Eicosapentaenoic acid (EPA) (Oishi et al. 2016). 
The TCA cycle is also linked to NO production through the arginosuccinate shunt (J. 
MacMicking, Xie, and Nathan 1997). NO is critical for clearance of bacteria by 
macrophages (Qualls et al. 2012; Morris 2004; El Kasmi et al. 2008). The 
arginosuccinate shunt has been shown to be upregulated in M1 macrophages (Jha et 
al. 2015) and citrulline is produced at high levels in Μ1 ΜΦ during NO synthesis 
(Qualls et al. 2012). This excess citrulline along with aspartate from the malate 
aspartate shunt can be utilised by Argino-succinate synthase (ASS) to synthesise 
arginosuccinate. Arginosuccinate in turn can be broken down to arginine and fumarate 
by arginosuccinate lyase (ASL).  
The remodelling of the aspartate-malate shuttle and arginosuccinate shunt allows the 
macrophage to be autotrophic - support its requirements without external 
replenishment - for arginine, which is essential for NO synthesis by iNOS (J. 
MacMicking, Xie, and Nathan 1997). Additionally, the produced fumarate can 
replenish the TCA cycle. It could possibly also reinforce the generation of succinate 
by reverse function of SDH, although this has not yet been demonstrated in 
macrophages (Chouchani et al. 2014). Nevertheless, the ability to generate NO, 
regardless of the availability of arginine in the environment, is undisputed for M1 
macrophages.  
There is an interesting association between the fate of arginine in macrophages and 
their cell phenotype. Arginine can either be utilised by iNOS to produce NO or 
converted by Arginase (ARG) to ornithine (Rath et al. 2014). The first reaction is 
associated with proinflammatory response while the second is associated with the arise 
of a tolerogenic and wound healing phenotype in macrophages (Albina et al. 1988; 
Campbell et al. 2013).  
Finally, fatty acid oxidation (FAO) is another pathway that is altered during activation 
of macrophages. FAO takes place in the mitochondria and peroxisomes depending on 
the length of the FA. It is believed that FA longer than 22 carbon atoms are first 
oxidised in peroxisomes, to the size of medium chain acyl-CoAs, and then transported 
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to the mitochondria where they are further oxidised(Wanders, Waterham, and 
Ferdinandusse 2016). Peroxisomes are also able to oxidise odd-number and 
unsaturated fatty acids. FAO starts with the transfer of FA by carnitine palmitoyl 
transferase I (CPT1) and carnitine palmitoyl transferase II (CTP2) in mitochondria. In 
peroxisomes, the same function is performed by ATP-binding cassette (ABC) 
transporter ABCD1 and ABCD2. 
In immunity, increased FAO is associated with an anti-inflammatory phenotype(L. A. 
J. O’Neill, Kishton, and Rathmell 2016). Early studies indicated that M2 macrophages 
rely on FAO, which is perpetuated through PPARγ-co-activator 1β (PGC1β) and 
Signal transducer and activator of transcription 6 (STAT6) (Vats et al. 2006). This was 
further substantiated by a later study in murine macrophages (S. C.-C. Huang et al. 
2014). Interestingly, a study in human macrophages indicated that FAO was not 
essential for human macrophages (Namgaladze and Brüne 2014). A later short report 
indicated that mice CTP2 deficient BMDM were able to fully acquire a M2 phenotype 





Figure 1.4 Macrophage metabolism during immunity. A) M1 ΜΦ are characterised by increased i) glycolytic shunt via increased glucose 
import and upregulation of the glycolytic pathway on the transcriptional and posttranscriptional level ii)   
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increased oxidation of glucose via the PPP and production of NADPH. iii) The TCA 
cycle is broken down and citrate is shuttled out of the mitochondrion to provide carbon 
atoms for vi) FA synthesis. iv) OXPHOS does not operate and the electron transport 
chain (ETC) is utilised to produce ROS. v) Glutamine is imported into the cell to 
replenish the TCA cycle and help maintain the mitochondria. Finally, vii) the 
arginosuccinate shunt is utilised to produce NO, which has important bacteriocidic 
properties and viii) FAO is present on a basal level. B) M2 MΦ are characterised by 
i) low glycolysis and low ii) PPP shunt. Upregulation of SDK inhibits the PPP and 
glycolysis. Instead of glycolysis, M2 ΜΦ rely on viii) FAO for energy generation. iii) 
The TCA cycle and iv) are functional and intact, and glutamine is utilised to produce 
Polyamines or to replenish the TCA cycle. Finally, vii) arginine is catabolised to 
ornithine by arginase and not utilised for the generation of NO Glc: Glucose; G6P: 
Glucose-6-Phosphate; F6P: Fructose-6-Posphate: F1-6BP: Fructoce-1,6-Phosphate; 
Pyr: Pyruvate; Lac: Lactate; FAO: Fatty acid oxidation; CTP: Carnitine 
Palmitoyltransferase; Ac-CoA: Acyl-CoA; GLN: glutamine; GLU: Glutamate Cit: 
citrate; NO nitric oxide; ArgSc: ArgininoSuccinate; Arg: Arginase; OTC: ornithine 
transcarbamylase; Orn: Ornithine. Adopted from (Ghesquière et al. 2014) and altered. 
Another piece of evidence linking decreased FAO with increased inflammation comes 
from a study on X-linked adrenoleukodystrophy (X-ALD). In X-ALD patients, 
mutations in the ABCD1 gene cause neurodegeneration and inflammatory cerebral 
demyelination (Engelen et al. 2012).  The microglia and bone marrow derived 
macrophages appear to be the main drivers of the disease progression in humans. 
In mice, however, X-ALD does not exhibit the same strong phenotype as in humans. 
Previous studies have demonstrated that murine Abcd1 deficient macrophages 
exhibited a highly pro-inflammatory phenotype because of accumulation of very long 
chain saturated fatty acids (VLCSFA) (Yanagisawa et al. 2008). Using Abcd1 and 
Abcd2 single and double deficient mice, Muneer et al. demonstrated that ABCD2 
compensates partially for ABCD1 function. In mice deficient for both both Abcd1 and 
Abcd2, VLCFA accumulated at an increased rate in comparison to single Abcd1 
knockouts (KO) (Muneer et al. 2014). Based on their observations, and the fact that 
human BMDM and microglia do not express ABCD2, they hypothesised that this is 
the driver behind the metabolic phenotype in humans. Thus, BMDM and microglia in 
humans with X-ALD rapidly accumulate VLCFA and become more proinflammatory 
exacerbating the progression of the disease. These differences between mice and 
human macrophages reveal the complexity of immunometabolism and how small 
differences at the site of inflammation and the genetic background of the cells can lead 
to great differences in the outcome of an infection, and or other underlying pathology. 
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Interestingly, there is a great deal of studies in other human pathologies that reveal a 
correlation between accumulation of FA and lipoproteins and inflammation(Lusis 
2000; Shoelson, Lee, and Goldfine 2006). Additionally, proinflammatory 
macrophages exhibit only basal levels of FAΟ (Ghesquière et al. 2014). Finally, in 
conjunction with the above, overexpression of CPT1A in human macrophages 
increased FAO and reduced the production of inflammatory cytokines (Malandrino et 
al. 2015).  
Despite the huge advances in the field of immunometabolism, little has been done to 
study metabolism and immunity in the context of infection. Most of the studies 
presented above are examining metabolism during immunity using either ΜΦ or DC 
that have been activated by TLRs. Usually the TLR ligand used is LPS, which is 
prototypical of a response to bacterial infection, specifically by gram negative bacteria. 
During an immune response, immune cells are going to be engaged by numerous PRRs 
and cytokines, which should further tune metabolism and immune response. 
Furthermore, bacterial infections are different from viral ones, especially when the 
pathogen can infect immune cells, like MCMV infects ΜΦ. In this case, ΜΦ integrate 
signals from immune signalling, metabolism and the pathogen itself. 
1.5.5.1 Metabolism in T cells 
The changes observed in the metabolism of macrophages and DCs upon activation are 
not only limited to cells of the innate immune system. Cells of the adaptive immune 
system exhibit similar alterations to their metabolism. 
The adaptive immune system is comprised of T lymphocytes and B lymphocytes. T 
lymphocytes are key elements of the immune system and they include a wide subset 
of cells, including CD4+ (helper) and CD8+ T (cytotoxic) cells. These cells are 
important in the process of eliminating pathogens and regulating the progression of 
non-infectious diseases such as cancer and diabetes 2 (Iwasaki et al. 2015; Gajewski, 
Schreiber, and Fu 2014; Eheim, Medrikova, and Herzig 2014). There are three stages 
that T cells undergo when mounting an immune response: priming, expansion and 
contraction. Each stage in the life of a T cell has different metabolic demands, which 
need to be met to ensure that the cell can realise its function. 
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Similar to quiescent cells, naïve T cells have low metabolic demands and, thus, a 
similar metabolic phenotype. Upon priming by an antigen, T cells are activated and 
must undergo great metabolic changes to support their need to rapidly proliferate and 
generate large amounts of cytokines. After expansion and clearance of the pathogens, 
a small population of antigen-specific long-lived memory T cells (T memory cells, 
TM) is left behind (Pearce et al. 2013). 
All effector T cell subtypes, including CD8+ T cells, T helper cells1 (TH1), T helper 
cells17 (TH17) and T helper cells2 (TH2) have been shown to rely heavily on 
glycolysis(Shi et al. 2011; Gubser et al. 2013; Michalek et al. 2011; Buck, O’Sullivan, 
and Pearce 2015). Despite this, and unlike DCs and MΦ, effector T cells have 
functional TCA and OXPHOS, and can function without glycolysis, but with impaired 
effector functions (C.-H. Chang et al. 2013; Sena et al. 2013; Cham et al. 2008). T 
effector cells have increased FAS while at the same time reduced FAO (Robichaud et 
al. 2013; Metallo et al. 2011). On the other hand, T regulatory cells (Treg) rely heavily 
on FAO and not glycolysis (Michalek et al. 2011). Similar to myeloid cells, changes 
in the metabolism of T cells can influence their phenotype; inhibition of FA synthesis 
in TH17 was shown by Berod et al. to result in the acquisition of a Treg phenotype 
(Berod et al. 2014). 
TH17 cells are important cells during inflammation, but some can become 
“pathogenic” by inducing tissue inflammation and promoting responses to self-
antigens. A study demonstrated that the expression of CD5 antigen-like (CD5L) in 
TH17 promotes a non-pathogenic phenotype by regulating lipid metabolism in TH17 
(C. Wang et al. 2015). CD5L appears to bind fatty acid synthase and promote the 
generation of polyunsaturated fatty acids (PUFAs). It is hypothesised that PUFAs 
modulate cholesterol metabolites, which act as agonists for RAR-related orphan 
receptor gamma thymus (RORγt). This prevents RORγt from upregulating the 
expression of Il-23 and Il-17 synthesis, while at the same expression of Il-10 is 
increased (C. Wang et al. 2015). 
 Oishi et al. (presented above) has demonstrated that during resolution of 
inflammation, ΜΦ alter their FA metabolism to attenuate inflammation (Oishi et al. 
2016). Together, these two studies demonstrate clearly the ability of metabolism, and 
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lipid metabolism, to influence the outcome of inflammation during pathogen evasion 
or other pathology. This is now an area of intense research.  
1.6 Rationale and experimental design 
Accumulated evidence in the last 15 years support the notion that metabolism and the 
immune system interact and regulate each other in ways that were not though of 
previously. Immune cells have been demonstrated to drastically alter the metabolism 
upon immune activation in a clear and defined manner. These metabolic adaptations 
are important for the cells to acquire their effector functions and complete their 
function. 
On the other hand, viruses are extreme parasites that exploit and counter pathways, 
including metabolism, to effectively propagate. HCMV alters the metabolism of 
infected host cells in a way that resembles the metabolism that proinflammatory 
macrophages acquire when they become activated in a classical manner. Moreover, 
macrophages play a critical role in the dissemination and infection strategy of this 
clinically important pathogen. 
Viruses are known to exploit and counter-act signalling of the immune system. The 
parallels between the metabolism of HCMV infected cells and classically activated 
macrophages indicate that, metabolism might be a novel mechanism which viruses can 
exploit to subvert the immune response. Thus, I will attempt to investigate this 
integrative process by studying the metabolic programming of macrophages infected 
with MCMV. 
The main hypothesis of the thesis is that productive infection of macrophages by 
MCMV takes advantage of the early metabolomic reprogramming of activated 
macrophages, and modulates metabolism at late stages of infection towards fatty acid 
production to promote viral progeny. 




i. Does MCMV upon infection, similar to HCMV, alter the metabolomic 
programming of macrophages towards fatty acid synthesis? 
ii. Is metabolism of macrophages during early times of productive and non-
productive MCMV infection similar at the transcriptional and metabolomic 
level? 
iii.   Is metabolism of macrophages during late times of productive and non-
productive MCMV infection different? 
iv. Does productive MCMV infection alter the metabolism of infected 
macrophages and promote FA synthesis? 
v. Does MCMV infection take advantage of prostaglandin metabolism, a key 
component of FA metabolism, to evade the immune system response? 
Taking all these considerations into mind in the thesis presented here I attempt to study 
immunometabolism by employing a more suitable model. A novel and crucial aspect 
of my work is employing a viral infectious agent to study metabolism in immunity. To 
achieve this I, utilise a series of transcriptomics and metabolomics studies in 
combination with pharmacological/siRNA inhibition of metabolic pathways in an in 
vitro model for host pathogen interaction. In my model system, to study metabolism, 
MCMV is used as the model for viral infection and Bone Marrow Derived 
Macrophages (BMDM) are utilised as a model for the immune system. Crucially, 
MCMV is a natural infectious agent for murine BMDM and, thus, the generation of 
artefacts is reduced. 
In my model system, I mainly utilise MCMV-pSM3fr and MCMV-pSM3frdie3 strains 
(from now on MCMV-WT and MCMV-KO). MCMV-WT can infect and produce 
virally progeny (productive infection), while MCMV-KO can infect cells, but it does 
not produce infectious virions. BMDM were infected with both strains and from the 
analysis of the data between productive and non-productive infection the host-directed 
versus, virus-driven metabolic alterations could be unravelled.
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2 Chapter 2 Materials and Methods 
2.1  Cell cultures 
2.1.1 Cell lines 
All cell lines used in this thesis were grown at 37°C and 5% CO2 in tissue culture flasks 
or dishes (Corning, UK), and were handled in a class 2 tissue culture hood. The NIH-
3T3 immortalized cell line of embryonic mouse fibroblasts was obtained by American 
Type Culture Collection (ATCC) (Manassas, VA, USA). They were grown in 
Dulbecco's modified Eagle medium (DMEM) (Lonza, UK), supplemented with 5% 
calf serum (CS) (Invitrogen, UK), 2mM glutamine (Lonza, UK) and 100U/ml of 
penicillin/streptomycin (Lonza, UK). NIH-3T3-Bam25 cells were derived by co-
transfection of the pBam-25 and pPUR plasmid in NIH-3T3 cells, as previously 
described(Angulo, Ghazal, and Messerle 2000). The same growth conditions were 
used as for NIH-3T3 cells. p-53-/- Murine Embryonic Fibroblasts (MEF p53-/-) were 
purchased from ATCC. They were grown in DMEM, supplemented with 5% fetal calf 
serum (FCS) (Invitrogen, UK), 2mM glutamine and 100U/ml of 
penicillin/streptomycin. RAW264.7 murine macrophages from blood were grown in 
DMEM supplemented with 10% FCS, 2mM glutamine and 100U/ml of 
penicillin/streptomycin.  
2.1.2 Bone Marrow Derived Macrophages (BMDM) 
C57BL/6 JCR male mice, aged between 7 and 14 weeks were obtained and culled from 
Chancellor’s Building animal unit. Femur and Tibia bones, extracted from the hind 
legs of the mouse, were flushed in a 50ml flacon tube that contained DMEM/F-12 
(Ham 1:1) and L-glutaMax (LONZA, UK). The supernatant with the cells was passed 
through a 50 μm cell strainer and then centrifuged at 244 x g for 5 minutes at room 
temperature (RT). The supernatant was removed and the pellet was resuspended in 
DMEM/F-12 (Ham 1:1) and L-glutaMax, supplemented with 10% FCS, 10% L929 
and 100U/ml of penicillin/streptomycin. The cells were counted and seeded in 6 well 
(1 x 106 cells/ml) or 24 well (2.5 x 105) plates for 7 days. The medium was replenished 
on days 3 and 5. On day 7 the wells cells were ready for treatment. 
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2.1.3 Primary Murine Embryonic Fibroblasts(pMEFS) 
Embryos, aged 7-14 weeks, were obtained from C57BL/6 JCR mice. From the 
embryos the brain, intestines and eyes were removed and subsequently placed in 10 
cm dishes that were placed on ice. The embryos were homogenized manually using 
razor blades. The homogenized tissue was then suspended and stirred, for 1 hour at 
37°C, in a Falcon tube containing 30 ml 1x trypsin and glass pellets. An additional 30 
ml of 1x trypsin was added every 30 minutes. The cells were then filtered centrifuged 
at 244 x g for 5 minutes and washed 3 times with PBS, followed by collection and re-
suspension in EMEM (Lonza, UK) supplemented with 10% FCS, 2mM glutamine and 
100U/ml of penicillin/streptomycin. The cells were counted using haemocytometer 
and seeded in 175cm2 flasks (1 x 107 cells/flask). The following day, cells were washed 
once with 1x PBS to remove erythrocytes. The culture was then left to reach a 
confluency of 80%. Upon reaching that confluency, cells were harvested and then 
either frozen for later use or passaged for use. 
2.1.4 Preparation of L929 conditioned media for BMDM differentiation 
L929 cells were obtained from Sigma, UK. L929 cells are subclones of the parental 
strain that is derived from subcutaneous areolar and adipose tissues of the C3H/An 
male mouse strain. L929 cells produce Macrophage Colony Stimulating Factor 1 
(CSF-1), a cytokine essential for the survival, proliferation and differentiation of 
hematopoietic stem bone marrow cells into macrophages. L929 were grown in 
DMEM/F-12 (Ham 1:1) and L-glutaMax supplemented with 10%FCS and 100U/ml 
of penicillin/streptomycin for 14 days. The medium was then collected, sterile filtered 
and checked for the presence of endotoxin and mycoplasma. Each new batched of 
L929 media was tested for its ability to induce BMDM differentiation. 
2.1.5 Characterisation of BMDM by Flow cytometry 
Macrophages express on their surface a variety of markers than can be used to assessed 
the efficiency of differentiation by Flow cytometry. To ensure the maturation stage of 
BMDM after 7 days of maturation, cells were stained for F4/80 and CD11 markers.  
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On Day 7 of maturation, cells were washed twice with PBS and scraped off the bottom 
of the cell plates. The cells were then transferred to polystyrene FACS tubes (BD 
Falcon, UK). The tubes were centrifuged at 1,000 g for 5 minutes at 4°C to isolate the 
cells. The cells were washed twice with cold PBS (4°C) and suspended in blocking 
solution (Flow cytometry buffer +0.5μg/ml of Mouse BD Fc blockTM (BD 
Biosciences, UK:cat.no.553142) + 10% mouse serum  (Invitrogen, UK:cat.no.10410)) 
for 10 minutes on ice to avoid non-specific antibody binding.  The cells were then 
incubated, for 1 hour at RT, with Rat anti-mouse F4/80-PE (Invitrogen, UK, 
cat.no.MF48004) and with Rat anti-mouse Cd11b-FITC (Caltag, UK, cat. no. 
RM2801), which were both diluted 1:100 in flow cytometry buffer. Then the cells were 
washed three times with flow cytometry buffer and the pellet was suspended in 300 μl 
flow cytometry buffer. The cells were then transferred to ice for flow cytometry. The 
staining experiments were performed in collaboration with Dr. Muhamad Fairus Noor 
Hassim or Alan Ross. A BD FACScalibur (BD, UK) instrument was used to analyse 
the samples and FlowJO software (Treestar, USA) was used to analyse the data. 
2.1.6 Cell freezing protocol 
Cell were removed from their flask/dish with the use of trypsin, transferred to a 50 ml 
Flacon tube and centrifuged at 244 x g for 5 minutes. The pellet was then re-suspended 
in media containing 90% FCS or CS depending on the cell type and 10% DMSO. The 
media was then aliquoted into 1.8ml cryovials, which were placed in a 
cryopreservation chamber and kept overnight at -80°C before transfer to Liquid 
nitrogen for long-time storage. 
2.1.7 Thawing of Frozen cells  
Cryovials containing frozen cells were quickly thawed in a water bath at 37°C. The 
thawed cells were then transferred to a 50 ml Falcon tube that contained appropriate 
media, followed by centrifugation at 244 x g for 5 minutes. The pellet was re-
suspended in appropriate media and transferred to a T75 flask (T25 for (pMEFS)). The 




2.1.8 Cell passaging 
Cells were expanded by passaging them 1:10 – 1:2 depending on the cell type. 
Cultured cells were allowed to reach 70-80% confluency and were subsequently 
incubated with trypsin/EDTA for a few minutes at 37°C to allow cells to detach from 
the flask surface. After the cells were detached from the flask, the cells were collected 
in 50 ml falcon tubes and mixed with an equal volume of fresh media. The cells were 
then pelleted by centrifuged at 244 x g for 5 minutes and re-suspended in an 
appropriate cell media volume and re-seeded in new tissue flasks. The maximum 
passage number was 25 times. 
2.1.9 Cell counting and seeding 
In order to seed an appropriate number of cells in well plates, cell concentrations were 
determined by cell counting. To count cells, 10 μl of suspended cells were diluted in 
the appropriate volume of 0.4% Trypan Blue stain, (Invitrogen, UK). 10 μl of the 
solution was injected into a haemocytometer chamber and the number of alive cells 
per square was calculated using the formula. 


=  ∗ 	
 ∗ 10 
 N = number of cells counted 
 df= dilution factor 
2.2 General methods of virology 
2.2.1 Viruses 
MCMV-C3X (referred to as MCMV-WT in this thesis) was obtained from the 
recombinant bacterial artificial chromosome clone pSM3fr, which itself was derived 
from MW97.01(Messerle et al. 2000). Construction of the pSM3frdie3 mutant 
(referred to as MCMV-KO in this thesis) is described by Angulo et al. (Angulo, 
Ghazal, and Messerle 2000). MCMV-KO lacks the immediate Early (IE) 3 gene and 
is unable to replicate. From this mutant, a GFP-encoding revertant was constructed 
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originally named pSM3fr-rev (termed MCMV-GFP in this thesis). Figure2.1 shows a 
representation of the MCMV genome and its mutants. 
 
Figure 2.1 Schematic representation of the MCMV genome and its mutants. (A) 
The MCMV the region containing immediate early (IE) genes and the MCMV 
enhancer is expanded to reveal the structure of the ie1, ie2 and ie3 genes. Coding 
exons are shown in black and noncoding exons are shown as white rectangles. The 
arrows indicate the direction of transcription. (B) The parental MCMV strain derived 
from bacterial artificial chromosome clone pSM3fr. (C) MCMVdie3 strain (D) The 
MCMVdie3rev strain, which contains a GFP reporter gene (green box) and a HCMV 
enhancer (yellow) to promote GFP transcription. Adopted from (Angulo, Ghazal, and 
Messerle 2000) 
While this thesis was conducted, it was uncovered that the MCMV pSM3fr strain used 
to derive all the previously mentioned strains had a single base pair deletion positioned 
in the m129 ORF. This deletion affects the MCMV-encoded chemokine 2 (MCK2) 
resulting in a non-functional product(Jordan et al. 2011). The MCK2 protein has been 
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used to demonstrate increased viral titre in salivary glands of MCMV infected adults 
BALB/c mice(Fleming et al. 1999). Additionally, as described in the introduction, it 
has been proposed that MCK2 attracts myeloid cells helping the promotion of 
monocyte-associated dissemination within the host (Saederup et al. 1999). 
2.2.2 Preparation of virus stock 
Cells were seeded in flasks until they reached 70-80% confluency. The cells were 
subsequently infected with virus at a Multiplicity of Infection (MOI) of 0.001 plaque 
forming units per cell (PFU/cell). After 5-7 days, depending on the state of the culture, 
the cells with the media was harvested and stored at -80°C. 
2.2.3 Concentration and purification of viral stock 
The harvested virus media (stock) is not useful in the form that it is collected (see 
section 2-2-2) because of the low viral titre. In order to increase the viral titre and 
purify prepared stocks, the harvested virus was concentrated using high-speed 
centrifugation.  The harvested media containing the virus was centrifuged at 7,500 rcf 
for 20 minutes at 4°C. The Supernatant (SN1) was then kept on ice and the pellet was 
re-suspended in a total of 10 ml media and homogenized using a homogenizer. The 
mixture containing the disrupted cells was then centrifuged at 3,600 rcf for 20 minutes. 
Following centrifugation, the produced supernatant (SN2) was pooled with SN1, 
centrifuged at 30,000 rcf for 3 hours 4°C.  
Following ultracentrifugation, the SN was discarded and the pellets are collected and 
re-suspended in maximum 4 ml and disrupted by homogenision in a homogenizer. A 
20% sorbitol solution was added to 30 ml centrifuge tubes, into which the 
homogenized viral concentrate was then slowly pipetted (on top of the sorbitol). The 
tubes were then centrifuged at 30,000 rcf for 3 hours. The pellet was collected, re-
suspended in a total volume of 3 ml 20% sorbitol solution, aliquoted into Eppendorf 
tubes and frozen at -80°C. 
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2.2.4 Viral infection assays. 
Cells were seeded, one day prior to infection, into plates at the appropriate cell density. 
Based on the desired MOI and the cell number, the right viral PFU was calculated. 
Subsequently, the appropriate amount of virus was mixed with infection media and 
added to the plates. The virus was allowed to adsorb to the cells for 1 hour, after which 
the virus-containing media was removed. The cells were washed two times with 1x 
PBS and growth media was added. In the case of NIH-3T3, cells were not washed 
following adsorption due to the fragile nature of this cell strain. 
2.2.5 Viral titration (Plaque assay) 
The plaque assay is an assay to determine the viral titre and it is considered the gold 
standard. P53-/- MEF cell were seeded the day before in 24 well plates at a density of 
5x 104 cells/well. Serial dilutions of the samples that were to be titred were prepared 
and then used to infect the P53-/- MEF cells prepared earlier. After the adsorption 
period the cells were covered with growth media mixed with 2.5% agarose for a final 
concentration of 0.36%. After 3-4 days, the number of plaques formed on the 










Of note, the MCMV-KO strain cannot be titred in p53-/- MEF cells as it is unable to 
replicate. For this strain the Bam-25 cell line was used that expresses the IE3 gene, 
thus, allowing the virus to replicate. 
2.3 Genomics techniques 
2.3.1 qRT-PCR for quantitation of mRNA transcripts 
qRT-PCR is employed to quantify the relative abundance of mRNA transcripts. The 
mRNA isolated from harvested cells is transcribed into cDNA by reverse trancriptase. 
The cDNA transcripts are then amplified by PCR and the relative quantity is 
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determined by first normalizing the expression relative to the internal control values. 
based on comparative analysis of their Ct values.: The normalized data is then used to 
quantify the relative concentration of a given mRNA in accordance with the 
comparative cycle threshold (2−ΔΔCT) analysis(Livak and Schmittgen 2001; Lyman 
and Enquist 2009) 
2.3.2 One Step qRT-PCR 
Automated isolation of RNA from harvested cells was performed using Qiagen 
RNAeasy® Plus Mini Kit (cat. no. 74136) and QIAcube (Qiagen).  
All one step qRT-PCRs performed for this thesis had RT negative controls to ensure 
that the sample did not contain DNA contamination and non-template controls to 
ensure there was no RNA contamination. Quanta 1-Step RT-qPCR ToughMix (95123) 
was used to perform all the qRT-PCR assays. The assay was performed in 96 well 
plates supplied by ThermoScientific (AB-0600/W) on a MXPRO3000P cycler 
(Stratagene, CA, USA). All the probes/primes were obtained by Life Technologies and 
their details can be reviewed in the appendix. All reactions were performed in 10 μl 
volumes using 25-75 ng of total RNA. 
The reaction started with a 5 minutes cDNA synthesis step at 50°C, followed by an 
initial denaturation at 95°C for 1 minute. Finally, the samples are cycled from 95°C 
for 3 seconds to 60°C for 30 seconds (data collection step) for 40 cycles. 
Table 2.1 Probes Information 











Mboat2 Mm00509052_m1    
Dgat2 Mm00499536_m1    
Scd1 Mm00772290_m1 
 
2.4 Transfection and siRNA knockdown (KD) assays 
2.4.1 siRNA knockdown 
To transfect cells with siRNA two methods were employed. During reverse 
transfection, the transfection reagents are prepared and added to the well the same day 
that the cells are added. On the other hand, during the standard transfection method 
the cells are seeded into the wells and left overnight. The transfection reagents are 
added the next day. Reverse transfection has the advantage that it reduces the handling 
time and increases the absorption of siRNA by the cells. Forward transfection was 
utilized for some of siRNA targets, because it was found that it reduced the cell 
toxicity, while maintaining an acceptable KD level. 
Transfection were performed in a 96-well plate with a final siRNA concentration of 
25 nM/well.  All siRNAs (ON-TARGET plus SMARTpool) were obtained by 
Dharmacon at a concentration of 2nmol and diluted to 2μΜ using siRNA buffer (5x 
siRNA buffer # B-002000-UB-100). On the day of transfection 1.25 μl of siRNA 
SMARTpool was mixed with 8.75 μl Optimem reagent (Invitrogen). 0.4 μl of 
Dharmafect1 (Dharmafect) was mixed with 9.6 μl Optimem. Following incubation for 
5 min at room temperature the Dharmafect mix was added to the siRNA mix and 
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incubated for 30 minutes at room temperature. Subsequently, the siRNA mixture was 
added to the wells and 1.5x104 cells/well (pMEFs or NIH-3T3), in a volume of 80 μl, 
was added to the wells and incubated for 48 hours. During transfection cells were 
grown in their respective growth media without the presence of antibiotics. The 
volumes described here was calculated for one well, but was scaled up appropriately 
for the assay. 
After 48 hours the cells were treated depending on the experiment requirements. For 
all KD, three controls were used. A RISC free siRNA, which cannot be incorporated 
to the RISC complex, and a series of non-treated wells were used as negative controls. 
For viral infections M54 targeting siRNA was used as positive control. M54 targets 
specifically the MCMV polymerase and it was a custom made order from Dharmacon. 
Its 5’-3’ sense strand sequence is AGAAAGACGACCTGAGCTA.  
Table 2.2 SiRNAs Information 
siRNA target SiRNA name Order number 
Risc Free SiGenomeTM Control 0-001220-01-05 
M54 - - 
Hk3 TARGETplus SMARTpool - Hk3 siRNA L-045823-00-0005 
Pfkfb3 ON-TARGETplus SMARTpool - Pfkfb3 
siRNA 
L-050027-00-0005 
Elovl4 ON-TARGETplus ELOVL4 siRNA LU-010269-00-0002 
Elovl6 ON-TARGETplus ELOVL4 siRNA LU-040378-00-0002 
Elovl7 ON-TARGETplus SMARTpool - Elov17 
siRNA 
L-059708-01-0005 
Mboat1 ON-TARGETplus MBOAT1 siRNA LU-054725-01-0002 
Mboat2 ON-TARGETplus MBOAT2 siRNA LU-063482-01-0002 
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Dgatt2 ON-TARGETplus MBOAT2 siRNA LU-060914-00-0002 
Scd1 ON-TARGETplus SCD1 siRNA LU-005061-00-0002 
 
2.4.2 siRNA KD efficiency 
In order to monitor the transfection efficiency for siRNA, qRT-PCR was used to 
measure the reduction in the relative abundance for each targeted gene transcript. Cells 
were transfected as described in section 2.4.1 followed by harvesting, RNA isolation 
and qRT-PCR (performed as in section 2.3.2). Some of the genes investigated in this 
thesis have very low expression levels in mock-treated cells making it difficult to 
determine accurate KD efficiency values. These genes are, however, highly 
upregulated during late time points of viral infection. For these genes, a different assay 
was devised to calculate the KD efficiency. Cells were first transfected for 24 hours 
and subsequently infected with MCMV-GFP (MOI 1). After 24 hours of infection, 
RNA was harvested and the abundance of each transcript was assayed by qRT-PCR. 
2.5 Microarray gene expression analysis 
2.5.1 Microarrays designs and experiments 
Two microarrays datasets are used for this thesis, Macrophage Infection/Immunity 
Time-Course Hours 12 (MITCH12), and Macrophage Infection/Immunity Time-
Course Hours 24 Knockout (MITCHKO24). 
MITCH12 was performed for the thesis of Mathieu Blanc and MITCHKO24 for the 
thesis of Paul Lacaze(Blanc 2011; P. (University O. E. Lacaze 2011). Both 
experiments can be reviewed in detail in the thesis or the respective publications 
associated with them. Briefly, for MITCH12 BMDM from Balb/c mice were mock 
treated, or treated with MCMV-WT (MOI 1) or treated with 10 Units of IFN-γ. For 
each treatment, RNA was isolated every 30 minutes and used to perform the 




In MITCHKO24, BMDMs from WT and IFNAR or IFNB deficient C57/BL6 mice 
were used. These were mock treated or treated with MCMV-WT (MOI 1), or MCMV-
KO (MOI 1), or poly(I:C). The RNA from each treatment and cell type was isolated 
and high quality RNA was hybridised Affymetrix Mouse Gene 1.0ST microarray to 
profile the transcriptional response at 0, 2, 4, 6, 8, 10, 12 and 24 hours post treatment. 
2.5.2 Microarray analysis 
The MITCHKO24 raw data were imported into Partek Genomics Data 6.5 (Bilkei-
Gorzo et al. 2017). The data were normalized using the quantile RMA method. This 
was followed by a QC check during which sample number 49 (IFNAR-/- BMDM, 
mock 0 hpi) did not pass the test and was subsequently excluded from all analysis. 
Finally, a per gene normalization step was followed.  
The MITCH12 dataset was given to me, already normalized using Bioconductor R 
statistical package, by Dr. Thorsten Forster based at the Department of Infection and 
Pathway Medicine. The data were then smoothened using a lowess smoothing with 
span parameter of (f)=20% by Dr. Mizanur Khondoker to facilitate study and 
visualization. Further processing and analysis was performed by me using Partek 
Genomics Data 6.5 and Microsoft Excel. 
2.6 Metabolomics 
2.6.1 BMDM metabolome during productive vs. non-productive infection. 
To study the metabolome of BMDM during infection, a metabolomics study was 
devised. This was a collaborative study between our Lab and the lab of Dr. David 
Watson at Strathclyde University.  
BMDM from C57BL/6 JCR male mice were isolated and seeded in 6 well plates. After 
7 days of maturation they were mock treated or treated with MCMV-WT (MOI 1) or 
MCMV-KO (MOI 1). Metabolites were isolated from the cells at 4 hpi and 24 hpi and 
shipped for quantification at Strathclyde University. To isolate metabolites, the cells 
were quickly washed twice with 3 ml 37°C of phosphate-buffered saline (PBS). 
Quenching of the cell’s metabolism was performed by placing the culture plates on ice 
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and then adding 500 μl of ice cold extraction solution (methanol: acetonirile: water –
all HPLC grade – 50:30:20; pre-cooled by keeping on dry ice/methanol mixture). 
Subsequently the cells were scrapped off the plates, transferred to Eppendorf tubes and 
incubated on a rocker for 15 minutes at 4°C. The samples were spun down at 4°C 
(15,000 rpm) for 15 minutes and stored at -80°C, before being shipped to Dr. David 
Watson’s lab for LC-MS analysis. The data were obtained on a Dionex 3000 HPLC 
(Thermo Fisher Scientific) coupled to an Exactive Orbitrap (Thermo Fisher Scientific).  
LC-MS data were acquired on an Dionex 3000 HPLC (Thermo Fisher Scientific) 
coupled to an Exactive Orbitrap (Thermo Fisher Scientific) in both positive and 
negative mode set at 50,000 resolution (controlled by Xcalibur version 2.1.0; Thermo 
Fisher Corporation). The mass scanning range was m/z 75–1200, the capillary 
temperature was 320 °C and the sheath and auxiliary gas flow rates were 50 and 17 
arbitrary units, respectively. The separation was performed on a ZIC-pHILIC column 
(150 × 4.6 mm, 5 μm from HiChrom, Reading UK) in binary gradient mode. The 
mobile phase used was 20 mM ammonium carbonate buffer (pH 9.2) and pure ACN; the 
flow rate was 300 μL·min−1. The gradient was programmed as follows: 0 min 20% A 
80% B to time 30 min 80% A 20% B. The injection volume was 10 μL and the sample 
tray temperature was controlled at 12 °C during the measurement. 
The Raw LC-MS files were processed by using m/z Mine 2.14 and searched against 
an in-house metabolite database. Graphical representations, tabular features and 
statistical analysis (p-value generation) were performed in Excel (Microsoft Office 
2013).  
SIMCA-P version 14.0 (Umetrics, Sweden) was used for PCA analysis which included 
PCA. The data were centred, and Pareto scaled. 
2.6.2 Detection of eicosanoids in BMDM. 
This study was a collaborative project with Dr Vallerie O’Donnel based at the 
University of Cardiff. BMDM from C57BL/6 JCR male mice were seeded in 6 well 
plates and mock infected or infected with MCMV-WT (MOI=1) or MCMV-KO 
(MOI=1) or MCMV-MCK2+ GFP. At 0, 12 and 24 hpi the cells and the supernatant 
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were collected and flash frozen in Liquid nitrogen. Subsequently they were stored at -
80 0C before being shipped to Cardiff. 
At Cardiff the samples were analysed for eicosanoids with LC/MS/MS and they were 
quantified using a 4000 Q-Trap and in comparison to deuterated internal standards. 
Standards were added to the 1ml sample (5ng 15-HETE-d8, 13-HODE-d4 and PGE2-
d4 per sample) and the lipids were extracted by adding a solvent mixture of 1M acetic 
acid/isopropanol/hexane (2:20:30, v/v/v) to the sample at a ratio of 2.5ml solvent 
mixture:1ml sample. The new mixture was vortexed and 2.5 ml or hexane was added. 
Subsequently the sample was vortexed again and then centrifuged at 1500 rpm, 4oC 
for 5 min. The lipids were recover from the upper hexane layer and  a new extraction 
of lipids from the samples took place as described above. The hexane layers were 
combined and dried under N2 flow, or in vacuum (program1, vacuum 200, temp 30oC, 
Speed 35). The extracted lipids were stored at-70 oC. 
 
Eicosanoids were quantified using LC/MS/MS:  Samples were separated on a C18 
Spherisorb ODS2, 5 μm, 150 x 4.6-mm column (Waters, Hertfordshire, UK) using a 
gradient of 50–90% B over 10 min (A, water:acetonitrile:acetic acid, 75:25:0.1; B, 
methanol:acetonitrile:acetic acid, 60:40:0.1) with a flow rate of 1 ml/min.  Products 
were quantitated by LC/MS/MS electrospray ionization on an Applied Biosystems 
4000 Q-Trap using parent-to- daughter transitions of m/z 319.2 (HETE, [M-H]-) to 
m/z 179.1 (12-HETE), 219.1 (15-HETE), 167.1 (11-HETE), 115.1 (5-HETE), m/z 
351.2 (PGE, [M-H]-) to m/z 189.1 (PGD2), 271.1 (PGE2), and m/z 327.2 to 226.2 for 
15-HETE-d8, and m/z 355.2 to 275.1 for PGE2-d4 with collision energies of -20 to -
30 V.  Products were identified and quantified by mass spectrometry using standard 
curves generated with the equivalent HETEs and PGs against 15-HETE-d8 and PGE2-
d4 run in parallel under the same conditions. 
2.6.3 Study of metabolism using Seahorse XF Extracellular Flux Analyzer 
The Seahorse XF Extracellular Flux Analyzer can be used to directly measure the 
oxygen consumption rate (OCR) of cells and to indirectly measure the glycolytic 
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activity of cells by measuring the extracellular acidification rate (ECAR). I employed 
this instrument to compare the OCR and ECAR between mock treated and treated 
macrophage. 
Macrophage were grown for grown for 7 days as described in 2.1.1, in Teflon pots 
instead of culture flasks or plates. Cells were seeded in Seahorse XF24 V7 PS Cell 
Culture Microplates one day before the experiment. The following morning, cells were 
treated or mock treated, for the specified time required in each experiment. 
Subsequently they were washed 3 times with Seahorse XF base medium. Next the 
plate was placed at 37°C for 1 hour to equilibrated CO2 with the atmosphere, and then 
returned to the Seahorse XF Extracellular Flux Analyzer to perform the glycolysis rate 
assay.  The seahorse experiment took place with the help of Dr. Roderick Carter. 
2.6.4 Drugs used 
The following inhibitors were used in a number of experiments during the thesis. 
5-(Tetradecyloxy)-2-furoic acid (TOFA) Sigma Aldrich (T6575-5MG) 
4-Methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid (C75) Sigma Aldrich 
(C5490-5MG) 
2-Deoxy-D-Glucose (2-DG) Sigma Aldrich (D6134-5G)
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3 Chapter 3 Characterisation of productive and non-
productive MCMV infection 
3.1  Introduction 
The first aim in this chapter is to characterise the growth characteristics of the different 
viral strains; MCMV, MCMV-pSM3fr, MCMVdie3 and MCMVdie3rev (from now 
on MCMV-WT, MCMV-KO and MCMV-GFP) that were used as a model for 
infection throughout this thesis and are reviewed in (Angulo, Ghazal, and Messerle 
2000). The growth characteristics of the virus were studied in BMDM and NIH/3T3 
permissive cells that constitute the main cell systems used throughout this thesis.  
As a model for non-productive infection, MCMV-KO was used. MCMV-KO lacks the 
immediate early (IE) 3 gene, making it impossible for this viral strain to replicate 
outside of the complementing cell line Bam-25, which express the IE3 gene. For my 
thesis I had to corroborate that MCMV-KO can be used as a model for non-productive 
infection and does not replicate in NIH/3T3 or BMDM (Angulo, Ghazal, and Messerle 
2000). MCMV-KO has all the components of the MCMV-WT strain but lacks the IE3 
gene, which is essential for viral growth (Angulo, Ghazal, and Messerle 2000). Thus, 
MCMV-KO can, like MCMV-WT, enter cells, elicit an immune response, but unlike 
MCMV-WT cannot transcribe any gene apart from the IE1 gene (P. Lacaze et al. 
2011). By comparing the effects that MCMV-WT and MCMV-KO infection have on 
cells, it is possible to pinpoint which alterations of metabolic pathways are due to viral 
manipulation or part of the immune response.  
Regulation of metabolism is emerging as an important factor in infection. Multiple 
studies have demonstrated a tight integration of metabolism and immunity. The ability 
and need for both host and pathogen to alter the metabolome appears to be a key 
checkpoint that can determine the outcome of infection (Kotzamanis, Angulo, and 
Ghazal 2015). At the same time multiple viruses, including HCMV, have been shown 
to alter the metabolome of infected cells. HCMV, the human strain of MCMV, has 
been shown to manipulate lipid metabolism and FA biosynthesis extensively during 
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infection (Munger et al. 2006; Koyuncu et al. 2013; J.-Y. Seo, Yaneva, and Cresswell 
2011; Munger et al. 2008; Vastag et al. 2011).   
While similar studies have not been conducted for MCMV infection, it has been 
demonstrated that metabolic pathways are altered by MCMV infection. More 
specifically, the cholesterol metabolic pathway is downregulated on transcriptional 
level by the immune system (Blanc et al. 2011, 2013). Taking all the above into 
consideration I hypothesised that MCMV manipulates metabolic pathways associated 
with lipid and FA metabolism to promote viral progeny.  
To tackle this problem, I analysed a dataset consisting of the temporal transcriptomic 
response of macrophages during MCMV productive (MCMV-WT), or non-productive 
(MCMV-KO) infection. By studying the differences in the transcriptome between 
productively infected and non-productively infected macrophages I could set apart key 
transcriptional events that are initiated by the virus or the ΜΦ in response to the viral 
infection. The genes identified were then clustered according to function, revealing 
that MCMV induces the expression of genes that belong to metabolic pathways 
associated with FA elongation and membrane remodelling during late stages of 
infection. 
3.2 MCMV growth characteristics. 
BMDM have been shown to be less permissive to MCMV infection than fibroblasts 
(KKropp et al. 2011).  Kropp et al. 2011 demonstrated that BMDMs have a primed 
anti-viral state that can interfere with the MIEP of MCMV. BMDM-STAT1-/- were 
fully permissive to MCMV infection as they fail to induce IFN-I signalling, which has 
been to shown to inhibit MCMV growth in BMDM and fibroblasts (Gribaudo et al. 
1993). 
To corroborate these results and characterise my model virus, plaque assays were 
performed to study the growth kinetics of the MCMV-WT, MCMV-GFP and MCMV-
KO used in this study. In our lab, a live cell replication assay was developed that was 
sensitive enough to measure the effects of drug- and siRNA-treatments in fibroblasts 
infected with MCMV-GFP. After MCMV-GPF strain infects cells it produces GFP 
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and thus the viral infection level can be assessed by detecting GFP fluorescence. The 
assay does not require the destruction of the cell cultures and thus the kinetics of the 
infection can be monitored more often, faster and at a lower cost than by using a plaque 
assay. BMDM infection could not be assessed using this assay, because BMDM have 
high auto-fluorescence making it impossible to get good signal-to-noise-ratio and 
obtain meaningful data. 
According to this assay, NIH/3T3 were infected with a range of MOIs for 1 hour in a 
96 well plate. Subsequently, an OPTIMA Polarstar plate reader was used to monitor 
the increase of viral growth by measuring GFP signal. As shown in (Fig.3.1A), there 
is a correlation between the MOI with which the cells were initially infected and the 
GFP expression level over time. 
BMDM or NIH/3T3 fibroblasts were infected with MCMV-WT, MCMV-GFP or 
MCMV-KO at a multiplicity of infection (MOI) of 1. Subsequently, supernatant was 
collected every day for 5 days and a plaque assays was performed to determine viral 
titres. The plaque assay was performed on p-53-/- fibroblasts for the MCMV-WT and 
MCMV-GFP strains and in BAM-25 cells for the MCMV-KO strain. 
The results demonstrate that in each cell type MCMV-WT and MCMV-GFP have 
similar growth kinetics in either cell type used (Fig.3.1B, C). Additionally, it is shown 
that MCMV-KO growth was not detected in BMDM or NIH/3T3 beyond the initial 
day of infection revealing that it cannot replicate in the cells. MCMV-KO replication 
is detected in the media at day 0 because even after rigorous washing of the cells, from 
the infection media, it is impossible to remove all viral particles. It should be noted 
here that because NIH/3T3 cells are very fragile they were not washed after infection 




Figure 3.1 Growth kinetics of MCMV-WT, MCMV-GFP and MCMV-KO in BMDM 
and NIH/3T3. (A) NIH/3T3 cells infected at different MOIs with MCMV-GFP in 96 well 
plates. The GFP signal was measured using an OPTIMA Polarstar plate reader over 
5 days. Three independent experiments mean SEM ± with 6 biological replicates 
(n=6). (B) BMDM were infected at an MOI of 1 with MCMV-WT, MCMV-GFP or 
MCMV-KO. At the indicated time points, samples were taken and the viral titres were 
determined using plaque assay. Data are mean SEM ± for three independent 
experiments with 3 biological replicates (n=3) (C) NIH/3T3 cells treated as in (B) The 
data are logarithmic and because of that data only data with values greater than 0 
can be shown. Therefore MCMV-KO PFU/ml is only shown for day it the rest of the 
days 0 plaques were formed. Data are mean SD ± for three independent experiments 





3.3  Analysis of transcriptomics data of bone marrow derived 
macrophages (BMDM) following productive infection (MCMV-
WT), or non-productive infection (MCMV-KO) or poly(I:C) 
treatment. 
Previous microarray studies conducted in our lab have generated a data resource 
studying the temporal transcriptomic profiling of BMDMs treated with MCMV-WT, 
MCMV-KO, or poly(I:C). The experiment called MITCH24KO (Methods 2.4.12), 
was conducted for the needs of Paul Lacaze’s thesis and it can be reviewed in greater 
detail there (P. (University O. E. Lacaze 2011). I acquired the raw data from this 
resource and reanalysed it to study the differential effects that productive and non-
productive infection would have over time in BMDM. The first aim of this analysis 
was to establish whether productive and non-productive infection program BMDM 
similarly at the transcriptional levels during early times of infection. The second was 
to identify whether MCMV infection alters metabolic pathways in infected BMDM 
and if this is related to FA metabolism. 
MITCH24KO data set was generated by Paul Lacaze. Briefly, WT BMDM from 
C56BL/6 mice were treated with MCMV-WT (MOI=1) or MCMV-KO (MOI=1) or 
poly(I:C) over a 24-hour period. At 0, 2, 4, 6, 8, 10 and 24 hours post infection (hpi), 
RNA was isolated and used for the microarray analysis. In this experiment, poly(I:C) 
was used as a control for the non-productive infection. Poly(I:C) is a TLR-3 ligand 
which is a pattern recognition receptor that detects dsRNA and that has been shown to 
contribute to MCMV detection (Tabeta et al. 2004).  
The raw dataset was retrieved and imported them into Partek Genomic Suite (MO) for 
analysis. The raw data was normalized using the RMA algorithm followed by a per-
gene normalisation step. The normalised expression data was visualized for all the 
probes using a Principal Components Analysis (PCA) (Fig.3.2A). PCA is a statistical 
analysis that is useful in identifying patterns in complex data. PCA uses the covariance 
of these data to calculate the principle components (PC) with the first PC always 
having the bigger variance. 
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The 3D PCA graph of all probes in the dataset reveals how the transcriptomic profiles 
of the differently treated BMDM evolve spatially over time. At time point 0, the PC 
of MCMV-WT, MCMV-KO and poly(I:C) treatments are similar, indicated by their 
close clustering in the graph. This is expected as the genomic profile of all BMDM 
should be similar at time point 0, since the MCMV infections and poly(I:C) treatment 
have not had time to affect the cells’ transcriptome yet. Over time the clusters for each 
treatment deviate reflecting the divergent gene expression of the BMDM due to the 
different treatments. It is interesting that all treatments are clustered together until 4 
hours post treatment. After that time point, productive infection by MCMV-WT begins 
to increasingly deviate from the other treatments resulting in a different trajectory from 
the other treatments. This could be explained by the fact that by 4-6 hpi the virus would 
have initiated the expression of its Immediately Early (IE) genes allowing the virus to 
start taking control of the host cells and affecting its gene expression. 
The results presented in Fig 3.2A included all the probes present on the microarray, 
even those that represented genes with low expression levels or whose expression was 
steady during all three treatments. Genes with expression levels below the detection 
threshold were subsequently removed as part of the initial processing of the dataset. A 
filtering step was performed in which probes showing no difference in their expression 
levels during at least one treatment and/or were expressed at a very low level were 
filtered out. This reduced the dataset to 6377 probes. On this probe set a second PCA 
was performed, shown in (Fig.3.2B). 
The new dataset shows the same trend as indicated previously, namely that the 
productive infection diverges from the other two treatments over time (Fig.3.2B 
compared to Fig.3.2A). In this instance, though, the divergence is faster, possibly due 
to the filtering that was applied. The removal of very low expressed probes and/or non-
variant ones increases the variance the data set, as shown in the PCA used to calculate 
the principal components. The file of the 6383 probes can be found in the appendix 




Figure 3.2 The transcriptomic profile of BMDM during infection (A) Genome wide 
PCA analysis of BMDM following productive infection (MCMV-WT), non-productive 
infection (MCMV-KO) and poly(I:C) treatment. Each treatment is represented by 
different colour shown in the legend. Each ball represents a time point after treatment 




3.4  Bioinformatics analysis of the transcriptome of infected BMDM’s 
identifies fatty acid metabolism genes upregulated specifically 
during productive MCMV infection 
3.4.1 Genes upregulated specifically during MCMV infection 
Based on the results obtained above, it was hypothesized that there could be cellular 
genes that are critical for MCMV replication. Some of the genes that are pro-viral 
should therefore be expected to be upregulated, specifically during productive 
infection.  
As shown in Fig.3.2 A&B the differences in gene expression between productive 
infection, non-productive infection and poly(I:C) treatment are more pronounced at 10 
and 24 hpi. By focusing on these two-time points and filtering only the gene probes 
with a fold change of ≥1.5 in productively infected cells, I identified a subgroup of 
genes that represent a transcriptional response specifically associated with MCMV-
WT infection.   
Out of these of these gene probes, Elongation of very long chain fatty acid 7 (Elovl7) 
was identified. Elovl7 encodes for ELOVL7, an elongase that is involved in the 
elongation of very long chain fatty acids(Tamura et al. 2009). Since HCMV has been 
shown to induce synthesis of very long chain fatty acids and to investigate the 
hypothesis in this chapter I utilized the expression profile of this gene to identify other 
genes with similar expression profile (Koyuncu et al. 2013).  
Elovl7 was also a good candidate because it shows a high magnitude of expression 
(fold change of 22) at 24 hpi, in comparison to 0 hpi.  Furthermore, in mock, MCMV-
KO or poly(I:C) treated cells Elovl7 has a very low expression, close or even below 
the detection limit. This is also true for MCMV-WT treatment, up to 10 hpi. At 10 hpi 
or later Elovl7 expression is greatly induced further indicating that this is a pro-viral 
gene with important function for MCMV. This suggests that the gene is not normally 
expressed in ΜΦ, but it is greatly induced specifically by MCMV-WT infection. 
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To identify genes with similar expression profile to Elovl7, the Pearson Dissimilarity 
algorithm in Partek Genomics Suite was used to rank the list of 6838 probes previously 
obtained. The top 250 gene probes with expression profiles most similar to E ovl7 were 
filtered. After removing the duplicate probes 243 probes remained, corresponding to 
243 individual genes. A heatmap of the genes was created to show their change in 
expression over time (Fig.3.3A). As shown in the heatmap (Fig.3.3A) a significant 
increase in the expression level for all genes was observed only in the productively 
infected samples after 8 hpi.  Some of the genes, including Elovl7, have up to 22-fold 
change increase in their expression levels compared to their mean value. All the genes 
can be reviewed in the attached appendix file [250_proves_Elovl7]. 
Viruses have been known to exploit the host’s cell-machinery including the 
mechanisms used to regulate it (Bolinger and Boris-Lawrie 2009). Thus, it was 
hypothesised that MCMV could be hijacking several transcription factors (TFs). These 
TFs should be, in such case, induced specifically by MCMV productive infection in 
early stages of infection.  
Following the same workflow that was used for Elovl7, Foxo1, a well-known TF, was 
identified as being upregulated specifically during productive infection before 6 hpi. 
Foxo1 was selected because it was upregulated specifically at early stages of 
productive infection, (fold change >4), a similar expression profile with Elovl7 and it 
has been associated with regulating metabolism including FA. Using the Pearson 
Dissimilarity algorithm, the 6838 probes of differentially expressed genes were ranked 
based on their similarity to Foxo1. The transcription profiles of the top 250 most 
similar gene probes were selected. From these, 58 probes were common with the gene 
list generated using Elovl7 as seed list leaving 192 unique probes. These 192 probes 
were attributed to 192 genes and a heatmap of these genes was created and can be 





Figure 3.3 Subsets of macrophages genes based on the expression profile of 
Elovl7 and Foxo1. (A) Heatmap of the 243 most correlated genes to Elovl7’s 
expression profile. Pearson correlation was used to identify genes with expression 
profiles highly correlated with Elovl7. Each gene is represented in a row and has been 
normalised to its mean value to show relative expression. Blue indicates a decrease 
relative to the mean and red an increase. (B) As is (A) for 192 most correlated genes 
to Foxo1. 
3.4.2 Functional characterisation of genes identified to be upregulated specifically 
during MCMV infection 
The genes identified above was in overrepresentation analysis to determine enriched 
metabolic pathways. The KEGG pathway database was queried using DAVID 
(Database for Annotation, Visualization and Integrated Discovery) (D. W. Huang, 
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Sherman, and Lempicki 2008, 2009), which at the time this thesis was written could 
be found at https://david.ncifcrf.gov/.  
Out of the 243 genes in my list, 34.9% (85) were identified as being part of 21 KEGG 
metabolic pathways (Table 3.1).  
3.1 Significant metabolic pathways identified in the list of 243 genes 
KEGG pathway Count p-Value 
mmu04015:Rap1 signalling pathway 13 2.95E-06 
mmu04390:Hippo signalling pathway 9 2.21E-04 
mmu05200:Pathways in cancer 14 3.22E-04 
mmu04360:Axon guidance 8 4.81E-04 
mmu04810:Regulation of actin cytoskeleton 10 4.95E-04 
mmu04530:Tight junction 8 7.53E-04 
mmu04014:Ras signalling pathway 10 8.08E-04 
mmu04520:Adherens junction 6 0.001069 
mmu05205:Proteoglycans in cancer 9 0.001566 
mmu05217:Basal cell carcinoma 5 0.002918 
mmu04960:Aldosterone-regulated sodium reabsorption 4 0.009189 
mmu04151:PI3K-Akt signalling pathway 10 0.013634 
mmu04550:Signaling pathways regulating pluripotency of stem cells 6 0.016978 
mmu04310:Wnt signalling pathway 6 0.018465 
mmu05213:Endometrial cancer 4 0.018728 
mmu04961:Endocrine and other factor-regulated calcium reabsorption 4 0.018728 
mmu04010:MAPK signalling pathway 8 0.019853 
mmu04916:Melanogenesis 5 0.022485 
mmu00062:Fatty acid elongation 3 0.032112 
mmu05216:Thyroid cancer 3 0.039286 
mmu04918:Thyroid hormone synthesis 4 0.040389 
mmu04971:Gastric acid secretion 4 0.043336 
DAVID applies a Fisher Exact test to determine the p-value for the overrepresentation 
analysis. A p-value <0.05 was selected to filter out pathways. 
In my second list of 192 genes, 14.7% (28) of them, were identified as being part of 6 





Table 3.2 Significant metabolic pathways identified in the list of 191 genes 
KEGG pathway Count p-value 
mmu01100:Metabolic pathways 17 0.009665 
mmu03020:RNA polymerase 3 0.017793 
mmu04710:Circadian rhythm 3 0.018937 
mmu04146:Peroxisome 4 0.019086 
mmu00240:Pyrimidine metabolism 4 0.033398 
mmu00230:Purine metabolism 5 0.033912 
 
My hypothesis suggests that genes involved in lipid metabolism would be important 
for MCMV growth. With this in mind I compared the list of genes I had generated 
with a list of lipid genes that was generated in our lab based on the LIPIDMAPS 
database (Fahy et al. 2007).  This comparison identified 22 lipids (5%) out of 442 
genes that I had   previously identified as related to lipid metabolism. Additionally, I 
was attempting to identify host factors that MCMV exploits to target and alter 
metabolism in infected cells.  Thus I also compared the gene lists that I had generated 
with a list of genes that are either transcriptional factors (TF) or predicted to have TF 
function, according to Vaquerizas et al. (Vaquerizas et al. 2009).  This last comparison 
indicated that 70 (16.1%) out of the 442 identified genes were TF or predicted to be 
TF. 
3.4.3 Functional characterisation of genes using Ingenuity pathway analysis 
To corroborate my results, I used the Ingenuity pathway analysis (IPA) software to 
perform a pathway analysis. IPA uses the gene lists you provide to creates functional 
networks with other genes with known functions. The genes from my lists were 
imported to the software and a twin tailed Fisher’s exact test was performed using, this 
time, a more stringent p-value of <0.01. The results of the analysis can be viewed in 





Table 3.3 IPA analysis of the gene lists 








































































Most of the networks shown involve embryonic development or cellular assembly and 
organization. MCMV and HCMV are known to reorganise the cytoskeleton and affect 
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the morphology of infected cells (Lyman and Enquist 2009; J.-Y. Seo et al. 2011; Le 
et al. 2008). 
3.5 Discussion 
Metabolism is emerging as an important factor during immunity and viral infection (L. 
A. J. O’Neill, Kishton, and Rathmell 2016; Vastag et al. 2011). In this chapter I 
employed analysis of temporal transcriptomic data in MCMV infected BMDM to 
identify metabolomics pathways specifically induced by MCMV-WT. 
Following an unbiased initial analysis of the data I identified temporal expression 
profile of host genes in BMDM treated with MCMV-WT, MCMV-KO and poly(I:C).  
This indicates that at early time of infection, the immune system response triggered by 
MCMV or poly(I:C) is driving the cells programming. After 4 hours, MCMV has 
initiated its transcriptional program and, thus, starts interfering with the host cell before 
taking over infected cells. MCMV-WT infection begins diverging from the MCMV-
KO and poly(I:C) treatments at 4 hpi, and at 24 hpi it has diverged the most. MCMV-
KO and poly(I:C) treatments evolve differently, but they are very close spatially and 
they appear to follow similar paths. This is an indication that BMDM respond similarly 
to these two treatments, which is expected as both poly(I:C) and MCMV-KO initiate 
an immune response, but after the initial signalling there is no more interaction. The 
differences in the response could be explained by the fact that MCMV-KO is an 
inactive virus, but that it still has several tegument proteins. Some of tegument proteins 
are known to interact and subvert immune signalling during CMV infection 
(Chevillotte et al. 2009). Additionally, MCMV-KO is recognized by a wider range of 
PRR than poly(I:C). 
After the initial analysis, I wanted to focus on metabolic genes that were specifically 
induced by MCMV-WT infection during late time of infection. HCMV has been 
reported to upregulate genes related to FA synthesis strongly after 24 hours in its 96 
hours replication cycle in vitro (Purdy, Shenk, and Rabinowitz 2015; Spencer et al. 
2011). The initial induction of Elovl genes expression starts at 24 hours and FA 
biosynthesis inhibition is able to block HCMV replication at even 48 hours post 
infection (Spencer et al. 2011; Purdy, Shenk, and Rabinowitz 2015).  
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Genes that were upregulated specifically during MCMV-WT infection, with a fold 
change > 1.5, were filtered out from my gene list. Elovl4&7 genes were in this list of 
genes and because of the relevance of FA metabolism to HCMV, I chose to use their 
transcriptomic profile to identify genes with a similar strong induction, specifically 
during late stages of infection (Purdy, Shenk, and Rabinowitz 2015). This indicates 
that MCMV like HCMV is dependent on similar pathways.  
I chose to use the Elovl7 gene over Elovl4 for the generation of my list, because 
ELOVL7 has been associated with the generation of very long saturated fatty acids, 
the same kind of FA that HCMV induces during infection (Tamura et al. 2009; Vastag 
et al. 2011; Jakobsson, Westerberg, and Jacobsson 2006; Koyuncu et al. 2013). 
ELOVL4 is associated with the elongation of polyunsaturated fatty acids (Ohno et al. 
2010; Tamura et al. 2009) 
The use of Elovl7 on a genome wide analysis in MCMV infected BMDMs at late and 
early time of infection identified 243 and 192 genes specifically upregulated by 
MCMV productive infection. Out of these, 70 were predicted to be TF based on a list 
published by (Vaquerizas et al. 2009).The bioinformatics analysis indicated that 
MCMV might have a strong dependency on fatty acid and lipid metabolism, 
identifying 13 genes of the former and 9 genes of the latter, that are specifically 
upregulated during productive infection.  
Functional characterisation of the 243 genes using DAVID associated them with, 
amongst others, Rab & Ras signalling, regulation of actin cytoskeleton, PI3K-AKT 
signalling, Wnt signalling, fatty acid elongation pathway and pathways associated with 
cancer. As discussed earlier Rab & Ras proteins have been found to be crucial for 
HCMV and MCMV infection. Additionally, HCMV has been shown to remodel the 
cytoskeleton of infected cells (Lyman and Enquist 2009; J.-Y. Seo et al. 2011; Le et 
al. 2008). Furthermore, given the huge morphological changes that HCMV and 
MCMV infected cells undergo it is expected that both viruses would interact with cell 
development and cell organisation pathways, such as the Wnt and the cytoskeleton 
organisation pathways (Jones, Lewis, and Kilpatrick 1986; Angelova et al. 2012; 
Melnick, Deluca, and Jaskoll 2014). Finally, Munger et. al  have shown that FA 
synthesis is upregulated upon HCMV infection in Human Foreskin Fibroblasts (HFF) 
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(Munger et al. 2008). This pathway also came up in my functional analysis further 
supporting its role in CMV infection. IPA analysis also reinforces all of the above by 
revealing the presence of networks associated with developmental, cellular 
morphology, molecular transport and lipid pathways.  
The association of cancer-related pathways with MCMV is captivating. This 
association could be expected as the energy metabolism of HCMV infected cells and 
tumour cells is similar (Munger et al. 2008, 2006). The PI3K-AKT signalling pathway 
that was identified in my analysis has been shown to be crucial signalling pathway for 
survival and cell cycle control (L. Yang, Venneti, and Nagrath 2017). Among other 
functions it regulates proteins translation and energy metabolism. HCMV and MCMV 
have been shown to directly interact with it in numerous ways to alter metabolism and 
prevent the apoptosis of infected cells (Yatim and Albert 2011; Moorman et al. 2008; 
Poglitsch et al. 2012). It is interesting that cancer cells also manipulate the PI3K-AKT 
pathway for similar reasons, to promote survival and also alter their metabolism and 
support their need to propagate (Raja Singh et al. 2017; Tserga et al. 2016). 
Furthermore, based on several studies and data obtained by another member of our lab, 
Dr. Wein Hsiesh, the third network in Table 3.3, which includes many G-proteins, 
lipid metabolism and molecular transport associated genes, is of particular interest 
(Das and Pellett 2007; Das, Vasanji, and Pellett 2007; Liu et al. 2011; Indran and Britt 
2011).  The vesicular transport system, in which Rab proteins play an important role, 
has been shown to be crucial for HCMV replication (Das, Vasanji, and Pellett 2007; 
Liu et al. 2011; Indran and Britt 2011). Wein Hsiesh, has identified the prenylation 
pathway, which is directly linked to the vesicular transport system and is part of the 
mevalonate pathway, to be crucial for viral progeny during MCMV infection (Hsiesh 
2015). 
Additionally, the same network includes proteins involved in lipid metabolism and FA 
elongation. In eukaryotes, very long chain fatty acids (VLCFA) are formed form the 
elongation of fatty acids that are either produced by fatty acid synthase (FASN) or 
obtained by diet (Cinti et al. 1992). Despite their small presence in mammalian tissues 
VLCFA play an important role in number of biological processes and are essential for 
the synthesis of phospholipids and sphingolipids(Poulos 1995). Furthermore, FA 
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elongases, two of which are included in this network, have been shown to be important 
for HCMV replication (Purdy, Shenk, and Rabinowitz 2015). 
In conclusion, the data presented here support the notion that productive MCMV 
infection affects a plethora of genes in infected BMDM. The functional 
characterisation of these genes revealed an extensive manipulation of metabolic and 
cell developmental/organisational pathways by MCMV infection. This appears to be 
consistent with the known effects that MCMV and HCMV infection has in infected 
cells. Although the analysis alone in not sufficient to reach final conclusions it appears 
that productive MCMV infection has a dependency on a number of pathways 
associated with lipid metabolism. These pathways are related to FA elongation, and/or 
vesicular transporting supporting the notion that MCMV extensively manipulates the 
host cell’s molecular transport and resources.
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4 Chapter 4 Co-option of BMDM metabolism by MCMV 
productive infection during early time of infection 
4.1 Introduction 
Homeostasis is the ability of a system to maintain equilibrium by actively regulating 
itself and other systems that cross it. To maintain a dynamic equilibrium, a system 
must be able to respond to a wide range of external stimuli and tightly coordinate and 
integrate numerous diverse processes. It is a key characteristic of living organisms and 
underpins the regulation of metabolism and the immune system. 
Traditionally metabolism and immunity have been studied by different research 
communities and out of the context of each other. However, recently a number of 
advances in both fields revealed that they are tightly integrated(L. A. J. O’Neill, 
Kishton, and Rathmell 2016; Pearce et al. 2013). Immune cells alter their metabolism 
upon activation, a critical step for them to support their effector functions. This 
becomes evident in the case of T cells for example that upon activation have to 
proliferate extensively and rapidly.  For T cells to proliferate and mature they need to 
switch from catabolic to anabolic metabolism. To support these increased bioenergetic 
needs, naive T cells increase their oxidative phosphorylation along with inducing 
aerobic glycolysis(Palmer et al. 2015; Shi et al. 2011; Gubser et al. 2013; Michalek et 
al. 2011; Buck, O’Sullivan, and Pearce 2015). Inhibition of glycolysis doesn’t inhibit 
the ability of effector T cells to undergo clonal expansion, but prevents them from fully 
acquiring their effector functions(C.-H. Chang et al. 2013; Palmer et al. 2015; Cham 
et al. 2008).  
Similarly, classically activated DCs and ΜΦ upregulate their glycolytic pathway and 
alter their Tricarboxylic acid (TCA) cycle. In contrast to T-cells, MΦ and DCs exhibit 
a broken-down TCA cycle at two points, at citrate and succinate. Citrate is used by the 
cells to support FA and itaconate production, while succinate accumulation has been 
show to promote the secretion of certain cytokines. Because of their uncoupled TCA 
cycle these cells rely on glycolysis for ATP generation. It is not very well understood 
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why these cells change to this more inefficient way of producing energy. Several 
studies have indicated that Nitric oxide (NO), an important antimicrobial metabolite 
that is produced by classically activated DC and MΦ, inhibits the electron 
transport(Beltrán et al. 2000; Everts et al. 2012). 
Control of homeostasis is very important for viruses too, as upon infection viruses have 
to regulate metabolism to meet their own metabolic needs. Viruses are obligatory 
parasites that are dependent on their host’s cell machinery to replicate. They need to 
exploit and counter host pathways, including metabolism, to effectively propagate. A 
number of viruses have been shown to do that, including but not limited to, HCV, HIV, 
rift valley virus, and human cytomegalovirus (HCMV) (Vastag et al. 2011; Moser, 
Schieffer, and Cherry 2012; Zheng et al. 2003; M.-L. Chang 2016). 
The metabolome of HCMV infected human foreskin fibroblasts (HFF) has been 
studied extensively(Vastag et al. 2011; Munger et al. 2008; Koyuncu et al. 2013; 
Purdy, Shenk, and Rabinowitz 2015; Terry et al. 2012; Munger et al. 2006; Yu, 
Maguire, and Alwine 2011; Chambers, Maguire, and Alwine 2010). HFF infected by 
HCMV have increased glucose uptake and FA synthesis. Glucose is converted to 
lactate to a greater extent in HCMV infected HFF than in mock infected HFF(Vastag 
et al. 2011). The TCA cycle flux is, thus, increased enabling it to support energy 
production through oxidative phosphorylation and anabolic demands by providing 
important intermediates. (Munger et al. 2008; Purdy, Shenk, and Rabinowitz 2015) 
Through the TCA cycle, carbon atoms from the glycolytic pathway are shuttled to FA 
biosynthesis. The FA biosynthesis pathway is crucial for HCMV proliferation and 
inhibiting it blocks viral progeny (Koyuncu et al. 2013). In this context, the metabolic 
alteration that MCMV infected cells has not been studied yet. 
It becomes apparent that activated immune cells, and especially macrophages have 
similar metabolism to HCMV infected Human foreskin fibroblasts (HFF) (Vastag et 
al. 2011; Biswas and Mantovani 2012; Kotzamanis, Angulo, and Ghazal 2015). 
Interestingly the increased glycolysis rate and alteration in the TCA cycle appear to 
play a critical role both for the outcome of infection and the effector function of ΜΦ. 
According, to the central hypothesis that MCMV coops the metabolic programming 
of activated BMDM during early times of infection in order establish infection, I 
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propose that the glycolytic pathway and the TCA cycle should be primary candidate 
pathways for co-option during early times of infections. This raises a few questions 
that I will attempt to answer in this chapter. 
1) Does MCMV upregulate glycolysis during infection in macrophages, and is its 
growth dependent on this. 
2) Does MCMV infection affect the TCA cycle and/or other linked pathways 
early during infection. 
3) Are these alterations in the metabolic programming of BMDM driven by host 
or pathogen events?  
4.2 Early temporal activation of the glycolytic capacity and activity upon 
macrophage infection 
To investigate glycolysis in the context of viral infection, transcriptomic and 
metabolomics studies were performed on MCMV infected Bone Marrow Derived 
Macrophages (BMDM). I analysed MITCH12 raw data, a data resource available at 
our lab, which was performed by Mathieu Blanc. MITCH12 is a time series analysis 
of gene expression of MCMV infected Bone Marrow Derived Macrophages (BMDM) 
(Fig.4.1A-B). Briefly, BMDM were infected with MCMV and RNA was harvested 
every 30 minutes up to 12 hours post infection (hpi) and hybridised on an Agilent 
microarray chip.  
The expression of genes in the glycolytic pathways normalised at time point 0 of 
infection was plotted in a heatmap diagram. A rapid induction of key enzymatic steps 
in the glycolytic pathway was observed over the course of the infection (Fig.4.1A-B). 
The infection affects enzymes involved in at least three, of the four, key regulatory 




Figure 4.1 The glycolytic pathway is upregulated at the transcriptional level in 
MCMV-WT infected macrophages. (A) The glycolytic pathway. (B) Heatmap of the 
glycolytic pathway temporal gene’s expression over 12 hours in BMDM infected with 
MCMV-WT (MOI 1). Each time point corresponds to one independent biological 
sample, and columns indicate time in hours. Fold changes of expression levels are 
represented on a Log2 scale compared to time point zero. The * near a gene 
represents genes close to the level of detection. (A) Gluc: Glucose; Gluc-6p: Clucose-
6P; Fruc-6P: Fructore-6P; Fruc-1,6-P; Fructose-1,6P; Fruc-2,6-P; Fructose-2,6P; 
DHA-P: Dihydroxyacetone-P; GAD-P Glyceraldehyde-3P;  1,3BGP: 1,3-
Bisphosphoglyceric acid; 3-PG: 3-Phosphoglyceric acid; 2-PG: 2-Phosphoglyceric 
acid; PEP; Phosphoenolpyruvic acid; LAC: lactate; (B) Glut4: Glucose transport 4: 
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Glut6: Glucose transporter 6; Hk2: hexokinase 2; Hk3: hexokinase 3; Gpi1: glucose 
phosphate isomerase 1; Pfkfb3: 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3; Pfkp: phosphofructokinase, platelet; Aldoa: aldolase 1, A isoform; 
Tpi1: triosephosphate isomerase 1; Gapdh/s: glyceraldehyde-3-phosphate 
dehydrogenase /spermatogenic; Pgk1: phosphoglycerate kinase 1; Pgam1: 
phosphoglycerate mutase1; Pgam2: phosphoglycerate mutase 2: Pgam5: 
phosphoglycerate mutase family member 5; Eno1: enolase 1, alpha non-neuron; Pklr: 
pyruvate kinase liver and red blood cell; Ldha: lactate dehydrogenase A; Ldhb: lactate 
dehydrogenase B 
glycolytic pathway(Fig.4.1A). The first regulatory step of glycolysis is the import of 
glucose in a cell. The import of glucose is regulated by proteins that belong to the 
Solute Carrier Family 2 (Sl27a), commonly named Glucose Transporters (Glut). The 
expression of Glut4 and Glut 6 is rapidly induced in MCMV infected BMDM as early 
as 3.5 hpi and remains high until 12 hpi (F g.4.1B). This is similar to previous work 
shown in HCMV infected fibroblasts were Glut4 expression was also increased (Yu, 
Maguire, and Alwine 2011; J.-Y. Seo and Cresswell 2013). 
Following import, cytosolic glucose is converted to glucose-6-phosphate (glucose-6P) 
by hexokinase (HK). This step is kept under tight regulation in cells because it requires 
ATP and it could deplete the cell’s ATP reserves very quickly upon high accumulation 
of glucose. Microarray analysis indicates that Hk3 expression is induced by MCMV 
infection early in infection at 3.5 hpi. 
The conversion of fructose-6P to fructose-1,6-P, by phosphofructokinase (PFK), is the 
most prominent step in regulating the mammalian glycolytic pathway.  This 
conversion has a high negative ΔGo making it practically irreversible and it has the 
lowest kinetic rate in the glycolytic pathway. Moreover, this is the first commitment 
step for glucose to enter the glycolytic pathway. Alternatively, glucose-6P generated 
by HK can be utilised by other pathways such as the pentose phosphate pathway (PPP) 
or glycogen generation (Daemen, Kutmon, and Evelo 2013). 
Notably, MCMV infection appears not to directly induce Pkf, but instead induces the 
expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (Pfkfb3) as 
early as within 30 minutes of infection. PFKFB3 catalyses the conversion of fructose-
6P to fructose-2,6-P (fruc-2,6-P), which is a strong allosteric activator of the PFK. 
High levels of ATP allosterically inhibit PFK, while AMP reverses that effect. Fruc-
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2,6-P is a very strong allosteric activator of PFK and it can reverse the effects of ATP. 
Furthermore, PFKFB3 silencing using siRNA, has been shown to reduce glycolysis by 
up to 40% in some cell types(De Bock et al. 2013). Pfkfb3 upregulation has been shown 
to be crucial in proinflammatory macrophages (Jiang et al. 2016). 
To examine if these changes were reflected at the metabolomic level, a metabolomics 
analysis of intercellular metabolites from BMDM was conducted. BMDM were 
infected or mock infected with MCMV-WT; intracellular metabolites were isolated at 
4 hpi and analysed using LC-MS. Three metabolites were detected from the glycolytic 
pathway: Glucose-6P, Glyceldehyde-3P and Glycerate-3P (Fig.4.2A-C). The 
depletion of Glucose-6P and Glycerate-3P in combination with the increased levels of 
Glyceraldehyde-3P suggests increased levels of glycolysis in the infected BMDM.  
To investigate functional requirement of the glycolytic activity for MCMV infection, 
the glycolytic activity of MCMV infected or mock-infected BMDM was examined 
using Seahorse XF Extracellular Flux Analyzer. Seahorse XF Extracellular Flux 
Analyzer instrumentation can directly measure the oxygen consumption rate (OCR) 
and glycolytic activity indirectly of cells by measuring the extracellular acidification 
rate (ECAR) (C.-H. Chang et al. 2013; Wu et al. 2016; Berod et al. 2014) . BMDM 
were infected, or mock infected, with MCMV-WT and 1.5 hpi their OCR and ECAR 
were measured. The mock infected BMDM appear to have increased OCR levels in 
comparison to MCMV-WT infected MΦ before the addition of glucose in the media 
(Fig.4.2D). The high OCR levels of mock-infected cells were reduced after the 
addition of glucose, indicating that in the absence of glucose, these cells use oxidative 
phosphorylation to produce ATP. On the other hand, the MCMV-WT BMDM have a 
steady level of OCR through the duration of the experiment, indicating that despite the 




Figure 4.2 Upregulation of glycolysis on the transcriptional level is reflected on 
the metabolomic level. (A-C) Levels of glycolysis metabolites level of infected versus 
mock infected BMDM 4 hpi. Each bar point represents a mean ± SEM of one 
experiment with 6 biological replicates *p<0.05, **p<0.01, ***p<0.001 with an unpaired 
Student’s t test (D-E) Real-time changes of OCR and ECAR of BMDM 1.5 hours after 
they have been mock infected or infected with MCMV-GFP and subsequently treated 
with Glucose (Glug), Oligomycin (Oligo) and 2-Deoxyglucose (2-DG). Each data point 
represents a mean ± SEM from 2 independent experiments with 5 biological replicates 
each. 
phosphorylation. This is in agreement with the  previously published studies that 
indicate that DC cells do not utilise OXPHOS for energy generation when they are 
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engaged by the TLR ligand LPS, which is reflected by lower consumption of O2 
(Everts et al. 2014). 
The ECAR levels for both mock infected and MCMV-WT infected MΦ are close to 0 
at the start of the experiment, which is expected since there is no glucose in the media 
(Fig.4.2E). After the addition of glucose to the media both the mock and MCMV-WT 
infected cells increase their glycolytic activity significantly. The MCMV-WT infected 
MΦ have greater glycolytic activity in comparison to the mock infected cells, which 
corroborate the transcriptomics and metabolomics data presented in Fig.4.1B and 
Fig.4.2A-C. The data are also in accordance with previously published studies that 
demonstrate that under certain circumstances some immune cells rely mainly on 
glycolysis for energy production to support their effector functions (Krawczyk et al. 
2010; Pearce et al. 2013; Everts et al. 2014; Everts and Pearce 2014).  
Taken together these data demonstrate that MCMV-WT infected ΜΦ have increased 
glycolytic activity in comparison to mock-infected cells. The effects at the 
transcriptional and metabolomic level appear to take effect very early during infection. 
More specifically the effect on the mRNA levels of Hk3 and Glut6 are evident at 3.5 
hpi while Pfkfb3 expression is induced earlier, 30 minutes post infection (Fig.4.1B). 
The effects on the metabolome are evident as early as 1.5 hpi. This is an indication 
that the induction of the glycolytic pathway is triggered by the immune system and not 
by viral manipulation of the infected cells as MCMV could not have initiate its 
transcriptional program so early during infection. 
 
4.3 Enhanced glycolytic activity of MΦ is required for viral growth 
To investigate the importance of glucose metabolism for viral replication I next 
blocked the pathway pharmacologically as well as by knocking down (KD) the 
expression of two glycolytic enzymes Hk3 and Pfkfb3 using RNA interference (RNAi). 
NIH/3T3 and primary murine embryonic fibroblasts (pMEFs) were infected with 
MCMV-GFP and treated with increased doses of 2-Deoxyglucose (2-DG). The viral 
growth rate was then monitored over time by monitoring the increase in fluoresce. The 
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Inhibitory Concertation for the drugs was determined to quantify the IC50 levels of the 
drug on the viral growth. IC50 is the concentration of an inhibitor that reduces the 
activity of an enzyme or an effect by half. 
2-DG treatment inhibited viral growth in a dose dependent manner in both cells types 
(Fig.4.3A&B). Furthermore, the IC50 concentration for 2-DG was lower than the 
concentrations at which 2-DG exhibited cytotoxic effects (Fig.4.3C). In addition to its 
inhibitory effects on viral growth in NIH/3T3 cells, 2-DG was able, in a dose 
dependent manner, to inhibit viral growth in BMDM infected MCMV-GFP 
(Fig.4.3D). 
To further corroborate these results, I used RNA interference (RNAi) to KD Hk3 and 
Pfkfb3 in NIH/3T3 cells. I used ON-TARGET Plus siRNA from GE Dharmacon that 
reduces the chance of off targets effects by using 4 different siRNAs to target the same 
gene. The KD efficiencies for Hk3 was below the 50% reduction threshold commonly 
used as a cut off for a successful KD (Fig.4.3E) and thus I cannot exclude that any 
effects observed are not due to side targets of the siRNAs.  Despite the KD of either 
gene product, adverse effects on the cell viability of the treated cells was not observed 
(Fig.4.3F). The M54 siRNA targets M54, which is the viral DNA polymerase and acts 
as positive control for the treatment. 
Despite the reduced KD efficiency of Hk3, both treatments inhibited the viral growth 





Figure 4.3 Inhibition of the glycolytic pathway Inhibits MCMV growth. (A) 
NIH/3T3 cells were infected with MCMV-GFP (MOI 0.1) and subsequently treated with 
varying concentrations of 2-DG. GFP was measured to measure the level of infection 
over time. (B) Similar to A for p-MEFs data points represent a mean ± SEM of three 
independent experiments with n = 6 for each experiment. (C) NIH/3T3 cells were 
treated with varying concentrations of 2-DG. 48 hours post treatment the cell viability 
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was asserted using Celltiter-Blue. Data points represent a mean ± SEM of three 
independent experiments with n = 6. (D) BMDM were infected with MCMV-GFP (MOI 
1) and subsequently treated with varying concentrations of 2-DG. Data points 
represent a mean ± SEM of three independent experiments with n = 3 for each 
experiment. (E) NIH/3T3 cells were transfected with 25 nM of siRNA hour ON-
TARGET Plus siRNA smart pool for 48 hours, and then infected with MCMV-GFP 
(MOI of 0.1). The graph represents growth rate of viral replication normalised to RISC 
free treated cells. Data points represent a mean ± SEM of four independent 
experiments with n = 6 for each experiment. (F) NIH/3T3 cells were transfected with 
25 nM ON-TARGET Plus siRNA smart pool for 48 hours, subsequently the cell 
viability was asserted using Celltiter-Blue. Data points represent a mean ± SEM of 
three independent experiments with n = 4. (G) NIH/3T3 cells were transfected with 25 
nM ON-TARGET Plus siRNA smart pool for 48 hours. Subsequently the KD 
efficiency for each siRNA was asserted with qRT-PCR in comparison to RISC free 
treated cells. M54 is a control siRNA treatment that targets the viral DNA polymerase. 
C and D* an unpaired Student’s t test. E,F,G One way ANOVA with Dunnett’s 
correction for multiple comparisons p<0.05, **p<0.01, ***p<0.001 
The reduced KD efficiency could explain the minimal effect that the treatment Hk3 
KD had on viral growth. Nevertheless, the inhibition of viral growth was statistically 
significant when either Hk3 or Pfkfb3 was knocked down. This, in in combination with 
the clear inhibitory effect of 2-DG on MCMV growth, presented above, demonstrate 
the dependency MCMV growth on the glycolytic pathway. Inhibition of glycolysis 
uptake also blocks HCMV growth (Yu, Maguire, and Alwine 2011). 
4.4 Enhanced glycolytic activity coincides with metabolic 
reprogramming and adaptation of the TCA cycle breakpoints in 
infected macrophages 
After glucose is converted to pyruvate it can either be broken down to lactate by lactate 
dehydrogenase (LDH), or it can enter the TCA cycle (Fig.4.4A) where it is oxidised 
and the protons generated during the process generate ATP. In quiescent cells the TCA 
cycle and the oxidative phosphorylation (OXPHOS) are the main pathways for 
generating energy, but this is not the same for all cell types (De Bock et al. 2013; 
Groschner et al. 2012). 
After the glycolytic pathway, I investigated the TCA cycle of MCMV-WT infected 
macrophages at the transcriptomic and metabolomic level. The transcriptional profile 
of all the genes that encode enzymes for the TCA cycle was generated using the 
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MITCH12 microarray dataset (Fig.4.4B). Although glutamate dehydrogenase 1 
(Glud1) is not part of the TCA cycle, the temporal transcriptional profile of the gene 
was added here because of the importance that glutaminolysis plays during CMV 
infection(Chambers, Maguire, and Alwine 2010; Yu, Clippinger, and Alwine 2011). 
It should also be noted here that a lot of the TCA cycle enzymes are composed of 
subunits that are encoded by distinct genes, and this is illustrated with a rounded 
rectangle around these genes (Fig.4.4A). 
The temporal transcriptional profile of genes in BMDM infected by MCMV-WT 
demonstrates that there is a change in the transcription of genes encoding TCA cycle 
enzymes, albeit not as big as for the glycolysis genes. Nevertheless, even small 
increases in cellular enzyme concentration can have immense impact on the substrate 
turnover time, especially in a pathway like TCA. Additionally, in the TCA a lot of the 
enzymes are regulated allosterically, which is essential for the TCA cycle, as it is the 
linking point between multiple metabolic pathways and need to respond and adapt fast 
to stimuli.   
The TCA cycle in the infected BMDM experimentally appears to be broken at two 
points on the transcriptional level. The enzymes leading up to isocitrate dehydrogenase 
(IDH) are downregulated, and the rest up to malate dehydrogenase MDH upregulated. 
Thus, two mini cycles appear to be formed. Fumarate Hydratase (FH) appears to be 
downregulated too, but the microarray platform employed here does not distinguish 
between the cytosolic and the mitochondrial isoforms of FH and, thus, does not allow 
for clear picture. 
The division of TCA cycle in two minicycles was first proposed after studies 
conducted in the 1990s. It was observed that the flux in the TCA cycle appears to be 
conscripted at two steps due to the limited availability of oxaloacetate and α-
Ketoglutarate (α-KG). These two products are in constant balance with their 
transamination products, aspartate and glutamate. Thus, a model was proposed that 
allows the TCA cycle to be broken into two small minicycles between these two 




Figure 4.4 TCA cycle transcriptomics during MCMV-WT infection of BMDM 
indicate uncoupling of TCA cycle. (A) Schematic of the TCA cycle (B) Temporal 
gene’s expression over 12 hours in BMDM infected with MCMV-WT (MOI 1). Each 
time point corresponds to one independent biological sample, and columns indicate 
time in hours. Fold changes of expression levels are represented on a Log2 scale 
normalised to time point zero. Pc:pyruvate carboxylase; Pdha1:pyruvate 
dehydrogenase E1 alpha 1; Pdhb: pyruvate dehydrogenase (lipoamide) beta; Dlat: 
86 
 
dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase 
complex); Dld: dihydrolipoamide dehydrogenase; Cs: citrate synthase; Aco2: 
aconitase 2, mitochondrial; Idh3a: isocitrate dehydrogenase 3 (NAD+) alpha; Idh3b: 
isocitrate dehydrogenase 3 (NAD+) beta; Idh3g: isocitrate dehydrogenase 3 (NAD+), 
gamma; Ogdh; oxoglutarate dehydrogenase; Dlst: dihydrolipoamide S-
succinyltransferase (E2 component of 2-oxo-glutarate complex); Dld: 
dihydrolipoamide dehydrogenase; Suclg1: succinate-CoA ligase, GDP-forming, alpha 
subunit; Sucla2: succinate-Coenzyme A ligase, ADP-forming, beta subunit; Sdha: 
succinate dehydrogenase complex, subunit A, flavoprotein (Fp); Sdhd:succinate 
dehydrogenase complex, subunit D, integral membrane protein; Sdhb: succinate 
dehydrogenase complex, subunit B, iron sulphur (Ip); Mdh1: malate dehydrogenase 
2, NAD;  Mdh2: malate dehydrogenase 2, NAD (mitochondrial); Glud1: glutamate 
dehydrogenase 1 
In order to corroborate the transcriptomics data of the infected BMDM I analysed the 
set of untargeted metabolomics data from infected BMDM that I had previously 
generated, focusing on metabolites of the TCA cycle. In agreement with the 
transcriptomics data and the model described above I was able to capture, the break-
up of the TCA cycle in the two minicycles (Fig.4.5A-H). The metabolites of the first 
three enzymatic steps in the TCA cycle are depleted in the infected cells, while 
succinate and fumarate are not changed and malate accumulates. 
This suggests that citrate is either being consumed by another process in the cells or 
that there is a reduced generation of citrate, which limits the flux to the other 
metabolites. The decreased concentration of α-KG, the increase in Glud1 expression 
and the steady concentrations of succinate and fumarate suggest that citrate is probably 
being consumed by other biochemical pathways while α-KG replenishes the TCA 
cycle. The reactions from malate to succinate are all reversible and this could indicate 
the reversal of TCA cycle, but this is not likely due to α-KG concentration being 
reduced.  Moreover, at the same time Glud1 expression is increased, indicating 
increased production and consumption of α-KG. Oxaloacetate was not captured in this 
experiment, but this could be anticipated as oxaloacetate has usually very low 
concentrations in cells. 
When combined, the transcriptomic and metabolomic data indicate that citrate is being 
shuttled outside of the mitochondrion while the rest of the TCA cycle works in an 
anaplerotic mode to replenish other intermediates and to maintain the mitochondrion 
membrane potential. This is crucial because without the mitochondria membrane 
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potential, the mitochondrial membrane could break up, which activates caspases and 
apoptosis (Henry-Mowatt et al. 2004). 
 
Figure 4.5 TCA metabolomics of MCMV infected BMDM. (A-H) TCA cycle 
metabolites. BMDM were infected with MCMV-WT (MOI 1). At 4 hpi the metabolism 
was quenched and metabolites were extracted from the cells, followed by metabolite 
quantification using LC-MS. Each bar point represents mean ± SEM of one 
experiment with 6 biological replicates. *p<0.05, **p<0.01, ***p<0.001 with an 
unpaired Student’s t test 
4.5 Enhanced arginosuccinate and citrulline in Urea/NO cycle in 
infected ΜΦ is concurrent with the TCA cycle reprogramming. 
One of the many metabolic cycles that is connected to the TCA cycle and crucial for 
proinflammatory macrophages, is the Urea cycle. The Urea cycle plays a central role 
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in the removal of nitrogen from cells by converting NH4+ to the less toxic urea, which 
is produced during the conversion of arginine to ornithine (Fig.4.6A) (Crombez and 
Cederbaum 2005). Arginine from this process can be used to produce nitric oxide 
(NO), which plays an important role in the effector functions of proinflammatory 
macrophages (Qualls et al. 2012; Morris 2004; El Kasmi et al. 2008; Jha et al. 2015). 
This comes without its own harmful consequences, as NO can inhibit cytochrome C 
oxidase, a key enzyme in the electron transport chain, and therefore blocks the 
production of ATP through oxidative phosphorylation(Beltrán et al. 2000; Everts et al. 
2012). As mentioned in the introduction the fate of arginine is entwined with the 
phenotype of the macrophage. With the M1 phenotype promoting NO production 
while M2 macrophages promote degradation of arginine to ornithine (Qualls et al. 
2012; Jha et al. 2015; Campbell et al. 2013; El Kasmi et al. 2008).  
The transcriptomic profile for the enzymes in the urea cycle reveal an increased shunt 
towards NO production, with increased expression of argininosuccicanate synthase 
(ASS) (Fig.4.6B). iNOS expression was below the detection threshold in MITCH12 
dataset, while the MITCH24KO dataset indicate a strong induction (Fig.S7.1). In 
MITCH12, BALB/c mice were used while in the MITCH24KO dataset, BMDM from 
C57BL/6J were used. The difference could be attributed to differences in mouse strain. 
Nevertheless, the metabolomics data indicate that iNOS is induced too. The 
metabolomics data are in agreement with the transcriptional profile of these enzymes, 
revealing that L-aspartate and N(L-Arginino)succinate accumulate, probably due to 
the upregulation of arginosuccinate synthase, and not that of Argininosuccinate lyase 
(Asl) (Fig.46C-G). At the same time L-arginine remains steady, while L-citrulline 




Figure 4.6 Increased NO production form Urea cycle. (A) the Urea cycle. (B) 
Temporal gene’s expression over 12 hours in BMDM infected with MCMV-WT (MOI 
1). Each time point corresponds to one independent biological sample, and columns 
indicate time in hours. Fold changes of expression levels are represented on a Log2 
scale normalised to time point zero. (C-G) Urea cycle metabolites. BMDM were 
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infected with MCMV-WT (MOI 1). At 4 hpi the metabolism was quenched and 
metabolites were extracted from the cells and the metabolites were quantified using 
LC-MS. Each bar point represents mean ± SEM of one experiment with 6 biological 
replicates. *p<0.05, **p<0.01, ***p<0.001 with an unpaired Student’s t test. Got1; 
glutamate oxaloacetate transaminase 1, soluble; Got2: glutamate oxaloacetate 
transaminase 2, mitochondrial; Ass1: arginosuccinate synthetase 1; Asl: 
argininosuccinate lyase; Arg2: arginase type II; Nos2: nitric oxide synthase 2, 
inducible 
is driven towards NO production. This is expected as the macrophages studied here 
are of the proinflammatory type that would favour NO production. 
Arginase 2 (Arg2) expression is also induced early during infection (1 hpi). This might, 
in the first instance appear controversial as arginase activity is associated with M2 
macrophage phenotype and not a proinflammatory one(Campbell et al. 2013; EL 
Kasmi and Stenmark 2015). However, while this is true for ARG1, the effects of 
ARG2 on MΦ phenotype have not been studied extensively(Z. Yang and Ming 2014). 
There are, however, studies that have associated ARG2 activity specifically to 
proinflammatory macrophages and thus the association between ARG2 activity and 
M2 phenotype can be dismissed (Hardbower et al. 2016; Ming et al. 2012). 
4.6 Type-I IFN signalling is essential for the early upregulation of 
glycolysis for productive and non-productive infection of 
macrophages 
The changes observed above, on the transcriptional and metabolomics level, appear 
very early during infection (3-4 hpi) with some starting as early as 30 minutes post 
infection. Transcription of viral genes have not initiated, apart from maybe some IE 
genes, suggesting that these early metabolomic events might be a host driven response 
to the infection and not an event driven by de novo viral synthesised viral products. 
To examine this further, I sought to investigate the effect that different types of 
treatment had on the glycolytic pathway of infected BMDM. BMDM were mock 
treated or treated with MCMV-WT, or MCMV-GFP or poly(I:C) and the glycolytic 
activity was tested by Seahorse XF Extracellular Flux Analyzer at 1.5 hours post 
treatment (Fig.4.7A). The data reveal that at 1.5 hours, all three treatments 
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significantly increased the glycolytic capacity of the cells in comparison to the mock 
treated cells. This is in agreement with previously published data in DCs and MΦ, 
where, in comparison to untreated cells, cells treated with TLR ligands significantly 
upregulate their glycolytic flux early after treatment (Jha et al. 2015; Everts et al. 2014, 
2012). 
The ability of poly(I:C) treatment to increase the glycolytic activity of treated cells in 
ΜΦ indicates that this is a host driven event. The virus might not be the master 
regulator of some of the metabolomics changes that were observed during infection, 
but instead the immune system is.  To further substantiate these results the experiment 
was repeated using MCMV-GFP, MCMV-KO and poly(I:C). The results clearly 
demonstrate that all the treatments induce the glycolytic activity of BMDM (Fig.4.7B) 
revealing a common regulator behind the induced glycolytic efflux. Since the cell type 
(MΦ) is the only thing all treatments have in common, it is deduced that the response 
of the macrophage to the stimuli must be triggering the metabolic changes observed. 
Since all treatments have in common only the MΦ it can be deduced that the response 
of the macrophage to the stimuli must be triggering the metabolic changes observed. 
To further investigate the role of the immune response in regulating the transcriptomic 
changes of metabolic genes the whole MITCH24 dataset was used. The MITCH24 
data presented in the previous chapter included the transcriptome of WT BMDM 
treated with MCMV-WT, or MCMV-KO, or poly(I:C). The entire MITCH24 data 
includes also the same data for BMDM that are IFNB1, or IFNAR1, deficient. I 
analysed the temporal expression profile of the key glycolytic genes, (Glut6, Hk3 and 
Pfkfb3) identified earlier (Fig.4.1A), in all conditions. 
 The data demonstrate that Glut6, Hk3 and Pfkfb3 are all upregulated early upon 
treatment of the WT macrophages with either MCMV-WT, or MCMV-KO or 
poly(I:C) (Fig.4.7C-E). This suggests that the upregulation of the genes is an event 
associated with the immune response reprogramming of the macrophage upon 




Figure 4.7 Type-I IFN signalling is essential for the upregulation of glycolysis. 
(A) BMDM were mock treated, or treated with MCMV-WT (ΜΟΙ 1), or MCMV-GFP 
(ΜΟΙ 1) or poly(I:C). 1.5 Hours post treatment ECAR was measured using Seahorse 
XF Extracellular Flux Analyzer and were treated with Glucose (Gluc), Oligomycin 
(Oligo) and 2-Deoxyglucose (2-DG). Each data point represents a mean ± SEM from 
one experiment with 5 biological replicates each. Poly(I:C) treatment results are 
obscured by MCMV-WT(B) As in (A) for BMDM, mock treated or treated with MCMV-
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WT (ΜΟΙ 1), or MCMV-KO (ΜΟΙ 1), or poly(I:C). (C-E) MITCH24 data. Fold change 
of expression of glycolysis genes (Glut6, Hk3 and Pfkfb3) over 24 hours in WT, or 
IFNB1-/-, or IFNAR1-/- macrophages that they have been infected with ΜCMV-WT 
(MOI 1), or MCMV IE3KO-KO (MOI 1) or treated with poly(I:C). 
TLR3 and/or TLR9 which are known to be engaged by MCMV-WT (Tabeta et al. 
2004), and other PRRs. 
The upregulation of Glut6 and Hk3 is almost completely ablated in the IFNB1-/- and 
IFNAR1-/- BMDM. This suggests that the increased expression of these genes is 
dependent on type-I IFN signalling under these conditions. The Pfkfb3 has slightly 
increase expression during WT infection in the deficient BMDM, suggesting that 
MCMV interferes with the expression of this gene, but further experiments are 
required to reach this conclusion as the current data are insufficient (Fig.4.7E). 
Nevertheless, Pfkfb3 expression is higher in the WT BMDM and its expression does 
not alter in the deficient BMDM in the other two treatments, suggesting that type-I 
IFN signalling is also required for the upregulation of the gene expression. 
Taken together, these results demonstrate that, during the early time of infection, type 
I IFN is crucial in affecting glycolysis and the TCA cycle, two pathways important for 
virus replication. 
4.7 Profiling IFN-γ stimulation of macrophages shows correlated and 
non-correlated glycolytic, TCA and Urea cycle  
Based on the beneficial role that IFN-I appears to have during early time of MCMV 
infection we decided to investigate the effects of INF-γ, a key cytokine for 
macrophages, on the previously investigated pathways. 
I analysed the MITCH12 dataset to examine whether the effects of IFN-γ treatment on 
BMDM was sufficient to induce gene expression of metabolic pathways. Similarly, to 
the experiment previously described, mature BMDM were treated with IFN-γ and the 
RNA was harvested every 30 minutes for up to 12 hours post infection (hpi) for 
microarray analysis. The first pathway investigated was glycolysis (Fig.4.8A). The 
heatmap reveals that INF-γ treatment has a profound effect on the transcriptomic 
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profiles of glycolytic genes. More specifically, all three glycolytic enzymes previously 
identified (Glut6, Hk3, Pfkfb3) exhibited increased expression levels similar the ones 
they had during MCMV-WT infection. 
There are key differences though; the expression of Glut4 and Ldhb was not 
upregulated from IFN-γ treatment (Fig.4.8A). This suggests that the expression 
induction observed for these genes in the MCMV infected MΦ could be a virus driven 
event or due to differences in signalling. Importantly, at six hours post infection, a 
distinct expression profile of almost all genes is observed (Fig.4.8A). IFN-γ 
ubiquitously upregulated the expression of almost all glycolytic enzymes especially at 
5 hours post treatment. In contrast MCMV-WT infection suppress some of these genes 
post 5 hours indicating differences in both treatments. It is interesting that earlier 
studies in type-IFN and their relationship to MCMV have indicated that it takes 6 hours 
for MCMV to block IFN-β signalling. 
The next pathway investigated was the TCA cycle (Fig.4.8B). Similar to MCMV-WT 
infection, IFN-γ appears to not have an effect on the TCA cycle, at least not on the 
transcriptomic level. The expression of the genes involved in the TCA cycle does not 
change as dramatically as in the glycolytic genes do upon with IFN-g treatment, 
making it difficult to draw clear conclusions. Further experiments are required to 
support the transcriptomics data. 
Finally, the transcription of the genes encoding enzymes in the urea cycle was studied 
(Fig.4.8C). There are similarities here between the two treatments and some 
differences as well. Ass i  upregulated along with Arg2 indicating that NO production 
is as expected favoured in proinflammatory macrophages. On the other hand, in 
contrast to what was observed during productive infection, were the genes had a slight 




Figure 4.8 Effects of IFN-γ on BMDM metabolome. (A-C) MITCH12 data for 
glycolysis. BMDM were treated with 10 Units/ml of IFN-γ and subsequently RNA was 
harvested every 30 minutes for 12 hours and hybridized on an Illumina array. (A) 
Temporal gene’s expression over 12 hours of the glycolytic pathway. Each time point 
corresponds to one independent biological sample, and columns indicate time in 
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hours. Fold changes of expression levels are represented on a Log2 scale normalised 
to time point zero (B) as in (A) for TCA cycle (C) as in (A) for the Urea cycle. 
expression levels, the rest of the genes in the cycle appear to have no change in their 
transcription levels. 
Taken together, these results suggest that INF-γ alters the metabolism of macrophages. 
Additionally, during early times of IFN-γ treatment, glycolysis and the urea cycle have 
a similar transcriptional profile with the productive infection, in a similar manner to 
that of the early phase of MCMV infection. This further reinforces the concept that 
alterations of the metabolism from the immune system might be beneficial to the viral 
infection especially early after proinflammatory signals have been received, prior to 
the cells acquiring the full anti-viral state. 
4.8 Productive infection differentially reprograms infected macrophage 
at late time of infection, associated with enhanced depletion of 
energy reserves in infected macrophages 
I hypothesized, that part of the responses observed above are a result of increased 
energy demands associated with infection and/or activation of macrophages, for 
supporting   viral progeny, and the effector function of the macrophages respectively.  
To test this hypothesis BMDM were mock infected, or infected with WT MCMV-WT, 
or MCMV-KO. After four hours and 24 hours of infection their intracellular 
metabolites were isolated and analysed using LC-MS. ATP levels are decreased in 
MCMV-WT infected macrophages, while in both MCMV-WT and MCMV-KO 
infected macrophages an increase of ADP levels was observed at four hours post 
infection (Fig.4.9A).    Another source of ATP that is readily available to cells is 
Phosphocreatine(P-C). During rest, cells can store energy in the form of  P-C that can 




Figure 4.9 Energy state of BMDM cells. (A) The creatine-phosphocreatine energy 
shuttle. (B-C) ATP-ADP and P-Cr levels in BMDM infected with MCMV-WT (MOI 1). 
At 4 hpi the metabolism was quenched and metabolites were extracted from the cells 
and the metabolites were quantified using LC-MS. Each bar point represents mean ± 
SEM of one experiment with 6 biological replicates. (D-E) AS in (B-E) at 24 hpi. One 
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way ANOVA with turkey’s correction for multiple corrections *p<0.05, **p<0.01, 
***p<0.001  Non-significant results are not shown. 
the use of oxygen, be used to replenish the ATP pool of a cell (Fig.4.9A). Infection 
with both MCMV strains depleted Phosphocreatine and increased creatine levels. 
However, productive infection appears to be more energy demanding than non-
productive infection at 4 hours post infection. Creatine levels increased more in 
MCMV-WT than in MCMV-KO infected cells and at the same time MCMV-WT 
infection almost completely depleted the cells of Phosphocreatine (Fig4.9B-C). 
At 24 hours the MCMV-WT infected macrophages continued to exhibit depleted 
energy levels, indicated by low ATP levels and high ADP levels, in comparison with 
mock and MCMV-KO infected cells (Fig.4.9D). Interestingly the levels of these two 
metabolites in MCMV-KO infected macrophages have returned to levels similar to 
mock infected cells. Phosphocreatine levels are depleted for MCMV-WT infected 
BMDM, but similar for mock and MCMV-KO infected cells (Fig.4.9E). 
Another indication that the productive infection is more energy demanding is the 
increased expression of lactate dehydrogenase b (Ldhd) presented in MCMV-WT 
BMDM. Ldhd is responsible for converting pyruvate to lactate converting NADH to 
NAD+ during the process in the absence of oxygen. It is important to keep glycolysis 
active, as NAD+ is required at an earlier part of glycolysis and without its regeneration 
it would seize to function. This also indicates that BMDM are pushed toward anaerobic 
glycolysis. Ldhd appears to be targeted by MCMV specifically since it has its 
expression upregulated in all three macrophage types, while at the same time, infection 
with MCMV-KO virus, or treatment with poly(I:C) does not alter the expression levels 
of the enzyme (Fig.4.10A).  
Taken together these experiments indicate that infection of macrophages by MCMV-
WT or MCMV-KO adds an energy burden on the cells, expected by the numerous new 
process that an activated macrophage has to acquire. This demand for increased energy 
appear to be ablated in the MCMV-KO treated cells at 24 hours in contrast to the 
MCMV-WT infected ones. The upregulation of Ldhb that was also observed at the 
MICTH12 dataset (Fig4.1B) started at later time points, at 6 hpi and peaked at 24 hpi. 
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This demonstrates clearly that MCMV starts taking over the host cell and supports the 
notion that type-I interferon signalling at early time points of infection may positively 
contribute to establish infection in BMDM. 
 
Figure 4.10 Ldhb expression in infected BMDM. (A) MICTH24 dataset. Fold 
change of expression of glycolysis genes (Glut6, Hk3 and Pfkfb3) over 24 hours in 
WT, or IFNB1-/-, or IFNAR1-/- macrophages that they have been infected with ΜCMV-
WT (MOI 1), or MCMV IE3KO-KO (MOI 1) or treated with poly(I:C). 
4.9 Discussion 
The data presented in this chapter demonstrate that infection of MCMV alters the 
metabolome of infected BMDM significantly. More specifically, the expression of 
Glut6, Hk3 and Pfkfb3 was induced. These genes are involved in key regulatory steps 
of theglycolytic pathway. Functional assays using Seahorse XF Extracellular Flux 
Analyzer in agreement indicate an increase of lactate production in MCMV infected 
BMDM in comparison to mock-infected cells. The metabolomics data in combination 
with the transcriptomic data also reflect this change, indicating an increase in the 
glycolytic flux very early during infection. Multiple studies have been published by 
other groups demonstrating that DCs or macrophages treated with TLR ligands 
demonstrate an increase in their glycolytic fluxes, associated with transcriptional and 
post transcriptional changes in their metabolism(Everts et al. 2014; Krawczyk et al. 
2010; Jantsch et al. 2008; Rodríguez-Prados et al. 2010; Haschemi et al. 2012). 
The TCA cycle was also significantly altered. The expression of enzymes up to OGDH 
was down regulated. At the same time the expression of Ogdh, Scs, Sdh, was 
upregulated. The fact that the changes in mRNA level are small and that a lot of these 
enzymes are composed of multiple components do not allow for a clear picture. 
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However, combined with metabolomics data, these changes indicate that the TCA 
cycle is uncoupled at two points, at the enzymatic reaction catalysed CS and OGDH, 
Acetyl-CoA, Citrate and cis-Aconitate are all consumed this in conjunction with the 
transcriptomics data of the TCA cycle indicating that citrate is being consumed by 
other pathways outside of the mitochondria. At the same time α-KG levels are 
diminished while fumarate and succinate levels are steadily increasing, indicating a 
rapid conversion of α-KG to these two molecules. Malate appears to be accumulated, 
which could be attributed to increased synthesis of malate either by fumarate or 
oxaloacetate. Malate is used in the malate-aspartate shuttle to transfer NADH 
equivalent outside of the mitochondrion or oxaloacetate because both molecules 
cannot leave the mitochondrion (Jespersen et al. 2017).  
The data presented here support the notion that citrate is being shuttled outside the 
mitochondria, probably to support FA production in the cytosol, while the rest of the 
TCA cycle operates anapleroticly. Many studies  havedemonstrated that OXPHOS is 
abolished and the TCA cycle is uncoupled in DCs and ΜΦ treated with TLR ligands 
(EL Kasmi and Stenmark 2015; Mills et al. 2016; Everts et al. 2014; Jha et al. 2015; 
McGettrick and O’Neill 2013). It has been shown that under these conditions ΜΦ 
accumulate succinate that can promote ROS generation and inflammation through 
HIF-1a. I did not sought to observe these effects in my thesis, but it should be noted 
that the vast majority of these studies have focused on researching the effects of a 
single TLR molecule on the metabolism of these cells, which is usually  LPS.  
In my thesis, I study a more complicated and realistic model of infection. MCMV is a 
natural infectious virus for murine MCMV, and MCMV engages at the same time 
multiple PRR, as reviewed in the introduction. The multiple signalling inputs should 
tune the infected macrophage differently than the engagement of a single TLR. Finally, 
the virus will initiate its own transcriptional programming in the infected cells further 
modifying amongst others the metabolism of infected cells. 
The Urea cycle was also heavily altered to support NO production in MCMV infected 
BMDM. The transcriptomic data reveal a rapid induction of Ass1 and Arg2. The 
metabolomics data indicate that NO production is heavily favoured with accumulation 
of citrulline in the infected cells, indicating that the pathway is altered to support NO 
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production. The production of NO from proinflammatory macrophages is well 
established in the literature and has a protective role especially during bacterial 
infections (Qualls et al. 2012; Morris 2004; El Kasmi et al. 2008; Jha et al. 2015). 
Arginase activity though is usually associated with M2 macrophage and not 
proinflammatory ones. However, while this is true for ARG1, the association of ARG2 
activity and its effects on macrophage phenotype have not been studied so extensively 
(Z. Yang and Ming 2014) 
The amino acids homology of both enzymes is 50% and rises to 100% for amino acids 
at their catalytic centres. Moreover, both enzymes can hydrolyse arginine. Because of 
this it is usually extrapolated that induced expression of Arg2 would have the same 
effects as Arg1 in macrophages. While ARG1 localises in the cytoplasm and ARG2 
localises in the mitochondrion, and not enough is known about the consequences that 
their respective localisation has on the function of these enzymes (Crombez and 
Cederbaum 2005). Ming et al. have demonstrated induction of Arg2 expression in 
macrophage after LPS stimulation (Ming et al. 2012). They also note that the 
expression is induced in parallel with iNOS. Khallou-Laschet et al. have demonstrated 
that M1 BMDM express preferably Arg2 while M2 BMDM preferably express Arg1 
(Khallou-Laschet et al. 2010). There is no conclusive answer yet as of the role of 
ARG2 in macrophages, despite that these studies indicate that the induced expression 
of Arg2 in my dataset may not be an oddity. 
My experiments indicate that upregulation of glycolysis is critical for MCMV growth, 
as pharmacological inhibition of the pathway hampered viral growth. KD of Hk3 and 
Pfkfb3 by siRNA inhibited viral growth and 2-DG inhibition of the glycolytic pathway 
also blocked MCMV growth. The idea that inhibition of glycolysis will inhibit viral 
infection is not new, as Radsak and Weder used, in 1981, 2-DG to inhibit HCMV 
replication (Radsak and Weder 1981).  
Interestingly, while the virus appears to be dependent on the glycolytic pathway, so 
are macrophages during inflammation.  Although I have not conducted any studies to 
support this, it is well established by literature that proinflammatory DCs and 
macrophages require increased glycolytic activity to support their effectors functions. 
The inhibitory effects of NO in OXPHOS make glycolysis the only alternative 
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pathway in energy production. Thus, its upregulation promotes DC survival and allows 
the cell to acquire its full phenotype by upregulating receptor CD40, interleukin 6 (IL-
6), and TNF- among others(Everts et al. 2014; Krawczyk et al. 2010; Everts et al. 
2012). Similarly, upregulation of glycolysis supports ΜΦ proinflammatory function 
by a number of ways, such as promotion of IL1- production, efferocytosis of infected 
cells, cell migration, and NPLR-3 inflammasome (Tannahill et al. 2013; Jiang et al. 
2016; Palsson-McDermott et al. 2015; Xie et al. 2016; Semba et al. 2016). 
These observations by myself and others lead to the hypothesis that MCMV might be 
co-opting proinflammatory signals to promote a metabolic profile in infected ΜΦ that 
suitable to sustain viral progeny. My experiments indicate that the upregulation of 
glycolysis, crucial for both ΜΦ function and MCMV growth, is dependent on type-I 
ΙFN signalling. The induction of the Glut6, Hk3 and Pfkfb3 enzymes is evident 
predominately in WT macrophages, while BMDM deficient in type-I IFN signalling 
exhibited none or very low induction. This is in agreement with previously published 
data by Pantel et al. and Jiang et al. (Pantel et al. 2014; Jiang et al. 2016). Pantel et al. 
clearly demonstrated that the shift to glycolysis in poly(I:C) treated DCs was depended 
on type-I IFN and not MD5A/TLR signalling. Jiang et al. showed that IFN-β induces 
Pfkfb3 mRNA in treated BMDM. Moreover, the induction of the three enzymes takes 
place very early during infection (Pfkfb3 at 30 min post infection, Glut6 and Hk3 at 
3.5 hpi). At this time, it is unlikely for MCMV to have taken control of infected cells 
and it is more likely that immune signalling is directing the metabolic changes 
observed in the glycolytic pathway. Moreover, it has already been established that it 
takes more than 6 hours for MCMV to block IFN-β signalling in MΦ(Le et al. 2008). 
Thus, any effects that IFN-I on ΜΦ metabolism will be unhindered so early during 
infection. 
MCMV is, however, not a bystander, at later stages of infection the virus takes over 
the cell and alters its metabolome, as evident by the data presented in Chapter 3 and 
here by the temporal transcription of Ldhb. The induction of Ldhb transcription is 
driven mainly by the MCMV-WT infection as both non-productive infection and 
poly(I:C) treatment do not induce it. Furthermore, this induction is evident only at later 
time points in both MITCH12 and MITCH24 data sets at 8 hpi for both. The 
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upregulation of LDH is crucial as glycolysis to be active even when oxidative 
phosphorylation (OXPHOS) is not functional or when enough NAD+ cannot be 
generated. In the absence of OXPHOS or when not enough NAD+ is regenerated by 
the TCA cycle, e.g. when under exercise, LDH replenishes NAD+, which is a crucial 
coenzyme for GAPDH to function.  
Given the evidence provided, my hypothesis that MCMV coops the metabolic 
programming of activated BMDM during early times of infection is supported. I have, 
however, not generated any data to demonstrate that this adaptation of MCMV allows 
the virus to establish infection in the host in vivo during the first few hours of infection. 
However, MCMV has already been described to co-opt immune system signalling to 
establish infection in the host. Several studies have demonstrated that MCMV can co-
op the immune signalling by promoting its viral enhancer activity (K. A. Kropp et al. 
2015; Benedict et al. 2004). Kropp et al. have demonstrated  that there is a temporal 
opening early during infection when TLR activity promotes viral growth, after which 
TLR activity inhibitory because of the establishment of an antiviral state in the cells(K. 
A. Kropp et al. 2015). Similar evidence has been published for HCMV. LPS treatment 
of CD14+ monocytes promotes their permissiveness to MCMV (Kew, Wills, and 
Reeves 2017). Furthermore, it has been shown that APC-1 and NF-κB and AP-1 
activity promotes viral IE gene expression (Caposio et al. 2007; Isern et al. 2011; M. 
K. Isaacson, Juckem, and Compton 2008). Additionally, HCMV MIEP contains 
Gamma interferon activation sites (GAS) elements and, which can make the IE gene 
expression inducible by IFN-γ(Netterwald et al. 2005).  In fact multiple immune genes 
are hijacked by viruses are seen in this review (Santoro, Rossi, and Amici 2003). 
It is, thus, not difficult to hypothesise that since MCMV and HCMV have already 
evolved ways to co-op immune signalling, co-opting the metabolic programming in 
cells should not be that far-fetched. After all viruses grow in the niche environment of 
an immune response, so there should be an evolutionary pressure onto them to co-op, 
or counteract the environment they meet. During the first few hours of infection when 
few cells have been infected, the virus has not yet been detected by the immune system, 
but some cells included MΦ are infected and an immune response is triggered in them. 
Co-opting the cellular environment of host cells might be a good strategy to establish 
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infection during this time. Typically, in in vitro and in vivo MCMV infections, high 
MOIs are used, which can overwhelm an in vitro cellular system or an in vivo system. 
This is not the case in normal infections were very few cells are infected by the virus. 
Thus, while this strategy might not be important in artificial systems that are usually 
studied, it might be important for natural infections. Crucially, the deletion of the GAS 
elements from the HCMV MIEP appears to have an effect on viral growth only at low 
MOIs and not high ones, which is closer a natural infection scenario (Netterwald et al. 
2005). 
Regarding the functional role of glycolysis during MCMV infection some data are 
presented in this chapter. The data support the idea that it glycolysis is upregulated to 
sustain the increased energy demands by the activated macrophages early and viral 
replication later. Both productive and non-productive infection deplete macrophages 
of energy at early time points indicating, as expected that the activation of the ΜΦ and 
acquisition of their pro-inflammatory phenotype requires energy. At 24 hpi however 
non-productively infected BMDM appear to have replenished their phosphocreatine 
levels and have similar ones with mock-infected cells and only MCMV-WT infected 
BMDM remain depleted in energy reserves. The increased energy demands of 
MCMV-WT infected macrophages could be supported by the induction of Ldhb, while 
the non-productively. 
Increased energy demands are not the only reason for increased glycolysis and the 
alterations observed in the TCA cycle. Increased flux through glycolysis allows for the 
generation of extra energy and the shuttling of carbon molecules in the TCA cycle, 
where they can be oxidised up for more energy generation and/or to support 
biosynthesis of other molecules.  Several studies have demonstrated that HCMV 
increases the FA synthesis pathway (Purdy, Shenk, and Rabinowitz 2015; Koyuncu et 
al. 2013; Munger et al. 2008; Vastag et al. 2011). Briefly, the authors of these studies 
demonstrate using 13C labelling that citrate is being shuttled outside the mitochondria 
to support FA elongation in infected human fibroblasts. MCMV might be pushing 




5 Chapter 5 Fatty acid and signalling lipid metabolism 
during MCMV infection in BMDM 
5.1 Introduction 
This chapter will be separated in two smaller chapters that study different aspect of 
lipid metabolism. In the first section I will address the effect of MCMV infection in 
BMDM on FA biosynthesis. In the second smaller chapter I will extend this analysis 
on the study of signalling lipids and more precisely eicosanoids. 
5.2 Fatty acid metabolism during MCMV infection in BMDM 
5.2.1  Introduction 
In chapter 4, evidence is presented to suggest that MCMV infection opportunistically 
co-opts early pro-inflammatory changes that take place in infected MΦ (chapter 4). 
One of the pathways affected was the glycolytic pathway that was rapidly induced 
during infection. This response is under type-I IFN control, since type-I IFN deficient 
BMDM infected with MCMV did not exhibit the same induced expression in 
glycolysis enzymes. MCMV is dependent on the increased glycolytic flux and its 
inhibition blocks and appears to be co-opting the early response of the immune system.  
I did not study the effects of increased glycolysis on proinflammatory macrophages, 
but there are numerous studies that have demonstrated its importance and the ways it 
is beneficial, which was reviewed earlier(Jiang et al. 2016; Jha et al. 2015; Everts et 
al. 2012; Galván-Peña and O’Neill 2014) The dependency of MCMV growth on the 
glycolytic pathway, which is also required by innate immune cells had not yet been 
studied. I provided evidence demonstrating that the induction of the glycolytic 
pathway could support the increased energy demands of MCMV during productive 
infection. MCMV-WT infected BMDM have depleted energy reserves in comparison 
to mock and infected cells at 4 and 24 hpi. 
This is not conclusive though as the glycolytic pathway, apart from providing energy, 
also shuttles carbon atoms to the TCA cycle through its end product pyruvate. In the 
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TCA cycle pyruvate, can be further oxidised to generate energy or serve as precursor 
for other molecules in pathways that intersect with the TCA cycle. The increased 
carbon atoms flux though could be utilised by other biosynthetic pathways one of the 
most notables being FA. 
HCMV, the human homolog of MCMV, has been shown to dramatically alter the cell 
metabolome in a manner that resembles the metabolism of highly proliferating cancer 
cells  and induce FA synthesis(Yu, Clippinger, and Alwine 2011; Spencer et al. 2011; 
Swinnen, Brusselmans, and Verhoeven 2006; D. L. Diamond et al. 2010). Munger et 
al. demonstrated, using 13C labelling, that HCMV infection dramatically increases the 
uptake of glucose and alters the TCA cycle(Munger et al. 2008). During HCMV 
infection of Human foreskin fibroblasts (HFF) the TCA cycle was not used only 
catabolically to generate ATP, but also anabolically to facilitate the fatty acid (FA) 
production(Munger et al. 2008). In the TCA cycle, pyruvate is converted to citrate, 
which should be shuttled out of the mitochondrion to be converted in Malonyl-CoA, 
the building blocks for FA biosynthesis and elongation. 
By inhibiting two key FA biosynthesis enzymes; Acetyl-CoA carboxylase (ACAC) 
and FASN, Spencer et al. demonstrated that HCMV growth was also inhibited 
(Spencer et al. 2011). HCMV does not simply upregulate FA biosynthesis, but rather 
requires specifically the biosynthesis of saturated Very Long Chain FAs (VLCFA) to 
propagate effectively(Koyuncu et al. 2013).  Additionally, in this study it was shown 
that HCMV specifically upregulates Elovls, with Elovl7, 3, and 4 being the most 
important. 
Given the data presented in the previous chapter and the studies reviewed here it was 
hypothesized that: MCMV modulates metabolism in infected MΦ at late stages of 
infection towards FA elongation and lipid membrane remodelling to promote viral 
progeny: This raises a series of questions to be answered in this chapter. 
1) Does MCMV-WT infection specifically upregulate FA elongation pathway? 
2) Is this an effect triggered by the WT infection or the immune response? 
3) Does inhibition of FA biosynthesis block MCMV replication? 
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5.2.2 Temporal transcriptomics and metabolomics analysis of Fatty acid metabolism 
during MCMV infection in BMDM 
5.2.2.1 MCMV-WT specifically upregulates genes related to FA and lipid 
biosynthesis 
De novo FA biosynthesis starts in the cytosol by the conversion of citrate to Acetyl-
CoA via ATP Citrate Lyase (ACLY). Two Acetyl-CoA molecules are then converted 
by Acetyl-CoA Carboxylase Alpha (ACACA) to Malonyl-CoA which can then be 
used either by FASN (Wakil, Stoops, and Joshi 1983) to synthesise palmitate or by the 
elongation system in the ER to elongate FAs (Fig.5.1A). To investigate FA 
biosynthesis in the context of viral infection I performed (as described in Methods) a 
temporal analysis of the gene expression of infected BMDM cells. For this purpose, 
the microarray dataset MITCH24KO, a resource available in to our lab, was used. 
Briefly for MITCH24KO, BMDM from WT, or IFNAR, or IFNB1 deficient C57BL/6J 
mice were used. These were mock treated, or treated with MCMV-WT (MOI=1), or 
MCMV-KO (MOI=1), or poly(I:C). The RNA from each treatment and cell type was 
isolated at 0, 2, 4, 6, 8, 10, 12 and 24 hours post treatment and high-quality RNA was 
hybridised to an Affymetrix Mouse Gene 1.0ST microarray. 
An analysis of this data shows that MCMV infection of BMDM results in the induction 
of key enzymes that participate in the elongation of FAs (Fig.5.1B). The expression of 
Elovl3, 4 and 7 exhibit a substantial increase specifically during productive infection. 
Elovls catalyse the first and rate limiting step in FA elongation (Jakobsson, 
Westerberg, and Jacobsson 2006). ELOVL7 has been identified by Purdy et al. as the 
most important enzyme for the catalysis of the lipidome remodelling in HCMV 
infected cells (Purdy, Shenk, and Rabinowitz 2015). 
Acyl-CoA Synthetase Long-Chains (ACSLs) are essential proteins for the d  novo lipid 
synthesis, FA metabolism, and membrane remodelling. FA are chemically inactive 
because of the -COOH moiety. In order for the cells to use FA, they convert FA to 
their active thioester form. This reaction is being catalysed by ACLSs (Soupene et al. 
2012). In the treated BMDM (Fig.5.1B), Acsl1 was the only Acsl gene that exhibited 
changed temporal expression. This change was observed in all three treatments, 
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indicating it might be linked to alterations in the lipidome of activated macrophages, 
which has also been observed in LPS treated macrophage(Y. L. Huang et al. 2014). 
Membrane Bound O-Acyltransferases (MBOATs) do not contribute directly to FA 
biosynthesis, but are important for lipids processing (C. C. Y. Chang, Sun, and Chang 
2011). Mboat2 was significantly upregulated specifically during productive infection 
indicating that MCMV-WT induces the transcription of the gene. Additionally, 
Mboat1 also appears to be under viral control since the gene was initially 
downregulated, but returned to its previous transcription levels only during productive 
infection. Furthermore, the data from Ifnar1-/- and Ifnb1-/- BMDM indicate that the 
gene is not under type-I interferon control (Fig.5.2A-B), and the MITCH12 data reveal 
that Mboat1 is downregulated after IFN-γ treatment (Fig.S7.2).  
Mboats are divided in 3 subgroups; both Mboat1 and Mboat2 belong to the third 
subgroup named Lysophospholipid acyltransferases (LPATs). These proteins are 
essential in membrane phospholipid remodelling. Phospholipases can cleave the FA 
that occupies position two in a phospholipid and then a LPAT re-acylates the 
phospholipid (C. C. Y. Chang, Sun, and Chang 2011; Naganuma et al. 2011; Tamura 
et al. 2009).  
Diacylglycerol O-Acyltransferase 2 (DGAT2) expression is also specifically induced 
during MCMV-WT infection. Diacylglycerol O-Acyltransferases (DGATs) are 
proteins involved in the generation of triacylglycerols and catalyse the final and 
committing step in triacylglycerol synthesis (Stone et al. 2009). Triacylglycerols form 
Lipid Droplets (LD) in a cell were fatty acids and other lipids like, cholesterol, are 




Figure 5.1 Temporal transcriptomics analysis of FA biosynthesis in WT 
macrophages. (A) The FA biosynthesis and elongation pathway. (B) Heatmap of the 
FA biosynthesis temporal gene’s expression over a 24 hour period in BMDM treated 
with MCMV-WT (MOI 1), or MCMV-KO (MOI 1) or POLY(I:C). Each gene is 
represented in a row and has been normalised to time point 0. Mboat1: membrane 
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bound O-acyltransferase domain containing 1; Mboat2: membrane bound O-
acyltransferase domain containing 2; Mboat3: membrane bound O-acyltransferase 
domain containing 3; Mboat4: membrane bound O-acyltransferase domain containing 
4; Acly: ATP citrate lyase; Acaca: acetyl-Coenzyme A carboxylase alpha; Acacb: 
acetyl-Coenzyme A carboxylase beta; Fasn: fatty acid synthase; Acsl1: acyl-CoA 
synthetase long-chain family member 1; Acsl3: acyl-CoA synthetase long-chain family 
member 3; Acsl4: acyl-CoA synthetase long-chain family member 4; Acsl5: acyl-CoA 
synthetase long-chain family member 5; Acsl6: acyl-CoA synthetase long-chain family 
member 6; Elovl1: elongase of very long chain fatty acids 1; Elovl2: elongase of very 
long chain fatty acids 2; Elovl3: elongase of very long chain fatty acids 3; Elovl4: 
elongase of very long chain fatty acids 4; Elovl5: elongase of very long chain fatty 
acids 5; Elovl6: elongase of very long chain fatty acids 6; Elovl7: elongase of very 
long chain fatty acids 7; Scd1: stearoyl-Coenzyme A desaturase 1; Scd2: stearoyl-
Coenzyme A desaturase 2;  Scd3: stearoyl-Coenzyme A desaturase 3;  Scd4: 
stearoyl-Coenzyme A desaturase 4; Dgat1: diacylglycerol O-acyltransferase 1; Dgat2: 
diacylglycerol O-acyltransferase 2. 
Finally, Stearoyl-CoA Desaturases (SCDs) are essential for the desaturation of FAs. 
There are four isomers in mouse, and SCD1 is a Δ9 desaturase that converts 12-18 
carbon saturated FA, to monounsaturated FA by inserting a cis double bond at the 9th 
carbon atom(Sampath and Ntambi 2014). 
To confirm that the changes observed above were not induced by type-I IFN signalling, 
the temporal gene expression of the same genes was also generated in Infb1-/- and 
Ifnar1-/- BMDM. Heatmaps for the same genes were generated, as above, for both 
macrophage types deficient in type-I IFN (Fig.5.2A-B). The expression of Elovl3, 4 
and 7, Scd1, Mboat1 and Mboat2 increased specifically during productive infection 
even in these type-I deficient BMDM, suggesting that the genes are upregulated 
selectively by MCMV taking control of the host cells. Interestingly Scd1 appears to be 
upregulated in the poly(I:C) treated Ifnar1-/- ΜΦ. This could be either a false signal, 
or it could be the result of the differences in signalling among the different cell lines 
and treatments. Poly(I:C) treatment engages TLR3, but cells productive or non-
productive infection engage multiple PRR resulting in differences in the outcome. 
Scd1 might be under immune system control, but not type-I interferon. Acsl1, on the 
other hand, has an increased expression across all treatments and all BMDM types 
reinforcing the idea that this gene might be part of the immune system response, but 




Figure 5.2 Temporal transcriptomics analysis of FA biosynthesis in WT 
macrophages. (A) Heatmap of the FA biosynthesis temporal gene’s expression over 
a 24-hour period in IFNAR-/- BMDM treated with MCMV-WT (MOI 1), or MCMV-KO 
(MOI 1) or poly(I:C). Each gene is represented in a row and has been normalised to 
time point 0. (B) Like A for IFNB1-/- BMDM. 
To validate the results obtained by microarray, the expression level of some of the 
genes was confirmed using qRT-PCR, I chose at least one gene from each of the 
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protein categories listed above, Elovls, Dagts, MBoats and Scds, and genes that 
exhibited a fold change >1.5 in combination with high expression levels late in 
productive infection. It should be noted that Elovl3, 5 and 7, Scd1, Mboat1, Mboat2 
and Dgat2 expression is very low in uninfected cell or early during infection (6 < hpi) 
and it was a challenge to accurately measure them, even by qRT-PCR.  
The expression levels for all genes, except Acly, and Scd1, was significantly 
upregulated specifically during productive infection (Fig.5.3A-F). Scd1 expression is 
downregulated in both treatments (MCMV-WT and MCMV-KO) before the 
expression was induced specifically during productive infection. The down regulation 
of Scd1 during inflammation might be important and not an artefact. Another study 
has demonstrated that genes involved in the production of unsaturated FA are 
downregulated early in BMDM treated with Kdo2 LIPID A (KLA), while their 
expression is induced later to help resolve inflammation through the mediation of 
unsaturated FAs (Oishi et al. 2016).   
As mentioned above the expression levels of El vl4, Elovl7, Mboat2, and Scd1 are 
very low in uninfected cells making it very challenging to detect them. Their 





Figure 5.3 Fatty acid metabolism genes are induced specifically during 
productive infection. (A-F) BMDM were infected with MCMV-WT (MOI 1) or MCMV-
KO (MOI 1) and total RNA was harvested at 6, 12 and 24 hpi. The transcript levels of 
Acly, Mboat2, Dgat2, Elov4&7 and Scd1 were calculated in comparison to mock 
infected cell at 0 hpi. 3 Independent experiments with (n=3) mean ± SEM. T-test with 
Welch’s correction *p<0.05, **p<0.01, ***p<0.001. 
 
 
The two genes with the highest induction (Elovl4 and Elovl7) in the productively 
infected cells versus non-productively infected cells were chosen for further study. The 
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expression levels of Elovl4 and Elovl7 was also investigated using different MCMV 
strains (MCMV-GFP and MCMV-(MCK2+ GFP)) and measured using qRT-PCR. 
MCMV-(MCK2+ GFP) is discussed in more detail in the methods section. Briefly the 
MCMV-WT strain that I used during my thesis work does not express the MCK2 
protein. MCK2 increases infectivity of MCMV during in vivo infection via multiple 
methods, one of which is by attracting ΜΦ at the site of infection (Saederup et al. 
1999; Stahl et al. 2014). Based on my experiments i  vitro, infection of BMDM or 
NIH/3T3 cells by MCMV-(MCK2+ GFP) resulted in similar infection levels as that 
observed upon infection with MCMV-WT. 
For these experiments, BMDM were mock infected or infected with MCMV-KO, or 
MCMV-GFP, or MCMV-(MCK2+ GFP) for 24 hours. Elovl4 and Elovl7 both exhibit 
remarkably increased expression compared to non-productively infected cells or mock 
infected cells (Fig.5.4A). Taken together these data confirm that the productive 
infection, and not the immune system, specifically upregulates the expression of the 
Elovl4 and Elovl7. 
To determine if the upregulation of the Elovl genes was dependent on viral DNA 
replication, an experiment was devised using Ganciclovir. Ganciclovir, an antiviral 
drug, inhibits viral DNA replication (McGavin and Goa 2001) by targeting MCMV 
DNA polymerase and preventing DNA elongation. BMDM were infected with 
MCMV-KO or MCMV-WT, subsequently cells infected with MCMV-WT were 
treated with vehicle or with 10μΜ Ganciclovir. BMDM treated with Ganciclovir 
showed a similar expression profile for Elovl4 and Elovl7 as BMDM infected with 
MCMV-WT (Fig.5.4B). 
In herpes virology genes are classified as IE genes, Early genes and Late genes based 
on the timing of their transcription. IE early genes require no de novo viral protein 
synthesis to begin transcription, while Early genes required de novo viral protein 
synthesis and Late genes require both de novo protein and viral genome replication. 
Since Ganciclovir blocks late gene transcription, it can be inferred that the induction 




Figure 5.4 Fatty acid elongation genes induction occurs in the presence of 
Ganciclovir. (A) BMDM were mock infected or infected with MCMV-KO (MOI 1), or 
MCMV-GFP (MOI 1), or MCMV (MCK2+ GFP+) (MOI 1). At 24 hpi RNA was isolated 
and the relative expression of the transcripts was determined with qRT-PCR (B) 
BMDM were mock infected or infected with MCMV-KO (MOI 1), or MCMV-WT (MOI 
1). After 1 hour of absorption period cells infected with MCMV-WT were treated or not 
treated with 10μΜ Ganciclovir. 2 Way ANOVA with Sidak’s multiple correction method 
was used*p<0.05 **p<0.01, ***p<0.001. 
 
5.2.2.2 MCMV-WT greatly increases the presence of long chain FA in infected 
macrophages 
In productively infected cells, the increased gene expression of Elovls results in an 
altered metabolomics profile, as productively infected macrophages have increased 
levels of free FA during late stages of infection in comparison to non-productively 
infected cells (Fig.5.5A-I). All the long chain FAs identified in the macrophages, apart 
from docosahexaenoic (DHA), are more abundant in the productively infected 
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macrophages. At the same time the increase in biotin levels, an important FA 
biosynthesis coenzyme, and the depletion of Acetyl-CoA (Fig.5.5J-K) also support 
the notion that there is a switch to FA anabolism, as shown by the transcriptomics data 
presented earlier. 
In comparison to non-productively infected macrophages, DHA is the only fatty acid 
that is not detected as more abundant in the productively infected macrophages. DHA 
is an omega-3 fatty acid that has 22 Carbons and 6 double bonds with the first double 
bond at position 4 and the rest at 7, 10, 13, 16 and 19. For many years it was assumed 
that the synthesis of this fatty acid required the presence of a Δ4 desaturase (Sprecher 
2000). Contrary to this Howard Sprecher demonstrated that some polyunsaturated long 
FA, like DHA, are synthesised through the Sprecher shunt. More specifically, he 
concluded that polyunsaturated long FA, like DHA, are first elongated to 24 carbon 
atoms, they then get unsaturated and finally they are cleaved to the appropriate length 
(Voss et al. 1991; Leonard et al. 2002; Sprecher 2000). This might explain why DHA 
levels appear to be similar in BMDM infected with MCMV-WT and MCMV-KO. 
Since the production of DHA requires, in addition to the FA elongation pathway, the 
Sprecher shunt, which does not appear to be engaged according to my data at the 
transcriptional level. 
The data presented here complement the transcriptomic analysis that I undertook in 
section 5.2.2.1, and support the notion that there is an increase in the FA synthesis in 





Figure 5.5 Fatty acids levels in productively or non-productively infected 
macrophages. (A-K) BMDM were grown for 7 days. Then they were mock infected 
or infected with MCMV-WT or MCMV-KO. At 24 hpi intercellular metabolites were 
isolated by the cells and were measured with LS-MS. Mean ± SEM (n=6). One way 
ANOVA with Turkey’s correction correction *p<0.05, **p<0.01, ***p<0.001. Non- 






5.2.3 Inhibition of fatty acid biosynthesis attenuates MCMV growth  
5.2.3.1 Pharmacological Inhibition of fatty acid biosynthesis attenuates MCMV 
growth  
I hypothesised that productive infection of MCMV specifically requires fatty acid 
biosynthesis. To examine this hypothesis, I pharmacologically inhibited fatty acid 
biosynthesis using C75, a FASN inhibitor, and 5-(Tetradecyloxy)-2-furoic Acid 
(TOFA), an ACACA inhibitor (Jin et al. 2010; Kariya and Wille 1978). It is important 
to note that TOFA inhibits both fatty acid elongation and the de novo fatty acid 
biosynthesis, because it inhibits malonyl-CoA production, whereas C75 inhibits only 
the de novo fatty acid biosynthesis. 
To assess the level of cytotoxicity in NIH/3T3 cells, NIH/3T3 cells were treated with 
increased doses of C75 or TOFA and their cell viability was assessed 48 hours post 
treatment using CellTiter-Blue assay. Both drugs did not affect the cells’ viability at 
the concentrations used (Fig.5.6A-B).  
NIH/3T3 cells were then infected with MCMV-GFP and subsequently treated with 
increased doses of C75 or TOFA to determine the effect of both drugs on viral growth. 
The viral growth was assessed by measuring the GFP signal. The generated IC50 values 
for C75 and TOFA demonstrate that both drugs were able to inhibit viral growth at 
concentrations below any cytotoxicity effects(Fig.5.6C-D). Both drugs exhibited the 
same inhibitory effects on viral growth, as assessed using plaque assay, when they 
were tested in BMDM or RAW264.7 cells that were infected with MCMV-GFP 
(Fig.5.6E-F).  
Cells grown in lipid-deficient media would have increased need for fatty acid 
biosynthesis, thus, it is likely that any effects fatty acid inhibitors have will elicit a 
different response under these conditions. To test this, NIH/3T3 cells were grown in 
media supplemented with delipidated serum (DLPS). Subsequently, cells were 
infected with MCMV-GFP and treated with C75. The results demonstrate that in the 
presence of DLPS, MCMV-WT is more sensitive to inhibition of the FA biosynthesis 




Figure 5.6 Inhibition of fatty acid biosynthesis hampers MCMV growth. (A) 
NIH/3T3 fibroblasts were seeded in 96 well plates and treated with increasing dosage 
of C75 the following day. After 48 hours, their viability was assessed using the 
CellTiter-Blue Assay. Mean ± SEM of four independent experiments (n=6) (B) Same 
as B for TOFA. (C) NIH/3T3 fibroblasts were seeded in 96 well plates. Cells were 
infected with MCMV-GFP the following day (MOI 0.1) and subsequently incubated 
with media supplemented with C75 at increasing concentrations. The level of infection 
was determined by measuring the GFP signal. Mean ± SEM of four independent 
experiments (n=6). (D) Same as C for TOFA. (E) BMDM from C57BL/6J mice were 
seeded in 24 well plates. They were subsequently infected with MCMV-GFP (MOI 1) 
and incubated in media supplemented with C75. On day 4, post infection, the media 
was collected and the viral titre was assayed by plaque assays. Mean ± SEM of three 
independent experiments (n=3). (F) Same as E with RAW264.7 macrophages treated 




Taken together these results reveal the importance of FA biosynthesis pathways for 
MCMV in multiple cell types including the FA elongation pathway.  The evidence 
provided here is not conclusive regarding the effect of inhibition of FA elongation on 
MCMV growth. TOFA inhibits both pathways by restraining the production of 
Malonyl-CoA, which is the building block for FAs, while on the other hand C75 
inhibits only de novo fatty acid biosynthesis. Since both drugs exhibited antiviral 
effects it is impossible to characterise the effects that FA elongation has on viral 
growth. I can only conclude that de novo fatty acid biosynthesis inhibition attenuates 
MCMV growth. 
5.2.3.2 siRNA knockdown of fatty acids elongation and membrane remodelling 
pathways inhibits MCMV growth 
Previously, I demonstrated that pharmacological inhibition of FA biosynthesis 
attenuates viral growth in different cell types. However, the drug inhibitors to my 
disposal affected either de novo FA biosynthesis only, or affected both de novo FA 
synthesis and elongation pathways. Additionally, drugs can have off-target effects 
especially at higher concentrations.   
To independently corroborate the studies presented above and further investigate the 
effects of the FA elongation and lipid remodelling pathway, I utilised a siRNA 
knockdown (KD) assay. Several genes of the elongation pathway (Elovl4, 6 & 7), two 
genes of the Mboat family (Mboat1&2) and Dgat2, were chosen for knockdown in the 
knockdown assay in NIH/3T3 cells that were infected with MCMV. Prior to the 
infection experiments, the knockdown efficiency (KD) and the toxicity of the siRNAs 
were tested. To assess cell toxicity, NIH/3T3 were transfected for 48 h and 
subsequently cell viability was assayed using the CellTiter-Blue Assay. Figure 5.7A 
demonstrates that KD of Mboat2, Dgat2 and Scd1 was toxic to the cells. This was also 
apparent by visual examination of the wells, as the monolayer was severely damaged. 




Figure 5.7 siRNA knockdown of fatty acids elongation and membrane 
remodelling pathways inhibits MCMV growth. (A) NIH/3T3 fibroblasts were 
transfected in 96 well plates with 25 nM siRNA for 48 hours. Subsequently, the cell 
viability for each treatment was assessed using the CellTiter-Blue Assay Mean ± SEM 
of three independent experiments (n=6) (B) NIH/3T3 fibroblasts were transfected in 
48 well plates with 25 nM siRNA for 24 hours. Subsequently, the cells were infected 
for 24 with MCMV-GFP (MOI 1), and their RNA was isolated and the transcript level 
of each gene was determined using qRT-PCR. Mean ± SEM of two independent 
experiments (n=4). Comparison to Risc Free treated cells (C) NIH/3T3 fibroblasts 
were transfected in 96 well plates with 25 nM siRNA for 48 hours. Subsequently, they 
were infected for 24 with MCMV-GFP (MOI 0.1) and the level of infection was 
determined by measuring the GFP signal. Mean ± SEM of four independent 
experiments (n=6). One way ANOVA with Dunnett’s correction for multiple 
comparisons *p<0.05, **p<0.01, ***p<0.001. 
 
To determine the KD efficiency, NIH/3T3 were transfected and after 48 hours RNA 
was harvested and the abundance of each transcript was assayed by qRT-PCR. 
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Because of the very low expression values of these genes in cells, it was difficult to 
determine accurate KD values. To overcome this problem, an alternative method was 
employed described in Methods 2.4.2. Briefly, in order to induce the expression of the 
genes, cells were first transfected for 24 hours followed by infection with MCMV-
GFP (MOI 1). After 24 hours of infection (48h after transfection), RNA was harvested 
and the abundance of each transcript was assayed by qRT-QPCR. KD efficiencies 
greater than 90% was achieved for the genes assayed (Fig.5.7B).  
Knocking down the expression of the Elovl4,6, &7 and Mboat1 genes reduces viral 
growth in infected NIH/3T3 cells (Fig5.7C), demonstrating the importance of the FA 
elongation and membrane remodelling-pathways for MCMV replication. The 
importance of ELOVLs, and especially ELOVL7, in the growth of HCMV has already 
been demonstrated(Purdy, Shenk, and Rabinowitz 2015). MBOATs have not been 
implicated or shown to have an effect. This is the first time that one of these proteins 
has been shown to affect MCMV growth. 
To further study this interaction, a plaque number and size assay was also performed. 
The difference with previous plaques assays described earlier is that the diameter of 
the plaques was also measured in addition to their number. Additionally, for this assay, 
NIH/3T3 cells were transfected using the forward transfection method instead of 
reverse transfection (see methods 2.4.1). This transfection method reduced the toxicity 
of multiple siRNAs and no siRNA treatment appears to affect cell viability (F g.5.8A). 
Cells were forward transfected for 48 hours and were subsequently infected with 
MCMV-GFP at a low MOI of 0.025 to allow the observation of plaque formation on 
the monolayer. After 48 hours of infection, the cells were fixed and the plaque number 
and diameter were determined using Celligo Cell Counter. Celligo is a cell counter 




Figure 5.8 siRNA KD of FA elongation and lipid remodelling genes reduces the 
number and the size of the plaques in infected cells. (A) NIH/3T3 fibroblasts were 
transfected in 96 well plates with 25 nM siRNA for 48 hours. Subsequently, the cell 
viability for each treatment was assessed using the CellTiter-Blue Assay Mean ± SEM 
of three independent experiments (n=5) (B) ΝIH/3T3 cells were forward transfected 
with 25 nM siRNA for 48 hours. Subsequently, they were infected with MCMV-GFP 
(MOI 0.025). After 48 hours, the cells were fixed and the number of plaques was 
determined using photographs of the plates taken by Celligo cell counter. (C) Same 
as B, the mean area of plaques for each treatment was determined by the Celligo cell 







All siRNAs treatments inhibited viral growth, in comparison to RISC-free siRNA 
treated cells, when plaques were counted (Fig.5.8B). It should be noted here that 
despite the results of the cell viability assay some wells, specifically for Scd1 KD, 
showed reduced growth and not complete formation of the monolayer. Taking this into 
consideration along with the fact that Scd1 KD viability was close to the cut off value 
of 70%, the data for these the gene should be viewed with some scepticism. Another 
form of cell viability assay, such as caspase activation, to test apoptosis would be 
useful to determine the effect of the KD.  
The cell counter used can also count the mean area of the plaques formed on the 
monolayer during the infection as it can detect the GFP signal produced by the virally 
infected cells (Fig.5.8C). The results demonstrate that all treatments apart from Scd1 
KD inhibit MCMV growth. The results presented here complement my previous 
siRNA study, by demonstrating that KD of Elovl4,6&7 and Mboat1 is effective at 
inhibiting viral growth when the formation and size plaques is monitored on top of 
GFP signal induction. Furthermore, knockdown of Mboat2 appears to have no 
detrimental effect on the cell viability, when forward transfection is used, while at the 
same time successfully inhibit MCMV growth. This is also true for Dgat2 KD. Scd1 
KD has a smaller impact on cell viability, but because the results obtained are very 
close to the cut off set for this study and of the monolayer status in some treated wells, 
the antiviral effects exhibited should reviewed more critically. 
5.2.4 Discussion 
MΦ are known to engage their lipid metabolism when they are classically or 
alternatively activated. Although the function of lipid metabolism during inflammation 
is not clear yet, it is considered that FA oxidation is associated with tolerogenic events 
while FA synthesis is associated with inflammatory process(L. A. J. O’Neill, Kishton, 
and Rathmell 2016). Moreover, proinflammatory signals, like cytokines and LPS have 
been repeatedly demonstrated to induce FA synthesis in MΦ (Posokhova et al. 2008; 
Feingold et al. 2012). Additionally, SREBP1, a major FA metabolism regulator, has 




In this chapter I analysed the metabolism of FA biosynthesis and lipid remodelling 
genes during MCMV infection in BMDM. Analysis of temporal transcriptomics 
analysis of FA biosynthesis and membrane remodelling pathways indicated that 
MCMV-WT infection specifically upregulates enzymes in these pathways. In 
accordance to what has been published for HCMV, MCMV also upregulates the FA 
elongation pathway. Elovl4 & 7 are upregulated specifically during productive 
infection (Munger et al. 2008). ΜΦ from mice deficient in type-I IFN also have 
induced expression of Elovl4 & 7 indicating that this is an event associated with 
productive infection. These genes have a very low abundance in mock or non-
productively infected macrophages and are hard to detect even with qRT-PCR, which 
reinforces the idea that the genes are upregulated specifically by MCMV infection.  
Numerous studies have tried to characterise the enzymatic properties of ELOVLs. 
According to them, ELOVL 1,3,4,and 7 can elongate saturated FA, while ELOVL 2, 
4, and 5 elongate monounsaturated FAs (Ohno et al. 2010; Tamura et al. 2009; Ofman 
et al. 2010; Harkewicz et al. 2012; Leonard et al. 2002; Kitazawa et al. 2009). 
However, complete characterisation of these proteins and their functions remains 
difficult due to their nature (big membrane bound proteins) and the nature of their 
substrates. I cannot, for this reason, reach any conclusions regarding the specific FAs 
that Elovl4&7 produce in my system. Despite this, the metabolomics data presented 
here indicate that there is a markedly increase in FA synthesis in agreement with the 
transcriptomic data. 
Dgat2 was also upregulated specifically during productive infection. Dgat2 catalyses 
the last step in the formation of triglycerides (TAG). Macrophages challenged with 
LPS or poly(I:C) have been shown to have increased TAG formation and expression 
of Dgat2 (Feingold et al. 2012; Y. L. Huang et al. 2014). In my analysis, I do not find 
upregulation of Dgat2 in macrophages infected with MCMV-KO or treated with 
poly(I:C). This could be explained by the fact that these studies used peritoneal and/or 
RAW264.7 and J774 cell lines, which are different phenotypically from BMDM. 
Especially RAW264.7 and J774 cells are immortalised cell lines, which is bound to 
have a different metabolic profile than primary cells. Increased TAG synthesis leads 
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to accumulation of LDs, which certain viruses, including HCMV, have been shown to 
induce in infected cells (J.-Y. Seo and Cresswell 2013). 
Mboat1,2 and Scd1 are also upregulated specifically during productive infection. 
Interestingly, Scd1 has been shown recently to be implicated in the regulation of the 
inflammatory response in TLR4 activated macrophages(Oishi et al. 2016). At early 
time points after LPS stimulation macrophages downregulate FA genes, including 
Scd1. Later during the resolution phase of inflammation SREBP1 is upregulated, 
inducing the expression of FA synthesis genes, which produce FA that help resolve 
inflammation (Oishi et al. 2016). This is a prime example of FA acting as signalling 
molecules in addition to their structural and energy storage functions, which has been 
well characterised. 
These data indicate that MCMV infection manipulates FA metabolism in infected 
cells. FA metabolism is essential is cells for a lot of processes including the synthesis 
of phospholipids and sphingolipids(Poulos 1995). Apart from the FA elongation 
MCMV manipulates Mboat1&2 along with Dgat2, which contribute to the growth and 
maintenance of cell membranes and other organelles, such as lipid droplets, something 
crucial for several cellular functions (C. C. Y. Chang, Sun, and Chang 2011; Helle et 
al. 2013; Stone et al. 2009). 
Drug inhibition of de novo FA synthesis and FA elongation demonstrated the 
dependency of MCMV-WT on these pathways in multiple cell types. This dependency 
is increased when cells are grown in lipid-depleted media. The absence of lipids and 
FA forces the cell to de novo synthesise its own lipids as the cell now has limited 
supply of them. This in turn increases the effects that FA synthesis inhibitors have on 
viral growth. C75 does not directly affect the FA elongation pathways and TOFA 
inhibits both de novo synthesis and FA elongation, therefore I could not reach a 
conclusion regarding the importance of elongation versus de novo FA biosynthesis. At 
the same time, I was conducting these experiments there were no readily available 
drugs that could specifically inhibit FA elongation that would allow me to distinguish 
between the two pathways. Additionally, my temporal transcriptomics analysis 
indicated that more genes associated with lipid and membrane remodelling were 
specifically upregulated during MCMV-WT infection. 
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In order to overcome this problem, the genes were knock-downed using siRNA. This 
study revealed that productive infection is inhibited if FA elongases and Mboat1 are 
inhibited. Mboat2, Dgat2 and Scd1 KDs were toxic for the cells when the reverse 
transfection method was used. There was an improvement in cell viability when the 
forward transfection method was used, especially for Mboat2. The data obtained from 
Dagt2 KD also demonstrated inhibition of the virus while the cell viability is not 
affected. The results for Scd1 KD, on the other hand, could be dismissed because their 
toxicity was, even with this method, near the cut-off value of 70% viability. 
I hypothesised that the reason for why the forward transfection method works better 
for these genes might have to do with cell growth. According to the reverse 
transfection method, the transfection reagents are added on the same day as the cells 
are seeded in the wells of the plate. The cells are allowed to grow over 48 hours to 
form a monolayer. Cells that are growing need to process and divide their membranes. 
To do so Mboats and other lipid remodelling genes and processing genes are crucial. 
MBOATS participate in membrane remodelling by altering the FA composition 
phospholipid of membranes. Cell membranes are dynamic structures and alterations 
in their composition greatly affect their rigidity and their physicochemical properties. 
Disruption of the phospholipid and/or cholesterol content of membranes can have 
adverse effects on cell viability. Scd1 also has great effect on the composition of lipid 
membranes as demonstrated by the abnormal lipid metabolism that Scd1 KO mice 
have (Dobrzyn et al. 2005; Attie et al. 2002; Sampath and Ntambi 2014). Knocking 
down the expression of these genes, when there is increased demand for the enzymes 
they encode, prevents the cells from multiplying physiologically. This could also be 
observed under the microscope. The monolayer of the cells with these genes KD was 
not properly formed and the cells were growing abnormally. In the forward 
transfection protocol, cells are seeded 24 h in the plates, prior to the transfection, 
allowing them to grow and form a monolayer.  
Taken together, these results demonstrate that MCMV manipulates FA elongation 
system and remodelling of membranes upon infection. The upregulation in the 
glycolytic flux discussed in the previous chapter could be feeding into FA synthesis 
through the citrate shuttle. However, I did not perform any 13C labelling experiments 
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to trace the flux of carbon atoms and, thus, this conclusion cannot be derived by the 
data presented here. Additionally, the contribution of other metabolomics pathways 
that can provide carbon atoms to FA synthesis cannot be excluded for the same reason. 
According to the bibliography HCMV increases the production of saturated VLCFA, 
which it incorporates in its membrane(Koyuncu et al. 2013; Munger et al. 2008). One 
of the hypotheses is that these FA favour the membrane curvature. I did not analyse 
the MCMV viral composition and did not performed 13C experiments that would allow 
me to analyse which FA species are incorporated in the MCMV membrane. 
Additionally, my metabolomics data were not designed to target specifically FA and 
lipid metabolites, preventing me from make any claims regarding which FA species 
are being favoured by the productive infection. They clearly indicate, though, that 
there is increased production of long chain FA. However, my transcriptomic data in 
conjunction indicate that, at least in the case of MCMV, the virus engages with the 
lipid metabolism of infected cells extensively and does not only upregulate the FA 
elongation pathway. It is quite interesting that MCMV upregulates Dgat2. Dgats forms 
TAGs which decreases the availability of FA in the cell, something that would be 
contradictory if the virus needed FA.  
There must be an additional role for long chain fatty acids, apart from mere structural 
components for the viral membrane, indicated by the complex way that MCMV 
engages the pathway. As mentioned before, cell membranes are a dynamic structure 
and their physicochemical properties greatly affect cellular process like the formation 
of lipid rafts. Disruption of the phospholipid and/or cholesterol content of membranes 
has been shown to affect the growth and/or the entry of various pathogens in host cells 
(Makino and Jenkin 1975; Ohol et al. 2015; Orynbayeva et al. 2007; Haque et al. 2005; 
Vitiello et al. 2011). The formation of MCMV virions is a very complicated process 
that requires an initial envelopment at nucleus and a second one at the cytoplasm. 
Some FA, like C26:0 have been shown to affect the packing of phospholipids and 
promote the formation of lipid rafts. These studies were conducted in model 
membranes, but C26:0 has been shown to affect the localisation of an ATPse in yeast, 
independently of the phospholipid head group that it is attached to(Ho et al. 1995; 
Hannich, Umebayashi, and Riezman 2011). Additionally, Lipid droplets LDs are not 
129 
 
as passive organelles as it was believed. They actively regulate cellular lipids and 
different RAB proteins, and have been shown to specifically associate with them, 
presumably to facilitate lipid molecule exchange with other membranes(Martin and 
Parton 2006). This last procedure especially is very tightly regulated and allows for 
different organelles to have different membranes composition, something vital to 
maintain their functions (Mesmin et al. 2013; Helle et al. 2013). 
All these indicate that MCMV might be manipulating lipid metabolism extensively to 
facilitate virion assembly in addition to using FA as structural components. In fact, 
MCMV must be under selective pressure to regulate lipid metabolism closely rather 
than just upregulate FA elongation as the slightest abnormality in lipid metabolism 
could have adverse effects for the cellular processes. To this complicated picture I 
must add the function of FA as signalling molecules that regulate numerous processes 
like metabolism and immunity by interacting with G coupled receptors (Nakamura, 
Yudell, and Loor 2013; Alvarez-Curto and Milligan 2016; Miyamoto et al. 2016). The 
signalling properties of some FA like prostaglandins are already known and have been 
extensively studied, however, it is becoming more and more apparent that more FA 
can act as signalling molecules (Alvarez-Curto and Milligan 2016). Especially 
polyunsaturated FA, like DHA appear to be vital in maintaining homeostasis in the 
host and have extensive anti-inflammatory properties (Kuda et al. 2016). 
It should be noted here that even though MCMV appears to be dictating the metabolic 
programming in infected BMDM late during infection, I cannot be sure that this is not 
a host driven effect, even partly. The transcriptomic data clearly demonstrate that non-
productive infection does not induce upregulation of Elovls, Mboats or Dgat2. 
However, early studies in vaccines have clearly demonstrated that vaccines with live 
bacteria are more effective in generating antibodies. Sander et al. demonstrated that 
MΦ can distinguish between live or dead bacteria through the detection or prokaryotic 
mRNA (Sander et al. 2012). Thus, it cannot be excluded that MΦ might possess a 
mechanism to distinguish between a replicating virus and a non-replicating one. 
Despite that the data presented here demonstrate that FA and lipid metabolism 
manipulation is a very complicated process that could allow MCMV to manipulate and 
alter the host cell environment to facilitate growth. Based on this work my hypothesis 
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cannot be refuted. Namely, that MCMV modulates metabolism in infected MΦ at late 
stages of infection towards FA elongation to promote viral progeny. The exact 
mechanisms through which this is beneficial to the virus have, however, not been 
studied here. 
5.3 Study of Prostaglandins synthesis during MCMV infection in 
BMDM 
5.3.1  Introduction 
The first eicosanoids were discovered by Ulf von Euler in 1936, who called them 
prostaglandins because they appeared to be produced in the prostate gland of 
animals(von Euler 1936). What Ulf von Euler had discovered was a subclass of 
eicosanoids termed prostanoids. All prostanoids are fatty acids, composed of 20 
Carbon atoms, that have been are oxygenated and contain a cyclic ring. 
Prostaglandins (PG), which will be the focus of this chapter, have a cyclopentane ring 
while thromboxanes (TBX) contain a cyclo-hexane ring in their structure. There are 
four main naturally occurring prostaglandins termed prostaglandins D, E, F and I. The 
last letter D, E, F, or I is followed by a number, which indicated the number of double 
bonds that the side carbon chains have attached to the cyclopentane ring. The most 
commonly enzymatically synthesised prostaglandins are PGD2, PGE2, PGF2 and 
PGI2(Bos et al. 2004).  
Prostaglandin biosynthesis starts in the cytosol by the cleavage of Arachidonic acid 
(AA) from the phospholipids in the outer cellular membrane. PTGS11 and PTGS2 
(alternatively (COX1 and COX2) then synthesise PGH2, which is a precursor 
prostaglandin for thromboxane2 and all PG (Fig.5.9). COX1 is expressed 
constitutively in in most cells while COX2 is induced by inflammation, growth factors 
and hormones(Dubois et al. 1998). Each COX isomer associates preferably, but not 
exclusively, with specific prostaglandin synthases(Smyth et al. 2009). The profile of 
the produced prostaglandins differs depending on the prostaglandins synthetic 
enzymes present in each cell(Ricciotti and FitzGerald 2011). For example 
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macrophages produce mainly PGE2 and TXA2, while mast cells predominately 
synthesise PGD2 (Tilley, Coffman, and Koller 2001).  
 
Figure 5.9: The Eicosanoids pathway. 
PG act through rhodopsin-like 7-transmembrane-spanning G protein-coupled 
receptors. There is one PG receptor for each prostaglandin apart from PGE2, which has 
4 E proteinoids receptors (EP1 to EP4) (Ricciotti and FitzGerald 2011). 
PGD2 can spontaneously dehydrate and give rise to another class of molecules, 15-
deoxy-∆12,14-PGJ2 (15d-PGJ2)(Bell-Parikh et al. 2003). 15d-PGJ2 has been reported 
to have anti-inflammatory properties and pro-resolving properties (Surh et al. 2011). 
These appear to be exerted by a number of mechanisms including inhibition of NF-
B, and suppression of JAK-STAT pathway(Bernardo, Levi, and Minghetti 2000; 
Castrillo et al. 2000; S.-K. Seo et al. 2014).   Despite these findings, very little is known 
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about the pharmacokinetics and/or the biosynthesis of this molecule in vivo making it 
difficult to assess any potential effects it has in an in vivo setting. 
Lipidomics studies both in MΦ and DC have shown that PG production is increased 
upon TLR4 activation (Dennis et al. 2010). Depending on a number of factors 
including, but not limited to, cell type, site and length of exposure, PG have different 
effects, proinflammatory and anti-inflammatory(Biswas and Mantovani 2012; Hirata 
and Narumiya 2012; Tilley, Coffman, and Koller 2001). For example PGE2 has been 
shown to inhibit inflammation in DC and ΜΦ by blocking TNF- production in ΜΦ, 
stimulate IL-10 production and suppress MHC class II (Vassiliou, Jing, and Ganea 
2003; Harizi, Grosset, and Gualde 2003; Nataraj et al. 2001). At the same time PGE2 
can stimulate DCs by inducing IL-23 production (Yao et al. 2009). 
Due to the central role that PG can play during inflammation there is several viruses 
that appear to exploit their signalling properties. Coulombe et al. in 2014 demonstrated 
that PGE2 can inhibit type-I IFN signalling (Coulombe et al. 2014). HCMV has also 
been shown to upregulate the production of PG upon infection of fibroblasts(Browne 
et al. 2001; Simmen et al. 2001). The rhesus cytomegalovirus even encodes a COX2 
homolog indicating the importance of these enzymes for some viruses (Schröer and 
Shenk 2008). 
HCMV stimulates the expression of cytosolic phospholipase A2 (cPLA2) and 
cyclooxygenase-2 (COX2) leading to the production of PGH2 (AbuBakar, Boldogh, 
and Albrecht 1990). Inhibition of COX2 activity has been demonstrated to block 
HCMV growth in infected fibroblasts (Zhu et al. 2002). Later, studies by Jörg Schröer 
and Thomas Shenk revealed that COX2 inhibition blocks cell-to-cell spread of the 
virus (Schröer and Shenk 2008). Both studies indicated that addition PGE2 could 
reverse the effect that COX2 inhibition had on the viral growth. Similarly herpes 
simplex virus type 1 and pseudorabies virus infections of rat embryonic fibroblasts can 
be blocked using COX1/2 inhibitors, and PGE2 was able to reverse the effect (Ray, 
Bisher, and Enquist 2004). 
An earlier study on the effects of synthetic prostanoids on MCMV growth, 
demonstrated that prostanoids can affect MCMV growth depending on their chemical 
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structure (K. J. Lee et al. 1999). Together, these studies reveal that the regulatory 
functions of PG during the immune response can have profound effects on the growth 
of MCMV and determine the outcome of the infection. 
Thus, in this chapter I will attempt to examine the effects that MCMV infection has on 
A key regulatory lipid pathway the PG pathway, and conversely determine the role 
that the PG pathway has on the viral growth. Based on the studies above I hypothesise 
that MCMV regulates the PG pathway to produce specific PG that promote viral 
growth by inhibiting type-I IFN responses. 
5.3.2 Temporal transcriptomics and metabolomics analysis of prostaglandins 
biosynthesis during MCMV infection 
5.3.2.1 Transcriptomics analysis of Prostaglandin Pathway 
To investigate Prostaglandin (PG) biosynthesis in the context of viral infection I 
performed (as described in Methods) a temporal analysis of the gene expression of 
infected BMDM cells. For this purpose, I analysed a data from a resource available in 
the lab MITCH24KO (University O. E. Lacaze 2011). Briefly, for MITCH24KO, 
BMDM from WT, or IFNAR, or IFNB1 deficient C57BL/6J mice were used. These 
were mock treated, or treated with MCMV-WT (MOI 1), or MCMV-KO (MOI 1), or 
poly(I:C) (10μg/ml). The RNA from each treatment and cell type wasisolated at 0, 2, 
4, 6, 8, 10, 12 and 24 hours post treatment and high-quality RNA was hybridised to an 
Affymetrix Mouse Gene 1.0ST microarray. 
All treatments of BMDM resulted in the induction of COX2 at 4 hours post treatment. 
However, MCMV-WT infection and poly(I:C) treatment resulted in a higher 
expression of COX2 in treated BMDM compared to mock, or MCMV-KO treatments 
(Fig.5.10A). The increased levels of COX2 were expected to result in increased 




Figure 5.10 Temporal transcriptomics of the prostaglandin pathway in WT 
macrophage (A) Heatmap of the temporal gene expression of prostaglandin 
synthases (prostagladin pathway) over a 24 hour period in BMDM treated with MCMV-
WT (MOI 1), or MCMV-KO (MOI 1) or POLY(I:C). Each row represents the expression 
of a single gene in the presence of different treatments, and has been normalised to 
time point 0. (B) Temporal gene expression of Cox2 (blue) and Ptges (red) over a 24 
hour period in BMDM treated with MCMV-WT (MOI 1), MCMV-KO (MOI 1) or 
POLY(I:C). 
The expression of prostaglandin E synthase (Ptges) was induced in a similar manner 
that almost mirrored the expression of COX2 (Fig.5.10B). PTGES catalyses the 
production of PGE2 from PGH2. The increased expression of both enzymes (Cox2 and 
Ptges) at similar time points and similar levels indicates that the pathway is tuned 
towards PGE2 production. The rest of the enzymes, part of the pathway, detected by 
the microarray were also plotted, but they are not discussed further in this chapter. The 
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data can be found in the appendix (Fig.S7.3). The data indicate that the productive 
infection specifically induces the expression of arachidonate lipoxygenases (Alox) -8, 
-12 and -15 at 10 hpi till 24 hpi FigureS7.3. 
5.3.2.2 Metabolomics analysis of the prostaglandin pathway 
While the infection induced transcriptional changes in the COX2 and PGE2 genes, this 
is only indicative of an effect/change in the metabolome of prostaglandins. Therefore, 
to further examine the effects of MCMV infection on the eicosanoids pathway in 
BMDM a metabolomics analysis of PG was performed. 
BMDM were mock treated, or treated with MCMV-KO, MCMV-WT or MCMV-
(MCK2+ GFP). The cells were then scraped in the growth media and flash frozen using 
liquid nitrogen at 0, 12 and 24 hpi. The samples were shipped to Professor Valerie 
O’Donnell’s lab in Cardiff where they were analysed for eicosanoids using LS-MS. 
The only PG detected in the samples were PGE2 and PGD2. AA was also identified 
along with some Hydroxyicosatetraenoic acids (HETES). The data for HETES can be 
found in the appendix (FigS.7.4). Similar high concentration of AA was detected at 0 
hpi in all samples regardless of treatment (Fig.5.11A). At later time points the 
concentration of AA was reduced in all conditions, but it remained higher in samples 
infected with productive virus. The two productive infections also had similar levels 
of AA between them. Moreover, the non-productive infection with MCMV-KO, had 
the same concentration of AA at 12 and 24 hpi as the non-infected samples did.  
The data reveal a similar trend for the two detected prostaglandins, PGD2 and PGE2 
(Fig.5.11B-C). PGD2 concentrations is similar for all treatments at 0 hpi, apart from 
MCMV-WT infection where it is slightly decreased (Fig.5.11B). At 12 and 24 hpi the 
concentration of PGD2 is markedly increased in MCMV-WT and MCMV-(MCK2+ 




Figure 5.11 Levels of Arachidonic acid and Prostaglandins in productively or 
non-productively infected macrophages. (A-C) BMDM were grown for 7 days, 
followed by mock infection or infection with MCMV-KO, MCMV-WT, or MCMV-
(MCK2+ GFP). At 0, 12 and 24 hpi cells were scraped in the growth medium, flash 
frozen in liquid nitrogen and shipped to Cardiff for PG analysis using LS-MS. 1 
experiment with Mean ± SEM (n=6). 2 way ANOVA with Turkey correction for multiple 
comparisons *p<0.05, **p<0.01, ***p<0.001. Non-significant results are not shown. 
PGE2 is not detected in any sample at 0 hpi and remained undetected in mock treated 
cells at all time points (Fig.5.11C). At 12 hpi, the concentration increased significantly 
to the same level in MCMV-WT and MCMV-(MCK+GFP) cells. While MCMV-KO 
infected cells appeared to produce a small amount, it was not statistically significant 
in comparison to mock treated cells. 
Taken together, the data indicate that productive infection of MCMV specifically 
induces PG synthesis in BMDM. PGE2 and PGD2 are synthesised at increased levels 
in comparison to mock, or MCMV-KO treated BMDM at later time points of infection 
and, thus, the data presented here complement the transcriptional data of the 
eicosanoids pathway discussed earlier. 
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5.3.3 PGE2 promotes MCMV growth in fibroblasts 
Inhibition of COX2 has been shown to block HCMV replication and subsequent 
treatment with PGE2 can abrogate this effect(Zhu et al. 2002). Additionally, Coulombe 
et al. have demonstrated that PGE2 can inhibit type-I IFN signalling in macrophages 
(Coulombe et al. 2014). It was, thus, hypothesised that MCMV induces PGE2 
production in BMDM to block type-I IFN signalling during infection. 
To assess the effects of PGE2 on MCMV growth, NIH/3T3 were infected with MCMV 
and subsequently treated with PGE2 and/or EP4 (PF-04418948) antagonist. Addition 
of PGE2 to MCMV infected NIH/3T3 promoted viral growth in a dose dependent 
manner (Fig.5.12A). The EP4 antagonist did not affect viral growth on its own, but 
could reverse the effects of added PGE2. None of the treatments affected the viability 
of the cells (Fig.5.12B).  
 
Figure 5.12 Effects of PGE2 on MCMV growth (A) NIH/3T3 fibroblasts were 
seeded in 96 well plates. They were infected the following day with MCMV-GFP (MOI 
0.1) and subsequently incubated with media supplemented with DMSO (vehicle) 
PGE2, EP4 antagonist or with a combination of the two. Mean ± SEM of three 
independent experiments (n=6). One way ANOVA with Dunnett’s correction for 
multiple comparisons *p<0.05, **p<0.01, ***p<0.001. 
138 
 
These results demonstrate that PGE2 promotes MCMV growth in infected fibroblasts. 
The effect is elicited at least in part by EP4 since blockage of the receptor block the 
signal. 
5.3.4 Discussion 
In this chapter I studied the effect of MCMV infection on prostaglandin metabolism. 
Evidence was presented that revealed a correlation between productive MCMV 
infection and increased biosynthesis of two prostaglandins, PGE2 and PGD2, in 
infected macrophages. PGE2 was shown to promote MCMV infection in infected 
fibroblasts through at least EP4. 
The effect of MCMV infection on PG biosynthesis was specific on the transcriptional 
and post-transcriptional level, with an observed coordinated induction of both Cox2 
and Ptges over time, which showed a remarkable correlation between the two 
enzymes. 
On the post-transcriptional level, at 0 hpi, AA was detected in all samples at a similar 
level.  This could be attributed to the treatment of the cells before being harvested. In 
accordance to the infection protocol that we follow in our group, cell growth media 
was removed, followed by a 1 hour adsorption period in virus-containing media and a 
PBS wash before the addition of new growth media and cell harvesting. This handling 
of the cells could lead to AA production induced by the stress caused on the cells. The 
levels of AA are reduced over time, but they remain higher at the productively infected 
samples. 
At the same time, PGE2 synthesis was increased in a transient manner. PGE2 was not 
detected at 0 hpi in any sample, but was detected at 12 and 24 hpi, mainly in the 
productively infected cells. Similarly, PGD2 levels were increased in a transient 
manner from 0 to 24 hpi with the increase being predominant in the productively 
infected MΦ despite Ptgds not being upregulated. The data presented above are in 
agreement with a published study by Kihara et al. on the eicosanoid fluxes in 
BMDM(Kihara et al. 2014).  
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In their study, Kihara et al. provided evidence for a functional coupling of COX2 and 
PTGES in BMDM treated with Kdo2-Lipid A (KLA) and then stimulated with the 
ATP. The metabolomics and transcriptomics data of the pathway presented in this 
study are very similar with the PG data presented in this chapter.  
Treatment of PGE2 in MCMV in infected fibroblasts induced viral growth. Zhu et al. 
and Schröer et al. have published that COX2 inhibition blocks HCMV replication and 
that treatment with PGE2 could reverse the effect (Zhu et al. 2002; Schröer and Shenk 
2008). Although the inhibition of COX2 blocks the biosynthesis of multiple PG, 
neither study reported on the effects of other PG apart from PGE2, nor did they monitor 
the concentration of them over the course of infection. Additionally, Schröer et al. 
reported that the effect of COX2 inhibition blocked cell to cell spread of the virus 
(Schröer and Shenk 2008). Whether PGE2 treatment affects MCMV in a similar way 
remains to be seen. In contrast to what has been reported for HCMV, lemente et al. 
reported that post-infection with PGE2 blocked HIV cell to cell spread (Clemente et 
al. 2014). HIV is a completely different virus from HCMV and has no similarities 
HCMV, but this finding adds to the complicated picture of PG effects during 
inflammation. 
More recently, other studies have demonstrated that PGE2 could inhibit 
proinflammatory signalling and, thus, promote viral growth(Coulombe et al. 2014; 
Alfajaro et al. 2017). Coulombe et al. demonstrated that PGE2 inhibits IFN-I signalling 
and apoptosis in influenza A virus (IAV) infected alveolar ΜΦ via EP2 and EP4 
receptors (Coulombe et al. 2014). Interestingly, in their study infection with UV-
inactivated IAV (non-productive infection) did not induce production of PGE2 in 
alveolar ΜΦ, however, analysis was done only at 4 hours post treatment. In the study 
presented here, non-productive infection induced PGE2 production by only a small 
amount and at 24 hours post infection.  
Another more recent study demonstrated the effects of PGE2 during porcine sapovirus 
(PSaV) infection in LLC-PK cells (Alfajaro et al. 2017). PGE2 was shown to promote 
viral growth in the cells through inhibition of NO production. Since NO induction is 
downstream of type-I IFN the effects observed in this study could be attributed to 
inhibition of type-I IFN signalling by PGE2 like Coulombe et al. demonstrated. Both 
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studies suggest that PGE2 has anti-inflammatory properties that allows viruses to evade 
the immune system response by inhibiting signalling, but both studies routinely use 10 
μΜ of PGE2,a concentration much higher than the physiological levels at which PGE2 
is present in vivo. 
My results clearly demonstrated that productive MCMV infection of BMDM induces 
PG metabolism on the transcriptional and metabolomic levels. It was also 
demonstrated that PGE2 promoted MCMV growth in fibroblasts and that this occurs 
through an EP4 dependent manner, but other EP receptors might contribute too. The 
lack of an effect by the EP4 antagonist on its own might indicate that NIH/3T3 cells 
do not produce PGE2 or produce it at very low quantities. Thus, blocking signalling 
would not have an effect since the receptor would not be engaged by PGE2. 
The data presented here cannot support my full hypothesis. Productive infection of 
MCMV does promote the biosynthesis of specific PG, PGE2 and PGD2 in infected 
BMDM on the transcriptional and metabolomic levels. However, further 
experimentation is required to support or refute my hypothesis, namely that PG 
attenuates type-I IFN signalling during MCMV infection and, thus, promote viral 
growth.  
It is possible to study these effects on the post-transcriptional (mRNA levels of type-I 
IFN ISGs) and protein level of type-I IFN signalling. Using RT-qPCR in mock or 
MCMV infected BMDM that haven been treated with PGE2 and or EP4 antagonist, 
the mRNA levels of Stat1, Ifnb1, Irf3 and 25-hydroxycholesterol (25-hc) could be 
detected and compared between each treatment to assess any effect that PGE2 might 
have on them. Using the same experimental setup, the phosphorylation levels of STAT 
and IRF3 (activation) could be studied to detect, on protein level, the effects that PGE2 




In this thesis, evidence has been presented demonstrating the importance of 
metabolism for MCMV growth in infected macrophages. More specifically, 
transcriptomic and metabolomic data of MCMV infected BMDM reveal the 
upregulation of key regulatory steps in the glycolytic pathway early during infection. 
Critically, MCMV growth is blocked by inhibition of the glycolytic pathway. 
Additionally, when glycolysis is inhibited, activated DC fail to acquire a fully activated 
phenotype(Everts and Pearce 2014). 
These same data indicate that these changes in glycolysis are concurrent with altered 
TCA cycle function. The TCA cycle is broken at isocitrate formation and at -KG 
generation during MCMV infection according to my data. It is in agreement with work 
by other groups that have already demonstrated similar alterations in both pathways, 
in proinflammatory DCs and MΦ(Everts et al. 2014; EL Kasmi and Stenmark 2015). 
The transcriptomics and metabolomics data further indicate that MCMV infection 
alters the Urea cycle, a pathway intersecting the TCA cycle, to support NO production. 
The production of NO from ΜΦ has long being considered a hallmark of 
proinflammatory phenotype because of the bacteriostatic effects of NO (EL Kasmi and 
Stenmark 2015) 
The data presented here, with regard to MCMV effect on MΦ , show similarities in the 
metabolism of HCMV infected and MCMV infected cells. There are differences, 
which could be attributed to the cell type utilised in the studies and different viruses. 
In HCMV studies, the metabolism was studied in infected HFF while I utilised BMDM 
for my experiments. HCMV infected cells and activated macrophages use glycolysis 
for the generation of energy (Jha et al. 2015; Munger et al. 2008). HCMV infected 
HFF, among others, upregulate glycolysis and the TCA cycle during infection. The 
glycolytic pathway provides energy and extra carbon molecules that are shuttled to 
generate FA. HCMV increases the flux in glycolysis, the TCA cycle and FA synthesis 
to synthesise the precursor molecules required to replicate (Munger et al. 2008). It 
should be noted here that OXPHOS is still functioning in HCMV infected HFF unlike 
in proinflammatory DCs and MΦ(L. A. J. O’Neill, Kishton, and Rathmell 
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2016).However, a lot of carbon atoms are shuttled outside of the TCA cycle in HCMV 
infected HFF to support FA synthesis (Koyuncu et al. 2013).   
Functional assays using Seahorse Extracellular Analyser offered evidence that early 
during infection the glycolytic flux is greatly increased in BMDM infected with 
MCMV-WT, or MCMV-KO, or treated with poly(I:C). Thus, the programming for the 
induction of glycolysis has an immune driven component and appears not to require 
de novo viral protein synthesis. The temporal transcriptomic data of glycolytic 
enzymes (Glut6, Hk3 and Pfkfb3) expression further supported the hypothesis that the 
reprogramming of the glycolytic pathway and its subsequent induction is dependent 
on type-I IFN. Type-IFN deficient BMDM were not able to induce these glycolytic 
genes, or at least not as efficiently in the case of Pfkfb3. This is consistent with 
previously published data in DCs. Pantel et al. demonstrated using IFNAR-/- DCs that 
type-IFN is required for the glycolytic pathway to be engaged, while at the same time 
TLR3/MDA5 signalling on its own was not sufficient to initiate the same metabolic 
programming (Pantel et al. 2014). 
Thus, in this thesis, I present the first paradigm, to my knowledge, suggesting that a 
virus co-opts the metabolic programming induced in immune cells during their 
activation to establish infection in host cells. However, there are gaps to be filled in 
my studies such as whether this co-option takes place in vivo and if it confers any 
actual advantage to MCMV allowing it to establish infection in a host as discussed in 
chapter 4. The evidence provided in this thesis along with numerous publications 
suggest that MCMV co-opts the metabolomic environment in recently immune-
activated MΦ. More experiments are required to thoroughly test this part of my 
hypothesis.  
On the translational side of my research, even though glycolysis inhibition blocks viral 
growth it is not a recommended strategy. Numerous studies have indicated that the 
glycolytic pathway plays a key role in facilitating innate and adaptive immune cells to 
fulfil their effector functions (Pearce et al. 2013; L. A. J. O’Neill, Kishton, and 
Rathmell 2016; Jiang et al. 2016). Inhibiting it would be more detrimental, in the long 
run, to the host rather than the virus. MCMV infection appears to opportunistically 
utilise the metabolomic programming of early-activated macrophages, but this is 
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probably a temporal advantage much like the capture of TLR signalling as discussed 
in chapter 4. After some time, cells have an established antiviral state and the immune 
system is activated, which tilts the scales in favour of the host. 
It appears though that there are other pathways that could be inhibited to block viral 
growth without affecting the host. HCMV has been demonstrated to induce the 
generation of saturated Very Long Chain FA (VLCFA). Elovl3&7 have been shown 
to be specifically induced by HCMV infection, with Elovl7 being the most important 
elongase for viral growth in infected HFF (Purdy, Shenk, and Rabinowitz 2015). 
ELOVL7 has been implicated to support the generation of saturated VLCFA. 
In this thesis, I provided evidence that MCMV productive infection, similarly to 
HCMV, targets FA biosynthesis. Temporal transcriptomic data indicate that 
productive infection specifically upregulates the expression of Elovl3, 4 & 7 enzymes 
at later times of infection. The upregulation is specific to productive infection and 
driven by the virus and not type-I IFN signalling. In agreement, my metabolomics data 
reveal induction of long chain FA biosynthesis.  Moreover, pharmacological inhibition 
of FA biosynthesis blocks viral growth or siRNA KD of Elovl4,6 & 7 also blocks viral 
growth. 
Thus, both HCMV and MCMV in a similar manner appear to be inducing FA 
elongation. Furthermore, evidence is provided demonstrating that MCMV manipulates 
lipid metabolism in a broad context. Members of the Mboat (Mboat1&2), and Dgat 
(Dgat2) protein families are also specifically upregulated during productive infection. 
siRNA KD of these genes inhibited blocked viral growth. Additionally, MCMV 
extensively interferes with eicosanoid metabolism. My data indicate that MCMV 
promotes synthesis of PGE2. PGE2 treatments of MCMV infected cell promotes viral 
growth. Although, more experiments are required to unravel the mechanism through 
which PGE2 acts beneficially to the virus, my initial data and previous studies by other 
labs suggest that PGE2 can block type-I IFN signalling (Coulombe et al. 2014). 
Together these data suggest, as discussed in chapter 5, that MCMV manipulates lipid 
metabolism extensively to generate the lipid species required while also maintaining 
lipid homeostasis is the cell. These lipid species might support the generation of 
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structural components for virion assembly and/or create a cellular environment that 
facilitates their complicated assembly while also suppressing interference by the host 
immune system. More studies are required to determine what are functional 
requirements for these genes by MCMV. Nevertheless, it is becoming apparent that 
there are similarities in the metabolism of MCMV infected BMDM and HCMV 
infected HFF. Thus, this thesis has also provided evidence that demonstrate the 
suitability of studying metabolism induced by MCMV infection as model for HCMV 
infection. 
To summarise, my data indicate the MCMV co-ops the metabolism of recently 
activated immune cells to establish infection and then tunes host cell metabolism 
towards FA biosynthesis and lipid remodelling. It appears that MCMV is dependent 
on extensively manipulating metabolism and especially lipid metabolism. It is possible 
that one of the reasons behind this is latency. MCMV, like HCMV remains latent in 
cells of the myeloid lineage, but it reactivates only when they terminally differentiate. 
We still do not clearly understand which signals induce viral reactivation, but 
metabolism could be one of these. Metabolism has already been established to signal 
and regulate the immune response. Monocytes appear to exhibit the metabolism of a 
quiescent cell, but a dramatic upregulation to FA metabolism is observed upon 
differentiation (Munger et al. 2008; Ecker et al. 2010). Moreover, newly differentiated 
macrophages that are activated in a site of infection, and have not established an anti-
microbial state yet, will exhibit the high glycolytic metabolism and environment that 
MCMV is known to co-op to replicate. Thus, metabolic signals in conjunction with 
other ones might promote MCMV and/or HCMV reactivation. 
In conclusion, the evidence provided in this thesis do not refute my hypothesis, namely 
that: productive infection of macrophages by MCMV takes advantage of the early 
inflammatory metabolomic reprogramming of activated macrophages to establish 
infection, and modulates metabolism at late stages of infection towards fatty acid (FA) 
production to promote viral progeny. Part of my hypothesis is the notion that MCMV 
co-ops metabolic programming to establish infection in activated macrophages. 
Concrete evidence to support this notion has, however, not been provided in this thesis. 
Further experiments are required to prove that the co-option of metabolism by MCMV 
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in activated macrophages assists in the establishment of infection and to determine the 
role of lipid metabolism for MCMV infection. 
The thesis presented here is filling a niche in the fields of immunometabolism and 
virology by studying the manipulation of metabolism in the context a host-pathogen 
interaction. This increases our understanding about the importance of metabolism in 
determining the outcome of an infection. The study has arguably presented a new 
paradigm of viral manipulation of the immune response. MCMV co-opts the metabolic 
environment of host MΦ cells to establish infection. It also further establishes the 
suitability of MCMV as a model for HCMV infection in the context of metabolism as 







FigureS7.1 Increased iNOS expression during infection. Heatmap of the iNOs 
temporal expression over a 24 hour period in BMDM treated with 1 MOI MCMV-WT, 
or 1 MOI MCMV-KO or POLY(I:C). The gene is represented in a row and has been 
normalised to time point 0. 
 
 
FigureS7.2 IFN-γ supress expression of Mboat1.Temporal expression of Mboat1 




FigureS7.3 Figure 7.4 Temporal transcriptomics of the prostaglandin pathway 
in WT macrophage (A) Heatmap of the temporal gene expression of Arachidonate 
Lipoxygenases (Aloxs) over a 24 hour period in BMDM treated with MCMV-WT (MOI 
1), or MCMV-KO (MOI 1) or POLY(I:C). Each row represents the expression of a 





FigureS7.5 Levels HETES in productively or non-productively infected 
macrophages. (A-D) BMDM were grown for 7 days, followed by mock infection or 
infection with MCMV-KO, MCMV-WT, or MCMV-(MCK2+ GFP). At 0, 12 and 24 hpi 
cells were scraped in the growth medium, flash frozen in liquid nitrogen and shipped 
to Cardiff for eicosanoids analysis using LS-MS. 1 experiment with Mean ± SEM 




Abstract:   Homeostasis underpins at a systems level the regulatory control of 
immunity and metabolism. While physiologically these systems are often viewed as 
independent, there is increasing evidence showing a tight coupling between immune 
and metabolic functions. Critically upon infection, the homeostatic regulation for both 
immune and metabolic pathways is altered yet these changes are often investigated in 
isolation. Here, we summarise our current understanding of these processes in the 
context of a clinically relevant pathogen, cytomegalovirus. We synthesise from the 
literature an integrative view of a coupled immune–metabolic infection process, 
centred on sugar and lipid metabolism. We put forward the notion that under- standing 
immune control of key metabolic enzymatic steps in infection will promote the future 
development of novel therapeutic modalities based on metabolic modifiers that either 
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Introduction
Viruses are extreme obligate parasites that are strictly 
dependent on the host’s energy and biosynthetic pathways 
for their replication and morphogenesis, and therefore, these 
pathways, in particular, afford the host critical immune and 
non-immune checkpoints to control infection [1]. Notably, 
the homeostatic regulation of these pathways not only acts 
to maintain a dynamic equilibrium but also plays a vital role 
in responding to a wide range of external stimuli, such as 
infection, which at a systems level must integrate and coor-
dinate multiple diverse processes ranging from the homeo-
stasis of membranes to energy and immunity [2–4]. Using 
this line of reasoning, we previously put forward the con-
cept for the ‘homeostatic regulation of infection’ which is 
highly relevant to a wide range of pathogens including cyto-
megalovirus (CMV) and other members of the herpes virus 
family that are clinically important and well known to estab-
lish lifelong infections [3]. Homeostasis therefore underpins 
many of the regulatory principles discussed in this review.
Historically, the immune system and metabolism have 
been intensively investigated at different times and by sepa-
rated research communities (immunologist and biochem-
ists) leading to an unintended misperception that these act 
as independent systems. However, there is now increasing 
evidence to show that these two systems are intimately 
integrated, share resources and cross-regulate each other 
[5–10]. While we will highlight some of these recent stud-
ies in relation to cytomegalovirus infection, we refer read-
ers to a number of excellent recent reviews that cover the 
elucidation of the molecular mechanisms linking some of 
these systems [6–10]. At the cellular level, viral infection 
adds considerable burden to the cell with the increased 
demand for energy and metabolic building blocks that are 
commandeered for the production of new viral progeny. A 
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number of different viruses have been demonstrated to alter 
the metabolism of infected cells, including, but not limited 
to hepatitis C virus, rift valley virus, human immunodefi-
ciency virus and human CMV (HCMV) [11–14]. These 
changes may be pro, or antiviral, or simply bystander 
effects. In the case of cytomegalovirus infection of mac-
rophages, some of these metabolic alterations, in particular 
lipid biosynthesis, have been mechanistically linked to the 
interferon (IFN) response [15, 16].
Here, we provide a discussion of how cytomegalovi-
rus infection modifies metabolism of the host cell, how 
immune signalling regulates metabolism and how interme-
diate metabolites can regulate all three processes: infection, 
the immune response to infection and metabolism itself. 
Finally, as a perspective for grappling with this new and 
emerging understanding, we place metabolism at the cen-
tre of an immune–metabolic–infection axis that integrates 
signals from both the host and pathogen. We propose that 
metabolism provides a highly tunable switch used by both 
viruses and the immune system to regulate infection. Hence, 
the lessons learnt from how the immune system regulates 
metabolism will inform new therapeutic strategies targeting 
metabolic enzymes to control acute and latent infections.
Sugar requirement and immune regulation
In normal resting cells, glucose provides the main car-
bon energy source and is actively imported into cells and 
rapidly converted to pyruvate in order to enter the tricar-
boxylic acid cycle (TCA), where it is catabolised to CO2 
through oxidative phosphorylation and which leads to the 
production of ATP [17, 18]. These processes of using glu-
cose require oxygen. However, under anaerobic conditions, 
cells can switch to a more inefficient way of using glucose 
that converts it to lactate. This leads to a smaller number of 
ATP production per glucose molecule (two ATP molecules) 
in comparison with oxidative phosphorylation (36 ATP 
molecules) [19]. Importantly, this now allows the sugar car-
bons to be used as building blocks for anabolic processes 
rather than eliminating through the generation of CO2.
Indeed, it was Otto Warburg in 1924 that made the key 
fundamental observation that cancer cells, despite the fact 
that they have adequate supply of oxygen, utilise anaerobic 
metabolism [20]. He posited that in order for a cell to divide 
it needs to increase its biomass by reprogramming the TCA 
cycle for anabolic purposes [21, 22]. In this scenario, pyru-
vate (a product of the glycolytic pathway) in the TCA cycle 
can get converted to citrate that can be shuttled to the cyto-
sol instead of completing the whole TCA cycle (Fig. 1). 
There it can be converted to acetyl-CoA and be used for 
the biosynthesis of fatty acids which could be employed to 
form cell organelles and support division. In fact, a number 
of studies have shown that as cancer progresses, there is an 
increased production in fatty acid biosynthesis [23]. A simi-
lar process in reprogramming the TCA cycle also occurs 
during immune stimulation and upon infection of cells.
Glycolytic and glutaminolysis pathways
Virus infection
A series of systematic metabolomics studies documented 
that infection of fibroblasts with HCMV dramatically 
alters the cell metabolome towards fatty acid biosynthe-
sis [14, 24, 25]. A comparison of Figs. 1 and 2 will aid in 
following the discussion of the changes that occur upon 
infection. Studies investigating the flux of 13C labelling in 
infected fibroblasts revealed that during infection, uptake 
of glucose is greatly enhanced and through increased gly-
colytic activity, carbon atoms are shuttled from glucose 
to citrate and then to fatty acid biosynthesis [14, 25, 26]. 
There are multiple regulatory steps involved in this process: 
according to McArdle and co-workers, HCMV activates 
AMP-activated protein kinase (AMPK), an energy sensor 
responding to low ATP/ADP ratios in cells, which in turn 
up-regulates glycolysis [27]; PKR-like endoplasmic reticu-
lum kinase (PERK), an ER-associated stress sensor protein 
[28] is induced; the sterol regulatory protein 1 (SREBP-1), 
a transcription factor for regulating fatty acid biosynthesis 
is up-regulated at late times of infection [29]; and expres-
sion of Glut-4, a glucose transporter (GLUT), and carbo-
hydrate-response element-binding protein (ChREBP), a 
transcriptional factor that regulates glucose metabolism 
and lipogenesis [30, 31] are induced during HCMV infec-
tion. All these alterations lead collectively to higher glu-
cose uptake and increased lipogenesis [29–31]. Along with 
changes in glycolysis, the virus also increases glutaminol-
ysis, and glutamine gets converted to α-ketoglutarate and 
through anaplerosis allows the TCA cycle to function [32]. 
Thus, while in normal diploid fibroblasts glutaminolysis is 
not required, it is essential for infected cells, and blockade 
of glutaminolysis significantly impacts on the viability of 
HCMV-infected cells [32]. Finally, Seo and Creswell [33] 
suggest that this cascade may also be regulated by viperin. 
Viperin is an IFN-stimulated multifunctional antiviral pro-
tein that gets hijacked by viral mitochondrial inhibitor of 
apoptosis (vMIA), a HCMV protein, resulting in altera-
tion of its function [33–35]. HCMV appears to up-regulate 
these pathways and inhibition of them and/or of fatty acids 
synthesis leads to reduction in viral progeny [11, 25, 36]. In 
fact, the concept of inhibiting metabolic pathways to block 
CMV infection it is not so new. As early as 1981, 2-deoxy-
d-glucose (2-DG), a glycolysis inhibitor, was shown to 
potently inhibit viral replication [37]. A schematic of these 
alterations is shown in Fig. 2.
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Immune activation
The question arises as to whether these changes upon infec-
tion are in isolation of immune activation. A comparison 
of Fig. 3 with 1 will aid in following the discussion of the 
changes that occur upon immune activation. In this regard, 
it is now emerging that immune cell activation also leads 
to marked detectable metabolic changes in cells [38]. Upon 
activation, lymphocytes, macrophages and dendritic cells 
have all been shown to alter dynamically their metabolism 
[39–42]. The precise metabolic changes that occur differ 
not only from cell type to cell type, but also between differ-
ent phenotypes of the same cell type [43]. For the purpose 
of this review, we will focus on discussing macrophages 
and dendritic cells (DCs) that are permissive to CMV and 
play a key role in viral dissemination and latency. A sche-
matic summary of these changes is shown in Fig. 3.
Immune-activated dendritic cells and macrophages show 
enhanced glycolysis and are further compromised in their 
ability to sustain oxidative phosphorylation in the presence 
of immune-activated nitric oxide (NO) production, as this 
molecule potently inhibits oxidative phosphorylation in the 
mitochondria [44]. Furthermore, in the case of immune-
activated macrophages, the reduced mitochondrial respira-
tion is also highly effective at augmenting the generation 
of anti-infective reactive oxygen species (ROS) [45]. In the 
case of resting DCs, oxidative phosphorylation is mainly 
used for energy purposes. However, when treated with Toll-
like receptor agonists, these cells adopt a Warburg style 
metabolism and after 12 h of activation, mitochondrial oxy-
gen consumption ceases and glucose uptake is increased 
even though it is not using the TCA cycle for ATP produc-
tion [44, 46]. As described above, this change allows DCs 
to survive the production of NO and when DCs are treated 
with 2DG at early stages of activation (before 6 h), the 
development of the activated phenotype is inhibited [44, 
46]. More recent studies reveal that this Toll-like receptors 
(TLR) activation supports anabolic demands of DCs which 
include biosynthesis of fatty acids through the shuttling of 
















































Fig. 1  Metabolism of a resting uninfected cell. In a resting cell, glu-
cose is actively imported and used to fuel oxidative phosphorylation. 
The glycolytic pathway in the cytosol converts glucose to pyruvate. 
Pyruvate is imported into the mitochondria where it is used to gen-
erate NADH and FADH through the TCA cycle. NADH and FADH 
can be oxidised by the electron transport chain to generate ATP. Cit-
rate generated in the mitochondria can be shuttled out to generate 
cholesterol and fatty acids when this is required. Repression arrows 
indicate specific drug inhibitors. Glucose-6-P can also be shuttled to 
the pentose phosphate pathway where it can be used for generation 
of NADPH, nucleotides and purines. GLUT glucose transporter, TCA 
cycle tricarboxylic acid cycle
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synthesis of fatty acids and prostaglandins [47]. Similarly, 
IFN-activated macrophages are highly glycolytic and also 
adopt a Warburg style metabolism [42]. Much like DCs, 
macrophages shuttle glucose carbon to fatty acids and 
lipids synthesis, and at the same time, their pentose phos-
phate pathway (PPP) flux is increased [42]. These changes 
are required for meeting the demands for enhanced produc-
tion of membranes in the ER and golgi to accommodate the 
stimulated protein production as part of the immune-acti-
vated functions, including proteins for antigen presentation 
and cytokine production.
A critical part of this metabolic reprogramming is the 
very rapid (within minutes) accumulation and secretion of 
succinate, a metabolic intermediate of the TCA cycle, that 
has been shown to act as a signalling molecule for the acti-
vation of the alpha subunit of hypoxia-inducible factor-1 
(HIF-1a) and the induction of HIF-1a-dependent genes 
[48, 49]. A further interesting aspect of the crosstalk that 
occurs between metabolism and immunity is the availabil-
ity of substrates that may also alter the phenotype of mac-
rophages. For instance, overexpression of GLUT-1 leads to 
increases in glycolytic flux that drives a pro-inflammatory 
M1-like phenotype by macrophages without any other sig-
nalling [50].
Altogether, broadly comparing the isolated infec-
tion and immune activation studies, it appears that the 
alterations in energy and central carbon metabolism show 










































































Fig. 2  Metabolism of a cell infected by HCMV. A cell infected by 
HCMV has its metabolism heavily modified. Glucose importation 
is up-regulated due to up-regulation in the expression of GLUT-4. 
Glucose imported is converted to pyruvate, which can be oxidised 
to lactate for the generation of two molecules of ATP. Some of the 
pyruvate can be imported in the mitochondria and converted to cit-
rate and instead of being used in the TCA is rapidly shuttled out 
where it is employed for fatty acid biosynthesis. Glutamine importa-
tion is required in order to support the TCA cycle through anaplero-
sis, which is vital to maintain the mitochondrial membrane potential. 
If the mitochondrial membrane potential is lost, cytochromes get 
released in the cytosol and caspases are activated leading to apop-
tosis. The arachidonic pathway is also up-regulated, and there is 
increased release of arachidonic acid from membranes by lipases, 
which COX-2 converts to PGH2 a precursor for prostanoids. Repres-
sion arrows indicate specific drug inhibitors. TLR Toll-like receptor, 
IFN interferon, GLUT glucose transporter, TCA cycle tricarboxylic 
acid cycle, HK-II hexokinase-II, Akt protein kinase B, NO nitric 
oxide, NSAIDS non-steroidal anti-inflammatory inhibitory drugs, 
PPP pentose phosphate pathway
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investigations. The apparent parallel trajectories of infected 
and immune-activated cells (compare Figs. 2, 3) strongly 
suggest that rather than the virus driving these changes, it 
has the option for co-opting at early times of infection the 
TLR-mediated signalling of metabolism. It will be impor-
tant in the future to determine whether CMV-infected mac-
rophages also exhibit a similar alteration in flux and meta-
bolic functions.
Lipogenic requirement and immune regulation
Lipids are a diverse family of chemically distinct molecules 
that can be hydrophobic or amphipathic and serve multiple 
roles in a cell. They are used to store energy, signal and 
maintain cellular structure and have a key building role for 
all membranes and organelles [51] including for the growth 
of viruses. For instance, an important class of non-steroidal 
lipids that act as signalling molecules in immunity are reti-
noids, which are also known to directly and indirectly con-
trol HCMV and MCMV gene expression and viral replica-
tion [52–54].
Figure 4 shows the results of very early experiments 
that we conducted to directly test a potential lipogenic 
requirement for CMV growth in cells. For these studies, 
fibroblasts were incubated in medium supplemented with 
charcoal-treated serum (delipidised media), in which bio-










































































Fig. 3  Metabolism of a macrophage activated by immune signals. 
Upon activation of TLRs, the cell releases downstream IFN and at the 
same time, TBK1-IKKε kinases are activated leading to iNOS, Akt 
and NF-KB activation. This leads to increased glycolysis through 
activation of HK-II. NO production is also up-regulated from iNOS 
and blocks generation of ATP by mitochondria, and this also leads in 
up-regulation of glycolysis in order to produce ATP from pyruvate 
fermentation. Part of the pyruvate produced by glycolysis is imported 
to mitochondria where it gets converted to citrate and shuttled to the 
cytosol and used for fatty acids synthesis required by the cell for 
its activation. At the same time due to direct signalling by IFN, the 
mevalonate–sterol pathway is down-regulated. In the arachidonic 
pathway, COX2 is activated by NF-KB and prostanoids produced by 
are used as signals in an autocrine and paracrine way to regulate the 
immune response. Repression arrows indicate specific drug inhibi-
tors. The key differences to note in comparison Fig. 2 are TLR acti-
vation alone involving HK-II activation by Akt and that TLR agonist 
is the activator and not virus. TLR Toll-like receptor, IFN interferon, 
GLUT glucose transporter, TCA cycle tricarboxylic acid cycle, HK-II 
hexokinase-II, Akt protein kinase B, NO nitric oxide, NSAIDS non-
steroidal anti-inflammatory inhibitory drugs, PPP pentose phosphate 
pathway
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subsequently infected with murine CMV (MCMV) and 
analysed for viral production. As shown in Fig. 4, the 
growth of CMV was statistically strongly attenuated under 
these lipid-depleted conditions. It is worth noting that cell 
viability was not significantly affected by the removal of 
lipids in the culture medium in the conditions of the assay. 
We next asked whether a pro-viral lipogenic component 
in the serum was possibly removed. To test this notion, a 
chloroform–methanol method for removing lipids was used 
[55] whereby neutral lipids (triglycerides, waxes and pig-
ments) are extracted by chloroform and phospholipids; 
glycoproteins and cholesterol are removed by methanol. 
These extracted lipids were subsequently used to reconsti-
tute the delipidised serum. Notably, we found that addition 
of the reconstituted lipids to the delipidised media sub-
stantially reversed the viral growth defect exhibited after 
lipid depletion (Fig. 4a). It is possible that the delipidised 
media conditions simply impacts the cell by reducing an 
essential ‘lipid’ resource for the production of viral mem-
branes, or alternatively but not mutually exclusive, is the 
possibility for a pro-viral regulatory lipogenic factor. In 
order to distinguish between these possibilities, we sought 
to test whether the capacity of infected cells to generate 
infectious particles under delipidised media conditions is 
due to limited membrane lipid resources. In order to assess 
the maximal capacity for additional virus production under 
delipidised culture conditions, we employed a well-estab-
lished and potent regulatory lipid for enhancing CMV, 
9-cis retinoic acid (RA) [54]. Treatment of cultures in deli-
pidised medium with 9-cis RA led to a notable increase 
in MCMV growth that reached levels comparable or even 
higher than those obtained in cultures containing the nor-
mal medium, indicating that resources are not limiting the 
capacity of the cell to produce virus (Fig. 4b). Thus, these 
investigations reveal a requirement of lipogenic factors for 
optimal MCMV infection and indicate that this dependency 
is not only due to a deficit of membrane resources for viral 
growth in the cells. Please note that we do not infer from 
these experiments that retinoic acid is the regulatory lim-
iting lipogenic component although this possibility cannot 
be excluded. Most importantly, these experiments under-
score that careful consideration should be given to inter-
preting experiments that block or deprive cells of lipids 
and assessing the impact on viral growth. For this reason, 
the view that a pro-viral host lipid represents a depleted 
resource may not necessarily be the case and should be dis-
tinguished from possible effector or regulatory signalling 
functions. In the next section, we discuss the functional 
roles and alterations that occur for lipids upon infection and 
immune activation.
Long chain fatty acid pathway
Virus infection
As described above, HCMV infection shuttles carbon 
atoms to fatty acid synthesis (compare Figs. 1, 2). Fatty 
acids are carboxylic acids with long aliphatic tails. Fatty 
acid synthesis begins in the cytosol with the conversion of 
acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase 
(ACACA), the committing step in fatty acid biosynthesis 
(Fig. 1). Fatty acid synthase (FASN) then uses malonyl-
CoA to add two more carbon atoms to the aliphatic chain 
of a fatty acid. Fatty acids are elongated up to 16 carbons 
from FAS, and then, they can be elongated further in the 
ER by the elongation system in which fatty acid elongases 
(ELOVLs) play a vital role [56] (Fig. 1).
Drug inhibition of ACC with TOFA and of FASN with 
C-75 or other inhibitors have shown marked inhibition of 
HCMV replication [25, 36]. HCMV has also been shown to 
up-regulate ACC expression along with a number of other 
enzymes important for fatty acid biosynthesis. More recent 



























































































Fig. 4  Lipogenic factor requirement for MCMV growth. a NIH 
3T3 cells are pre-treated with normal (DMEM 3 % CS), delipidised 
(DMEM 3 % charcoal resin-treated CS) or reconstituted (DMEM 3 % 
charcoal resin-treated CS containing chloroform–methanol serum 
extracted lipids) medium for 4 h and then infected with MCMV at a 
multiplicity of infection (MOI) of 0.02. After infection, cells received 
the corresponding medium (normal, delipidised or reconstituted). 
Viral titers are determined by plaque assay at day 7 after infection 
from culture supernatants. n = 4, data are mean ± SD. b NIH 3T3 
cells are pre-treated with normal, delipidised or 10 μM 9-cis RA in 
delipidised medium for 4 h and then infected with MCMV at an MOI 
of 0.01. After infection, cells received the corresponding medium 
(normal, delipidised without or with 10−9 M 9-cis RA. Viral titres 
are determined as in a. n = 3, data are mean ± SD. **p ≤ 0.01; 
***p ≤ 0.001, determined with an unpaired Student’s t test
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chain fatty acids (VLCFAs) to replicate effectively [11]. 
Inhibition of specific ELOVLs attenuated the replication 
of the virus, and the fact that the envelope of the virus in 
untreated fibroblasts was strikingly enriched for those spe-
cific fatty acids, suggesting that indeed the requirement for 
this pathway may act at the viral membrane level. In fur-
ther support of this, it was also noted that inhibition of the 
pro-viral ELOVLs does not significantly reduce the num-
ber of virions, but instead greatly reduces infectivity. This 
was attributed to the ability of those VLCFAs to produce an 
envelope with correct curvature or other physicochemical 
properties necessary to bud virions from cells [11]. In this 
connection, phospholipids are essential membrane struc-
tural lipids consisting of a hydrophobic fatty acid tail. For 
HCMV, the glycerophospholipid composition of the virus 
membrane has been found to be very similar to synaptic 
vesicles suggesting a re-purposing or modelling of the host 
lipid membranes for its morphogenesis [57]. HCMV in 
general dramatically remodels the structure of a cell, lead-
ing to the gross enlargement of infected cells (cytomegalic) 
and the formation of a new compartment termed the virion 
assembly compartment (VAC) [58]. VAC is a kidney-
shaped structure adjacent to the nucleus that is crucial for 
HCMV replication and is formed by extensive remodelling 
of the secretory membrane apparatus [59–61].
Immune activation
The immune activation of cells also impacts on lipid and 
fatty acid metabolism [62–64], see Fig. 3 for a schematic 
summary of pathways. As described above, macrophages 
and DCs of specific phenotypes promote de novo fatty acid 
synthesis upon activation [47, 65]. Although still not well 
understood, these changes appear to be important for the 
activated function of the cell; for instance, inhibiting fatty 
acid synthesis can impair phagocytosis [65]. An activated 
macrophage leads to significant changes in phospholipids 
and fatty acids that promote the formation of filopodia and 
the biogenesis of new organelles such as mitochondria, 
lysosomal compartments, and expanded ER and golgi [47, 
65, 66]. These metabolic changes are therefore essential 
for activated macrophages and dendritic cells to be trans-
formed, from small quiescent cells to cells that are actively 
phagocytic, present antigens and secrete a huge number of 
cytokine and immune regulatory molecules.
Altogether, these immune-driven changes appear to 
have similarity to those observed in infected cells despite 
the studies being conducted in different cell types and 
point to a more unified response (compare Figs. 2, 3). This 
raises again the question of whether immune activation 
initiates the metabolic changes that upon infection also 
opportunistically favour viral growth. In this scenario, 
such immune-initiated re-programming of metabolism 
may be required and co-opted by the virus but alone may 
not be sufficient. Future studies should address whether it 
is likely that additional metabolic state changes are fur-
ther needed to encourage viral growth, and we speculate 
that viral gene products may have a contributory role in 
governing metabolic programming in the infected cell.
Prostanoid biosynthesis pathway
Virus infection
As mentioned at the start of the lipid section, not all lipids 
will necessarily have a structural role as membrane lipids 
but may also contribute regulatory functions or signals that 
promote or inhibit viral growth. In this regard, an interest-
ing class of signalling lipids that HCMV appears to depend 
on are eicosanoids. These are produced by oxidation of 
20 carbon fatty acids and play critical regulatory signal-
ling roles in immunity and inflammation. Upon infection 
of fibroblasts, HCMV up-regulates the expression of genes 
related to the eicosanoids pathway [67, 68]. Among them 
are cytosolic phospholipase A2 (cPLA2) and cyclooxyge-
nase-2 (COX-2) that are responsible for the generation of 
prostaglandin H2 (PGH2) acid from cell membranes and its 
conversion to prostaglandin H2 (PGH2) [69–71]. The inhi-
bition of COX-2 has been shown to reduce HCMV progeny 
while the introduction of prostaglandin E2 (PGE2) rescues 
the drug blockade [71]. While the antiviral mechanism for 
inhibition is not clear, PGE2 has been reported to stimulate 
the activity of the virus major immediate early promoter 
[72]. A later report from Schröer and Shenk [71] demon-
strated that inhibition of COX-2 also blocks cell-to-cell 
viral spread although the precise mechanism has not been 
defined.
In addition to the studies indicating that blocking pros-
taglandin synthesis inhibits viral growth, we have previ-
ously reported through evaluation of a highly selective and 
chemically diverse synthetic prostanoid library that the rep-
lication of MCMV can be enhanced or strongly curtailed 
depending on the specific prostanoid chemical structure 
[73]. Thus, altogether these studies suggest key regulatory 
functions for prostanoid signalling in determining the out-
come of a viral infection. In this context, we have been suc-
cessful, as a proof-of-principle study, to identify a potential 
therapeutic prostanoid that had potent anti-CMV activity 
[73].
Immune activation
The inflammatory induction of prostaglandins and other 
related lipids by macrophages and DCs have a critical sec-
ondary autocrine and paracrine signalling role in immunity 
[70, 74, 75]. Notably, lipidomic studies of the macrophages 
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have revealed that upon activation with a selective TLR4 
agonist, a rapid increase in eicosanoid synthesis takes place 
[76]. Depending on factors such as the nature of the signal-
ling or length of exposure to it, different outcomes on lipid 
alterations have been reported in macrophages and DCs 
[77, 78]. Moreover, differential gene regulation of enzymes 
that participate in the eicosanoid biosynthesis pathway 
has been documented in pro-inflammatory (M1) and anti-
inflammatory (M2) polarised macrophages [79]. Thus, IFN 
and LPS activation of M1 macrophages potently induced 
COX-2, and down-regulated COX-1 and other pathway-
related enzymes, such as leukotriene A4 hydrolase. In 
contrast, M2 macrophages activated with IL-4 exhib-
ited an up-regulation of COX-1. TLR treatment of mac-
rophages induced the microsomal isoform of PGE synthase 
(mPGES). On the other hand, Th2-associated cytokines 
IL-4 and IL-13 down-regulated the expression of mPGEs in 
macrophages [80].
In turn, prostanoids released from macrophages and 
DCs participate in autocrine loops to regulate COX-2 
expression. In macrophage cells, PGE2 has been reported 
to induce COX-2 and mPGES-1 [81]. In addition, released 
prostanoids are able to affect, either in a positive or in a 
negative manner, a number of macrophage and DC func-
tions [78]. As an example, PGE2 has been shown to usu-
ally exert inhibitory actions on macrophages and DCs, 
such as suppressing MHC class II expression and TNF-α 
production and inducing IL-10 expression [82–84]. How-
ever, PGE2 has also been documented to exert stimulatory 
effects on these two cell types, including the induction of 
IL-23 in DCs through cooperation of PGE2 with CD40-
mediated signalling [85]. Most significantly, PGE2 release 
from myeloid cells has been shown to restrain T cell activa-
tion, and clinical trials have revealed that blockade of PGE2 
synthesis exacerbates severe systemic inflammation. In this 
connection, it has also been suggested that PGE2 released 
from HCMV-infected macrophages may contribute to the 
immunosuppressive activity of HCMV [86]. Future studies 
elucidating the regulatory role of PGE2 in immunity will 
significantly advance our understanding of lipid host pro-
tection pathways modulated in cytomegalovirus disease.
Mevalonate–sterol pathway for cholesterol biosynthesis
Virus infection
Cholesterol is known to have a causal link to inflammatory 
diseases and its oxidised metabolites (oxysterols) alter adap-
tive and innate immunity, and innate immune signalling has 
been shown to modulate the dynamics of cholesterol homeo-
stasis [62–64, 87]. In this connection, over the last century, 
natural and experimental infection studies have reported for 
a wide range of pathogens a state of hypocholesterolemia 
during the acute phase (2–4 days) of infection that is often 
followed by a rebound period of hypercholesterolemia [88–
96]. Currently in the critical care of sepsis, monitoring of cho-
lesterol levels is used as a biomarker for prognosis. Although 
blood cholesterol levels for CMV infection have not been 
measured, acute hepatic infection by MCMV has been shown 
to increase total cholesterol levels in the liver [97]. Hence, the 
biosynthesis and metabolism of cholesterol takes centre stage 
in infection biology. Work from Alwine et al. [29] suggest 
that HCMV induces adipocyte-like lipogenesis and overrides 
normal sterol feedback controls in order to maintain high lev-
els of constitutive lipid synthesis during infection.
Cholesterol biosynthesis starts with acetyl-CoA whereby 
the reductase, HMGCR, represents a critical regulated step 
in the mevalonate arm of the sterol biosynthesis pathway 
(Fig. 1). The pathway is responsible not only for the pro-
duction of cholesterol but also for generating immune and 
sex steroid hormones while the upstream mevalonate arm 
of the pathway produces metabolites used in a diverse array 
of biological processes including the synthesis of ubiqui-
none for mitochondrial aerobic respiration with func-
tions in the electron transport chain, and other isoprenoids 
required for the N-gylcosylation and lipidation of proteins 
(farnesylation and geranylation of proteins). Thus, the inhi-
bition of HMGCR by statins not only reduces cholesterol 
but also has the ability to affect multiple products of the 
mevalonate side branch. Perhaps not surprisingly statins 
are potent inhibitors for human and murine CMV [15, 
98–100], and we were the first to show that the antiviral 
activity of statin on CMV can be metabolically reversed by 
mevalonate but not cholesterol treatment [15]. Recent stud-
ies have since independently confirmed the inhibition of 
HCMV by statins and metabolic rescue of antiviral action 
by using mevalonate [98]. The metabolic rescue experi-
ments unequivocally demonstrate the absolute requirement 
for mevalonate–sterol biosynthesis pathway for optimal 
CMV growth. In a series of systematic loss of function 
and drug inhibition assays, we have provided further evi-
dence implicating mevalonate-derived products such as 
isoprenoids involved in the lipidation of proteins for CMV 
growth [16, 101]. Inhibition of the mevalonate–sterol arm 
does not affect the binding or entry of CMV but evidence to 
date points to the suppression of the major immediate early 
gene expression as well as blocking cell-to-cell spread [16].
It is important to note that while these studies indicate 
that cholesterol alone is not the primary metabolite for sta-
tin antiviral action, they do not rule out an important bio-
logical requirement for cholesterol in the CMV life cycle. 
In this regard, studies evaluating the proteomes of fibro-
blasts cells before and after HCMV infection by mass spec-
troscopy identified LRP1, an LDL receptor-related protein 
involved in cholesterol uptake, as a transiently increased 
protein at 24 h after infection. In human fibroblasts, 
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knockdown of LRP1 was found to enhance HCMV infec-
tivity and also lead to increased cholesterol in released 
virions. Importantly, the cholesterol content of the virus 
envelope was shown to be critical for HCMV fusion with 
the host cell. These results indicate that increases in cel-
lular and virion cholesterol content lead to more efficient 
fusion of the virion envelope with the plasma membrane 
and therefore increased virion infectivity [102].
Upon infection of macrophages with MCMV, we found 
by metabolic and transcriptional profiling studies that one 
of the most statistically significant pathways suppressed 
upon infection was mevalonate–sterol metabolism. The 
reasons for this reduction are complex and may not be 
identical or equivalent in all cell types and media condi-
tions as this pathway is directly regulated by the immune 
response and by extracellular cholesterol. For instance 
in macrophages but not fibroblasts, we find a highly spe-
cific and dramatic increase in the production of an oxi-
dised cholesterol metabolite generated by the hydroxylase 
CH25H. The regulation of CH25H appears to be highly 
cell type and tissue specific and is mainly restricted to 
immune (myeloid and lymphoid) and to certain epithe-
lial cell types. We, and others, identified and showed that 
the metabolic product of CH25H enzyme, 25-hydroxy-
cholesterol (25HC), a well-characterised inhibitor of the 
mevalonate–sterol biosynthesis pathway, acts as a potent 
antiviral regulatory factor by principally suppressing the 
isoprenoid branch of the pathway and through affecting 
cellular membranes [16, 66, 103]. It remains an open 
question if CMV encodes viral proteins that counter these 
inhibitory effects. Previous studies from Alwine et al. 
[29] have suggested that HCMV infection of fibroblast 
can override normal sterol feedback control in order to 
maintain high levels of constitutive lipid synthesis during 
infection.
Overall, these studies underscore that the interplay 
between immune activation, infection and metabolic 
changes cannot be considered in isolation.
Immune activation
Similar to the early infection studies examining blood cho-
lesterol, in completely unrelated early investigational stud-
ies of recombinant IFN treatment in humans, for a range 
of different disease indications, a transient drop in blood 
cholesterol levels has also been repeatedly documented. 
Radiolabelled metabolic studies have further indicated 
that this particular side effect of IFN treatment is due to 
a suppression of endogenous sterol synthesis [94]. Strik-
ingly, mechanistic and functional physiological linkages 
between the observational based infection and IFN studies 
have not, until recently, been investigated or considered. 
IFN and TLR activation are now known to coordinate the 
reduction in cholesterol biosynthesis for human and murine 
macrophages [10, 15, 66, 76, 104]. We demonstrated that 
IFN-induced inhibition of sterol biosynthesis serves as an 
integral component of the very early cellular response to 
virus infection [15]. Metabolic profiling [15] and molecular 
screening [103] studies led ourselves and others to identify 
IFN-elicited 25HC as an important effector of the IFN-
induced antiviral response in macrophages [15, 16]. This 
lipid has emerged to have broad-spectrum antiviral and 
immune modulatory functions [10].
We demonstrated that CMV infection leads to a TLR-
induced type I IFN-mediated down-regulation of the mas-
ter transcription factor for sterol biosynthesis, SREBP2 
[15]. More recently, we have also shown that IFN signal-
ling specifically targets in a SREBP-independent manner 
the statin-targeted reductase, HMGCR, for rapid proteoso-
mal degradation that is strictly coupled to the endogenous 
synthesis of 25HC [105]. Our studies of immune-activated 
macrophages identified STAT1 transcriptional regulation 
of the cholesterol hydroxylase, CH25H, as a direct mech-
anistic link between IFN-mediated antiviral activity and 
the regulation of sterol metabolism [16]. Investigations 
of SREBP2-dependent IFN effects have implicated the 
sterol biosynthesis pathway involved in both antiviral and 
anti-inflammatory pathways [16, 106]. Further studies are 
required to more fully understand the role of SREBP2 and 
the mevalonate–sterol pathway in immunity and infection.
Therapeutic perspective
Here we have discussed how cytomegaloviruses are criti-
cally dependent on and co-opt many aspects of cellular 
sugar and lipid metabolism to facilitate their life cycles 
across species and how the inhibition of these processes 
can curtail virus replication. Overall, we find a remark-
able level of metabolic cooperation between infection and 
immunity. Defining how immunity and metabolism are 
integrated, share resources and cross-regulate one another 
during infection is therefore an essential yet incompletely 
understood area of infection biology. Notably, unbiased 
systems biology approaches are providing valuable new 
insights into this integrative complexity and computational 
studies based on predictive modelling will be essential in 
the future functional design and control of an immune–
metabolic–infection axis [107].
In this regard and to advance this future perspective, 
Fig. 5 summarises and shows as a schematic representa-
tion of the inputs and outputs for this axis, with metabo-
lism positioned in the middle connecting in an integrative 
manner the various distinct biological processes. Conceptu-
ally, this diagram extends our previous ‘cellular clockwork 
model of infection’ [1] that underscored the dependency of 
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pathogens on cellular pathways as a means for therapeutic 
drugs or the immune system to control infections. Here we 
extend the previous model to emphasise, at a systems con-
trol level, an important design principle suggesting that cel-
lular metabolism behaves as a ‘tunable device’ and that the 
control of metabolic flux in these pathways is necessary for 
driving the range and type of biological response (Fig. 5).
While the concept of metabolism acting as a ‘tunable 
device’ for governing cellular functions is new, it remains 
speculative yet testable for the future. Thus, we believe that 
further understanding and identifying the host molecular 
circuitry for new and recently discovered immune-regu-
lated metabolites and enzyme pathway systems will aid in 
the development of new therapeutic innovations to prevent 
infection (as an anti-infective) or enhance immunity (as 
adjuvant-based metabolic modifiers).
Although we have focussed our discussions on sugar 
and lipid pathways, these are not the only examples of an 
immune–metabolic–infection axis known to control infec-
tions. In particular, the immune-activated metabolism of 
amino acids has been long established. Stimulation of 
macrophages with IFN results in the rapid induction of the 
tryptophan-catabolising enzyme indoleamine-2,3-dioxyge-
nase resulting in broad-spectrum antimicrobial and immu-
nosuppressive effector functions. Other examples include 
the immune-regulated activities of the arginine-hydrolysing 
enzymes nitric oxide synthase 2 (iNOS) and arginase 1 
(Arg1). In the case of these enzyme systems, NO produc-
tion by iNOS acts as an important pro-inflammatory and 
antiviral mediator, while Arg1-expressing macrophages 
contribute to the resolution of inflammation and wound 
repair. In the context of viral infections, expression of 
these enzymes can result in a variety of outcomes for the 
host [108]. Interestingly, HCMV infection of fibroblast is 
capable of effectively impairing this response [109] and 
might suggest a similar mode of action for blocking the 
IFN-induced suppression of sterol biosynthesis.
Strikingly, the glycolytic and fatty acid metabolism 
changes that favour CMV growth in fibroblasts, parallels 
the metabolic profile of the pro-inflammatory immune-
activated macrophages, but not the anti-inflammatory 
macrophages. In future, it will be important to determine 
whether the metabolic cooperation in glycolytic and fatty 
acid pathways also occurs upon CMV infection of mac-
rophages. Since CMV remains latent in monocytes and 
reactivates upon immune activation and differentiation, 
it is plausible that CMV may also exploit these different 
metabolic stages of the macrophage phenotypes to remain 
latent and reactivate when conditions favour replication. If 
so, then therapeutic targeting (‘tuning’) of metabolism in 
latently infected monocytes may provide a means for cur-
ing or eliminating latently infected cells.
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